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ABSTRACT
COMPUTATIONAL STUDIES OF TOLL-LIKE RECEPTOR 4
This Thesis is focused on the molecular modeling and computational study of
the molecular recognition processes involving Pattern Recognition Receptors (PRRs), in
particular, Toll-like receptors (TLRs). TLRs are the main actors in innate immunity and
are specialized in the recognition of pathogen associated molecular patterns (PAMPs).
In particular, TLR4 is located in the plasma membrane where, together with the
MD-2 protein, it binds to lipopolysaccharides, membrane constituents of Gram­
negative bacteria, forming a heterodimeric complex. TLR4 agonists can be used as
adjuvants in vaccine development and in cancer immunotherapy. TLR4 antagonists
have also been studied for their promising application in septic shock, chronic
inflammation and autoimmunity. However, the mechanism at atomic level for such
activation/inactivation process remains unknown. Our research has been focused on
the study of the mechanism of the TLR4/MD-2 system by means of computational
approaches.
In order to carry out our research objectives, we use a combination of several
computational tools: geometry optimization, charges calculations, docking, virtual
screening, and molecular dynamics simulations of protein complexes and membranes.
The main objective of this Thesis is to elucidate the ligand-protein interactions
of TLR4 at atomic detail through computational techniques. Computational
methodologies will be applied to the study of the molecular mechanisms involved in
the TLRs functionality, and in the recognition of PAMPs. Ligand-protein docking and
virtual screening will be used as a source of new compounds able to modulate the TLRs
behavior with possible therapeutic applications, and also as biological probes.
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CHAPTER 3: Theoretical binding modes will be predicted for reported
modulators of the TLR4/MD-2 system with agonist and antagonist activity. In
particular, we will focus our work in synthetic LPS analogues and small molecules with
a non LPS-like structure. We will undertake a computational study of some
representative compounds to unveil some of these patterns of interactions.
CHAPTER 4: The cationic glycolipid IAXO-102, a potent TLR4 antagonist, will be
used as scaffold to design new potential TLR4 modulators and fluorescent labels for
the TLR4 receptor complex. These compounds will be synthetized by collaborators. Our
modelling studies will led us to the proposal of 3D models for the interaction with
CD14 and TLR4/MD-2 accounting for their binding properties and also for their
antagonistic activity.
CHAPTER 5: Virtual screening strategies from commercial, in-house and generic
drugs libraries, followed by biological assays, will allow us to identify new chemical 
entities for the development of novel TLR4 modulators with a LPS non-related
structure. 
CHAPTER 6: The computational study of the full TLR4/MD-2 system will be
performed, simulating the TLR4/MD-2 complex in the membrane environment. Several
models of the monomer TLR4/MD-2 system inserted in different membranes will be
built and simulated. These different models will be useful for the final building of the
complete TLR4/MD-2 dimer and will provide us insights into the mechanism of TLR4
agonism/antagonism. The analysis of the molecular dynamics simulations will lead us 
to understand the key ligand-receptor and protein-protein interactions implicated in
the molecular recognition events and the dimerization process.
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Our work has led to the following conclusions:
Theoretical binding modes have been predicted for reported modulators of the
TLR4/MD-2 system, with agonist and antagonist activity. In particular, we focused our
work in synthetic glycolipids and non LPS-like molecules. For all these TLR4
modulators, it is clear that, despite their different chemical structure, they must share
a common pattern of interactions with TLR4. We have undertaken a computational
study of some representative compounds to unveil some of these patterns of
interactions.
The cationic glycolipid IAXO-102, a potent TLR4 antagonist targeting both MD-2 
and CD14 co-receptors, has been used as scaffold to design new potential TLR4
modulators and fluorescent labels for the TLR4 receptor complex (membrane
TLR4/MD-2 dimer and CD14). Our modelling studies have led to the proposal of 3D
models for the interaction with CD14 and TLR4/MD-2 accounting for their binding
properties and also for their antagonistic activity.
To propose new chemical scaffolds for the development of new ligands able to
modulate TLR4 functions, we have performed virtual screening. Virtual screening
strategies from commercial and in-house libraries, followed by biological assays, have 
allowed us to identify new chemical entities for the development of novel TLR4
modulators with a LPS-non-related structure. So far, we have identified seven novel
compounds with a promising TLR4 antagonist activity.
The computational study of the full TLR4/MD-2 heterodimer was performed,
simulating the full complex inserted in the membrane environment. The analysis of the
molecular dynamics simulations led us to understand the key interactions implicated in
the dimerization process at atomic level.
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Summarizing, molecular modelling approaches have been used to elucidate the
molecular recognition mechanisms of TLR4/MD-2 modulation, with focus on the
agonist/antagonist conformational changes of the TLR4/MD-2 system, and to provide
some hints for the design of novel binders, hopefully with therapeutic potential. We
also have collaborated with experimental groups to synthesize the designed
compounds and to perform biological assays. The study of the binding mode of several
reported TLR4/MD-2 modulators has been undertaken and the simulation of the
TLR4/MD-2 system in different membranes environments, by means of a combination 
of docking calculations, molecular dynamics simulations and virtual screening
protocols have been performed. 
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RESUMEN
ESTUDIOS COMPUTACIONALES DEL RECEPTOR TOLL-LIKE 4
En esta Tesis Doctoral se han empleado técnicas de modelado molecular y se ha
llevado a cabo el estudio computacional de los procesos de reconocimiento molecular
que implican Receptores de Reconocimiento de Patrones (PRRs), en particular, los
receptores Toll-like (TLRs). Los TLRs son los principales actores en la inmunidad innata
y se especializan en el reconocimiento de patrones moleculares asociados a patógenos
(PAMPs).
En particular, el receptor TLR4 se localiza en la membrana plasmática donde,
junto con la proteína MD-2, se une a lipopolisacáridos, constituyentes de membrana
de bacterias Gram-negativas, que forman un complejo heterodimérico. Los agonistas
de TLR4 pueden ser útiles como coadyuvantes en el desarrollo de la vacuna y en la
inmunoterapia contra el cáncer. Los antagonistas de TLR4 también han sido estudiados
por su prometedora aplicación en choque séptico, inflamación crónica y 
autoinmunidad. Sin embargo, el mecanismo a nivel atómico para tal proceso de
activación/inactivación sigue siendo desconocido. Nuestra investigación se ha centrado
en el estudio del mecanismo del sistema TLR4/MD-2 mediante métodos
computacionales.
Con el fin de llevar a cabo nuestros objetivos de investigación, hemos utilizado
una combinación de varias herramientas computacionales: optimización de la
geometría, cálculos de carga, docking, cribado virtual y simulaciones de dinámica
molecular de complejos y membranas de proteínas.
El objetivo principal de esta Tesis es elucidar las interacciones ligando-proteína
del receptor TLR4 a nivel atómico a través de técnicas computacionales. Metodologías
V
  
 
     
     
     
         
       
 
 
       
       
   
   
 
       
      
   
     
      
   
 
     
  
   
   
 
     
    
      
    
   
      
computacionales se aplicarán para el estudio de los mecanismos moleculares
involucrados en la funcionalidad de los receptores Toll-like, y en el reconocimiento de
los PAMPs. Técnicas de acoplamiento ligando-proteína y cribado virtual serán
utilizadas, dando lugar a una fuente de nuevos compuestos capaces de modular el
comportamiento de los TLRs con posibles aplicaciones terapéuticas, y también como
sondas biológicas. 
CAPÍTULO 3: Para los moduladores descritos del sistema TLR4/MD-2 se
predecirán modos de unión teórica. En particular, nuestro trabajo se centrará en
análogos de LPS. Realizaremos un estudio computacional de algunos compuestos
representativos para desvelar algunos de estos patrones de interacciones.
CAPÍTULO 4: El glicolípido catiónico IAXO-102, un potente antagonista de TLR4,
se utilizará como esqueleto para diseñar nuevos moduladores de TLR4 y marcadores
fluorescentes para el complejo TLR4. Estos compuestos serán sintetizados por otros
colaboradores. Nuestros estudios de modelado nos permitirán diseñar nuevos
compuestos y proponer modelos de interacción tanto para el CD14 como para el
complejo TLR4/MD-2.
CAPÍTULO 5: Las estrategias de cribado virtual de diferentes bibliotecas de
compuestos, seguidas por ensayos biológicos, nos permitirán identificar nuevas
entidades químicas para el desarrollo de nuevos moduladores de TLR4 con una
estructura diferente al LPS.
CAPÍTULO 6: Se llevará a cabo el estudio computacional del sistema TLR4/MD­
2, simulando el complejo TLR4/MD-2 con diferentes modelos de membrana. Varios
modelos del monómero TLR4/MD-2 insertado en diferentes membranas serán
construidos y se llevará a cabo la simulación de dinámica molecular. Estos diferentes
modelos serán útiles para la construcción final del dímero TLR4/MD-2 completo y nos 
proporcionarán información sobre el mecanismo agonista/antagonista del receptor
VI
  
 
     
  
    
 
     
 
      
       
     
       
       
     
    
 
     
     
     
       
      
    
 
 
    
       
  
    
 
     
    
TLR4. El análisis de las simulaciones de dinámica molecular nos permitirá comprender
las interacciones clave ligando-receptor y proteína-proteína implicadas en los eventos
de reconocimiento molecular y el proceso de dimerización.
Nuestro trabajo ha llevado a las siguientes conclusiones:
Se han predicho modos de unión teórica para los moduladores descritos del
sistema TLR4/MD-2. En particular, hemos centrado nuestro trabajo en glicolípidos
sintéticos y moléculas que no tienen estructura de tipo LPS. Para todos estos
moduladores de TLR4, está claro que, a pesar de su diferente estructura química, 
deben compartir un patrón común de interacciones con el receptor TLR4. Hemos
llevado a cabo un estudio computacional de algunos compuestos representativos para
revelar algunos de estos patrones de interacciones.
El glicolípido catiónico IAXO-102, un potente antagonista de TLR4, se ha 
utilizado como esqueleto para diseñar nuevos moduladores de TLR4 y marcadores
fluorescentes para el complejo TLR4/MD-2. Nuestros estudios de modelización nos han
permitido diseñar nuevos compuestos y nos han permitido proponer modelos de
interacción tanto para el CD14 como para el complejo TLR4/MD-2. Todos estos
compuestos han presentado una actividad antagonista para el complejo del TLR4/MD­
2.
El estudio computacional del heterodímero TLR4/MD-2 completo se realizó
simulando el complejo completo insertado en la membrana. El análisis de las
simulaciones de dinámica molecular nos llevó a entender las interacciones claves
implicadas en el proceso de dimerización a nivel atómico.
Resumiendo, técnicas de modelado molecular se han utilizado para elucidar los
mecanismos de reconocimiento molecular de la modulación del receptor TLR4/MD-2,
VII
  
 
     
     
      
     
        
  
    
  
 
 
centrándonos en los cambios conformacionales agonistas/antagonistas del sistema
TLR4/MD-2, que nos ha permitido el diseño de nuevos ligandos, con cierto potencial
terapéutico. También colaboramos con grupos experimentales para sintetizar los
compuestos diseñados y realizar ensayos biológicos. Se ha realizado el estudio del
modo de unión de varios moduladores TLR4/MD-2 y se ha llevado a cabo la simulación
del sistema TLR4/MD-2 en diferentes entornos de membranas, mediante una
combinación de cálculos de docking, simulaciones de dinámica molecular y protocolos
de cribado virtual.
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1. INTRODUCTION
1. Introduction
1.1 Understanding Toll Like Receptors 
All living organisms constantly face attack from environmental microorganisms 
and need to cope with perpetual invasions into the body. The vertebrate immune
response can be classified into innate and acquired immunity, being innate immunity 
the first line of defence against pathogens. Toll-like receptors (TLRs) have a
fundamental role in early innate immunity, and are responsible for initiating and
propagating inflammation. Evidences indicate a role for TLRs in immune and
inflammatory diseases,1 and increasingly in cancer.2 Its relevance was highlighted in
the award of the 2011 Nobel Prize in Medicine3 to Beutler and Hoffmann for their
studies on the activation of the innate immune system. Therefore, TLRs have emerged
as novel targets for drug design. TLR agonists are currently under development for the
treatment of cancer, allergies, and viral infections, and also as adjuvants as part of
potent vaccines to be used in prevention or treatment of cancer and infectious
diseases. As inappropriate TLR stimulation leads to inflammation and autoimmunity,
significant efforts have also been directed towards the development of compounds as
TLR antagonists.4 
TLRs trigger two mechanisms of the immune response, the innate and the
adaptive immunity, that work together to combat infection in mammals. The adaptive
response generates antibody-secreting B cells and cytotoxic T cells that are specific and
efficient at targeting pathogen. One disadvantage of this mechanism is that require
more time to be developed than the innate response. 5 Since TLRs are the first
responders to danger signals, they are pivotal in the research for fighting infectious
and inflammatory diseases. New strategies for modulating the immune response 
depend on the understanding of the TLRs cell biology: structure, cell localization, signal
transduction pathways and expression patterns.
In 1989, Janeway proposed that cells use pattern recognition to identify 
pathogens. Receptors recognize and subsequently bind to structural shapes or
patterns called pathogen-associated molecular patterns (PAMPs) which are present in
3
  
 
      
       
        
     
        
      
     
        
        
        
      
       
      
   
     
    
     
      
       
        
 
     
  
    
         
        
 
     
          

 
1. INTRODUCTION
entire groups of pathogens,6 but not in the host. According to Janeway's theory, 
receptors cannot precisely recognize a particular microbe, but they can identify it as a
foreign entity. Ten years after Janeway´s proposal, the first human pattern-recognition
receptors (PRRs) were identified. Using the amino acid sequence of the Toll gene from
the fruit fly,7 related sequences were searched in the Human Genome Project
database, finally leading to the identification of TLRs.8 
Since some TLR binders are originated from the host, these new ligands are
hypothesized to act as damage signals (damage-associated molecular patterns, or
DAMPs) to alert the body of cell and tissue injury, this is evident in cases of necrosis,
ischemic injury, etc.9 For example, blocking various TLRs (such as TLR2 and TLR4) with
antagonists may be useful in these circumstances to prevent an overactive immune
10-11 response. There is also evidence that TLRs contribute to the development of
atherosclerosis and Alzheimer's disease through sensing of damage signals in the form
of oxidized lipoproteins.12 
Given their therapeutic potential, there is considerable interest in
pharmaceuticals that modulate TLR activation. TLR antagonists hold great clinical
promise for the treatment of numerous inflammatory conditions and are under
investigation for the treatment of viral infections, redirecting allergic helper T cell
responses and as anticancer therapeutics. Some TLR agonists have also proven to be
safe and efficacious as vaccine adjuvants in humans and are currently used in
Europe.13-16 
The human TLR family comprises of 10 to 12 type I transmembrane
glycoproteins with a single transmembrane domain, a conserved cytoplasmic Toll­
like/interleukin-1 receptor signaling domain,17-20 and an extracellular antigen
recognition domain comprising of 19–25 tandem leucine-rich repeat (LRR) modules.21 
The LRR modules have 20~30 amino acid residues with conserved ‘‘LxxLxLxxN’’
motifs.22-23 
TLRs generally function as heterodimers. Many ligands with distinct PAMPs
exist, so the ten human TLRs are able to recognize more than ten different PAMPs. In
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1. INTRODUCTION
fact, the list of known TLR binders keeps growing. Heterodimer formation also
increases binders diversity. For example, TLR2 associates with TLR1 and TLR6, and the
association with proteins outside the TLR family also increase diversity, for example,
TLR4 recognizes LPS in association with the accessory proteins MD-2 and CD14. Upon
binding of the ligands to the extracellular domains of TLRs, rearrangement of the
receptor complex is promoted, thus triggering the recruitment of specific adaptor
proteins to the intracellular TIR domains.24 In particular, MyD88 is a universal adapter
protein used by almost all TLRs (except TLR3) to activate the transcription factor NF-κβ/
Mal (also known as TIRAP) is another adaptor protein necessary to recruit MyD88 to
TLR2 and TLR4. TLR expression is particularly significant in different types of white
blood cells: mast cells, macrophages, and dendritic cells. The innate immune response
is initiated by mast cells and macrophages, whereas the adaptive immune response is
primarily initiated by dendritic cells.25 
TLRs 1, 2, 4, 5, and 6 are located primarily in the plasma membrane, where they
recognize components of microbial cell walls and membranes unique to pathogens
(Figure 1.1). The best characterized ligands are bacterial, examples include:
lipopolysaccharide (LPS) and lipoteichoic acid from the cell wall, lipoproteins from the
cell membrane, and flagellin, a structural component of bacterial flagella. TLRs 3, 7, 8,
and 9 are situated in the membranes of endosomes and lysosomes, these TLRs bind to
microbial nucleic acids, such as DNA from most organisms, and double and single
stranded RNA from RNA viruses. Since these TLRs cannot distinguish self-nucleic acids
(those of the host cell) on structural differences alone, and recognition of foreign
nucleic acids (those of the pathogen) largely depends on the location in the cell.26 
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1. INTRODUCTION
Figure 1.1. Human Toll Like Receptor family.2 
1.1.1 Relevance of TLR4 as Therapeutic Target
TLR4 and the Inmune Response
TLR4 was the first TLR identified,8 and was characterized as the receptor for LPS
as it generates an innate immune response upon LPS stimulation.27-29 LPS, glycolipids
produced by Gram-negative bacteria, are composed of an oligosaccharide core and a
highly variable O antigen polysaccharide component, along with a hydrophobic lipid A
segment containing multiple lipid acyl tails and a phosphorylated glucosamine
disaccharide headgroup (Figure 1.2). TLR4 was found to require to be associated to an
additional protein, MD-2 (myeloid differentiation factor 2), to be activated by LPS, and
it was discovered that mice lacking MD-2 do not respond to LPS. There have been
identified a number of MD-2 polymorphisms that modify LPS binding and/or
activation.30 MD-2 is very flexible, and allosterically transmits this conformational
plasticity, in a ligand dependent manner, to a phenylalanine residue (Phe126) in the
cavity mouth previously implicated in TLR4 activation. The assumption is that Phe126
is the “molecular switch” in endotoxic signalling/ 
LPS interaction with TLR4/MD-2 involves at least two other proteins, these are
lipopolysaccharide binding protein (LPB) and cluster of differentiation 14 (CD14). LPS
6
  
 
          
    
       
           
           
      
       
   
    
        
 
  
      
        
      
     
     
 
  
   
  
 

 
1. INTRODUCTION
first binds to LBP in serum and it is then transferred to CD14 (Figure 1.2). The major
role for CD14 is to enhance the sensitivity of the TLR4/MD-2 signaling complex, causing
the binding affinity toward LPS to drop to picomolar concentrations. It was identified
that mice without CD14 are resistant to endotoxic shock. Unlike the rest of the TLR
family, TLR4 does not recognize the lipid in isolation, but when bound to MD-2.31 
TLR4 activation has been associated with certain autoimmune diseases,
noninfectious inflammatory disorders, and neuropathic pain, as well as metabolic
syndrome in multiple tissues and cardiovascular diseases, suggesting a wide range of
possible clinical settings for the application of TLR4 antagonists.32-33 However, agonists
of TLR4 can be useful as adjuvants in vaccine development and in cancer
immunotherapy.29 
Targeting TLR is actually a sparkling field for translational cancer research. The
expression of TLRs mediating innate immune response on tumor cells, influence in the
proliferation and migration of these cells. The activation of TLRs may play opposite
role, antitumor or protumor. Better understanding the mechanism of TLRs in cancer
biology will contribute to expand the opportunities for pharmacological intervention
and discovery new strategies and new candidates for drug against cancer.34 
Figure 1.2. Left: Bacteria engulped by a macrophage during infection. Right: Detail of the LPS 
recognition by TLR4, in concert with the accessory proteins LBP (LPS-binding protein), and
CD14 (who transfers LPS from bacteria membranes or aggregates in serum to MD-2).
7
  
 
  
       
      
     
       
       
      
      
      
       
      
      
       
       
        
     
       
      

 
1. INTRODUCTION
Therapeutic Applications of TLR4 Agonists
TLR agonists have shown to improve currently applied anticancer vaccination
protocols,35-36 and are also the focal point for new vaccine development as non­
infectious subunit vaccines.16, 36 For example, the natural product monophosphoryl
lipid A (MPLA), a detoxified component of LPS from Salmonella Minnesota which
contains the lipid A (Figure 1.3) moiety that binds to TLR4/MD-2, is incorporated into
several vaccines,16, 37 including vaccines for Hepatitis B (Fendrix™),38 and cervical
cancer (Cervarix™)39-40 and in the immunotherapy for melanoma.41 
Also synthetic TLR4 agonists have been designed and assayed. Compound
E602042 have shown good adjuvant activity with antitumoral trastuzumab,43 or
enhancing vaccine efficacy (Figure 1.3).44 Lipid A mimetics, such as the aminoalkyl
glucosaminide phosphates, have been developed as TLR4 stimulants45 with good
adjuvant activity,46 including the potent vaccine adjuvant RC-529,47 and the bioisoster
CRX-547, which has reduced toxicity in comparison to RC-529.48 Small molecules
pyrimido[5,4- b]indoles have shown to stimulate TLR4 and could potentially be used as
adjuvants or immune modulators,49 synthetic analogues of natural product Euodenine
A have exhibited potent and selective agonism towards TLR4,50 and synthetic peptides
to mimic the TLR4/LPS interaction have also been reported.51 
8
  
 
 
   
 
  
       
         
      
           
       
          
       
   

 
1. INTRODUCTION
Figure 1.3. Chemical structures of selected TLR4 agonists.
Therapeutic Applications of TLR4 Antagonists
The design of LPS mimetics with TLR4 antagonist activity is an emerging
strategy for the treatment of sepsis,52 combined with the challenge of obtaining good
drug-like properties. Lipid IVa is an underacylated lipid A analogue with intriguing
properties, being antagonist in human TLR4 but agonist in mouse (see Table 1.1 for
references). The tetraacylated synthetic compound eritoran (or E5564, Figure 1.4) 
reached phase III in clinical trials, but failed to demonstrate sufficient efficacy in late
stage human trials, although it has recently shown promising activity in preventing
influenza induced acute lung injury, through a TLR4 antagonism mechanism.53 
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1. INTRODUCTION
Simplified derivatives without the phosphate group have also been reported,54-56 
exploring the presence of a cation. Of merit, new glycolipids and benzylammonium
lipids (for example, IAXO-102 and IAXO-103, Figure 1.4) are the first family derived
from a monosaccharide core with effective TLR4 antagonist activity.55 Other synthetic
lipid A analogues include, for example, compound D1,57 and one lipid X mimetic (Figure
1.4),58 exhibiting a TLR4 antagonist mechanism by blocking the interaction of LPSs with
both CD14 and MD-2 proteins.
Figure 1.4. Chemical structures of selected TLR4 antagonists.
10
  
 
     
     
  
    
      
      
          
          
   
 
 
     
     
      
      
     
     
    
     
   
     
   
        
  
        
   
     
     
      

 
1. INTRODUCTION
Several small non LPS-like molecules with TLR4 antagonist activity have also
been developed (Figure 1.4), such as ethyl 4-oxo-4-(oxazolidin-3-yl)-butenoate
derivatives (OSL07), benzothiazole-based inhibitors, ethyl phenyl-sulfamoyl­
cyclohexene-carboxylate derivatives (TAK-242 or resatorvid), and β-amino alcohol
derivatives.59-62 However, no successful progress was shown when reaching clinical
phases (for example, in the case of compound OSL07). Examples of non-lipid TLR4
antagonists based on dendrimer architecture can also be found in the recent
literature, showing that the presence of lipidic chains is not an absolute requirement
for an MD-2 antagonist, and thus opening interesting opportunities for immunity
modulation.63-64 
1.1.2 Reported X-Ray Structures of TLR4: Key Interactions
Scientists have elucidated the three-dimensional structure of TLRs by means of
X-ray crystallography. Presently, the 3D structure is available for TLRs 1, 2, 3, 4, and 6,
as hetero/homo-dimers, and in complex with some ligands (agonists and antagonists)
65-66 and/or co-receptors. The analysis of the ligand-receptor interactions at atomic
detail gives understanding to the signaling processes which gives rise to the design of
molecules with properties required in TLR modulators (agonist/antagonist
properties).67-68 Still, the molecular features that drive the recognition processes have
yet to be unraveled.
Regarding TLR4, to the best of our knowledge, 15 X-ray crystallographic
structures have been reported containing any of the partners forming the TLR4/MD­
2/ligand complex (Table 1.1). Deposited at the Protein Data Bank (PDB), we can find: 1)
TLR4 protein, either the nearly complete TLR4 chain (PDB-ID: 2Z63) or either fragments
of the chain (PDB-ID: 2Z62, and 2Z66); 2) MD-2 protein bound to different ligands
(PDB-ID: 2E56, and 2E59); 3) the TLR4/MD-2 complex not forming the dimeric (active)
symmetric complex, either bound to antagonist ligands (PDB-ID: 3ULA, and 2Z65), or
without any ligand (PDB-ID: 5IJB, 2Z64); and 4) the complete multimeric complex of
the active TLR4 (PDB-ID: 5IJB, 5IJD, 3FXI, 3VQ1, 3VQ2, and 4G8A) composed by two
11
  
 
    
    
       
     
 
   
 
      
     
     
 
 
 
 
 
 
 
     
 
 
 
 
 
   
 
 
 
 
 
 
 
 
  
       
       
       
       
    
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
     
 
 
 
 
 
    

 
1. INTRODUCTION
TLR4/MD-2/ligand units interacting in a symmetric manner, forming the extracellular
complex which finally triggers the TLR4 signaling pathway through the interaction of
each intracellular TIR domain belonging to the TLR4.67 Table 1.1 also contains
information about the relevant protein CD14.
Table 1.1. X-Ray crystallographic structures of TLR4 and CD14 deposited at the Protein Data
Bank. aThe structures are noted as multimer when two TLR4/MD-2 heterodimers are found in 
the structure. bNot natural complexes. cE. coli LPS. dRe-chemotype of E. coli LPS. eHuman TLR4
polymorphism D299G and T399I. fHuman TLR4 decoy. gThree units of myristic acid.
PDB-ID Organism Proteins Ligand Structurea
MD-2
Confor 
mation
Resolution
(Å)
5IJD69 
Mouse-inshore
hagfish hybrid
TLR4/MD-2 Re-LPSd Multimer Agonist 2.7
5IJC69 
Mouse-inshore
hagfish hybrid
TLR4/MD-2
Neoseptin 
-3
Multimer Agonist 2.57
5IJB69 
Mouse-inshore
hagfish hybrid
TLR4
fragment/
MD-2
None
Heterodim 
er
Agonist 2.91
3FXI67 Human TLR4/MD-2 LPSc Multimer Agonist 3.10
3VQ170 Mouse TLR4/MD-2 Lipid IVa Multimer Agonist 2.70
3VQ270 Mouse TLR4/MD-2 Re-LPSd Multimer Agonist 2.48
4G8A71 Human TLR4/MD-2e Re-LPSd Multimer Agonist 2.40
2Z6472 Mouse TLR4/MD-2 None
Heterodim 
er
Antagon 
ist
2.84
3ULA73 
Human-inshore
hagfish hybridf
TLR4
fragment/
MD-2
E55
Heterodim 
er b 
Antagon 
ist
3.60
2Z6572 
Human-inshore
hagfish hybrid
TLR4
fragment/
MD-2
E55
Heterodim 
er b 
Antagon 
ist
2.70
2Z6372 
Human-inshore
hagfish hybrid
TLR4 None Monomer N/A 2.00
2Z6272 
Human-inshore
hagfish hybrid
TLR4
fragment
None Monomer N/A 1.70
12
  
 
 
 
 
 
 
    
      
 
     
 
 
       
     
 
  
 
   
       
      
     
     
     
           
     
        
          
       
       
      
      
       
         

 
1. INTRODUCTION
2Z6672 
Human-inshore
hagfish hybrid
TLR4
fragment
None Tetramerb N/A 1.90
2E5674 Human MD-2
Myristic 
acidg
Monomer
Antagon 
ist
2.00
2E5974 Human MD-2 Lipid IVa Monomer
Antagon 
ist
2.21
1WWL75 Mouse CD14 --­ --­ --­ 2.50
4GLP76 Human CD14 --­
Amino-
terminal
pocket
--­ 4.00
Structure of TLR4
From the structural point of view TLR4 belongs to the superfamily of the LRR
proteins, which are characterized for having a typical horse-shoe-like conformation,
which contains several parallel β-strands in its concave surface and loops in its convex
surface (Figure 1.7).67 Differences between the β-strands in the concave surface allow
dividing this region in three different domains. First, the N-terminal domain, which
includes modules from 1 to 6 (Figure 1.7), and has no sequence homology with the
typical LRR modules, preventing this region to be highly hydrophobic. Second, the C-
terminal domain is formed by modules 13 to 22 (Figure 1.5). And third, the central
domain, which is built by typical LRR modules, except one variable residue which has
different residue lengths over the set of β-strands, deeply related with the horse-shoe­
like shape of this kind of proteins. The surfaces of the N-terminal and central domains
provide charge complementarity in order to bind to its co-receptor MD-2, leading to a
stable 1:1 heterodimer.68 This heterodimer dimerizes when bound to the bacterial LPS,
leading to the multimeric complex, and triggering the immune response. When bound
to an antagonist ligand, the heterodimer is not capable of dimerization.
13
  
 
 
  
  
 
 
   
     
       
       
           
        
      
      
      
     
     
 

 
1. INTRODUCTION
Figure 1.5. Multimer complex composed of two copies of heterodimers of the TLR4/MD-2/LPS 
complex arranged symmetrically (PDB-ID: 3FXI). Highlight in the box shows the N-terminal,
central, C-terminal domains of the TLR4.
Structure of MD-2
Before describing any structural attributes of these crystallographic structures,
it is worth pointing out that the main structural differences observed between the
activated and inactivated (agonist and antagonist) conformations of the TLR4/MD-2 
complex are mainly related to the twist of a small loop of MD-2, comprised of Phe126
and Leu124 (Figure 1.6).74 The twist of this small loop acts as an ON/OFF switch,
allowing the binding of the agonist (ON) or the antagonist (OFF). The formation of the
TLR4/MD-2/agonist complex builds a hydrophobic region and a dimerization interface.
This promotes the coupling of the second TLR4/MD-2/ligand partner (referred to here
as TLR4*/MD-2*). Binding of antagonists leads to changes into the characteristics of
this hydrophobic interface precluding formation of the activated TLR4/MD-2/ligand
multimer.
14
  
 
      
       
         
       
     
   
           
      
 
    
 
  
 
    
       
       
       
      
     
        
       
      
       

 
1. INTRODUCTION
The structure of the MD-2 is characterized by two antiparallel β-sheets,
containing three and six β-strands respectively/ These two β-sheets adopt a β-cup-like
fold, forming a large internal hydrophobic pocket of 1000 Å2, open to host the large
lipophilic fatty acid (FA) chains from the LPS.74 This pocket is completely built by
hydrophobic residues on the interior, and positively charged residues surrounding the
entrance, allowing the binding of the polar groups from the lipid IVa (PDB-ID: 2E59).
The formation of the disulfide bond between Cys25 and Cys51, and the hydrogen bond
between Tyr34 and Tyr36, are crucial for the stability of the MD-2 structure.
Figure 1.6. Superimposition of agonist (PDB-ID: 3FXI) and antagonist (PDB-ID: 2E59)
conformations of the human MD-2. Purple circles show main conformational change which
mainly involves the loop containing Ile124 and Phe126.
Structure of the TLR4/MD-2 Complex
The TLR4/MD-2 complex interacts through a narrow and long interface, noted
as the primary contact interface67 which is formed before the binding of LPS, and is
divided by the A and B patches belonging to the N-terminal and central domains of
TLR4 respectively (Figure 1.9). On one hand, the A patch in TLR4 is characterized by
being highly evolutionarily conserved, and negatively charged, which allows the
interaction with the positively charged Arg68 and Lys109 residues of MD-2. On the
other hand, the B patch is built by a poorly conserved area, positively charged, and
interacts with the negatively charged residues in the F β-strand of MD-2 (Figure 1.7), 
patterns can be found in both, the apo and the eritoran-bound TLR4/MD-2 complexes.
15
  
 
        
        
      
       
   
 
    
                             
 
    
     
      
     
         

 
1. INTRODUCTION
Additionally, in the TLR4/MD-2/eritoran complex, it can be observed that eritoran does
not interact directly with TLR4, while the FA chains are placed deeply inside the
hydrophobic pocket, and the two phosphate groups interact with positively charged
residues at the entrance of the pocket, not observing direct polar interactions of the
disaccharide with MD-2.72 
Figure 1.7. Two views of the dimerization and the primary interfaces of TLR4/MD-2/LPS 
complex (PDB-ID: 3FXI).
Structure of the Activated TLR4/MD-2/Agonist Multimeric Complex
Analysis of the structures of the activated multimeric complex of TLR4/MD­
2/agonist, composed of two copies of the heterodimer TLR4/MD-2/ligand arranged
symmetrically, reveals that each copy of the heterodimer interacts through the so­
called dimerization interface.67 This involves the LRR modules 15-17 of the C-terminal
16
  
 
        
       
       
    
       
      
    
       
       
      
    
        
     
    
        
   
      
       
      
       
   
        
          
        
       
       
       
      
          
       

 
1. INTRODUCTION
domain (Figures 1.5, 1.7 and 1.8), and the Phe126 and Leu87 loops that connect the G­
H and the E-F β-strands of MD-2 (Figure 1.8). Some interesting interactions that can be
highlighted are the CH-π interactions between Phe463 (TLR4*) and Leu87 side chains,
and polar interactions between Glu439 (TLR4*) and Arg90 (MD-2). Interestingly, the
Phe126 loop of MD-2 is the one related with the main conformational change
responsible with the agonist/antagonist behaviour (ON/OFF switch). One of the FA
chains from the LPS does not penetrate into the MD-2 pocket, meaning this is partially
exposed to the outer, and thus completing the hydrophobic surface of MD-2 that will
interact with TLR4*. In particular, this FA chain interacts with the hydrophobic side
chains located at the G β-strands of the MD-2, which could be responsible for
triggering the conformational change of MD-2, which in turn, promotes the
dimerization, and the final activation of the TLR4 signaling pathway. In addition to this
particular (and key) interaction, other hydrophobic interactions contribute to the final
assembly of the full multimeric complex.
MD-2 can only be found in the antagonist conformation, either bound to
antagonists (MD-2/lipid IVa, PDB-ID: 2E59, and TLR4/MD-2/Eritoran, PDB-ID: 2Z65), or
without any ligand (TLR4/MD-2, PDB-ID: 2Z64). This observation may suggest that the
conformational change of the Phe126 loop which leads to the dimerization, and to the
activation of the immune response, is promoted upon agonist binding. The MD-2
conformational change could be explained by the induced fit paradigm rather than by
the conformational selection from the MD-2 conformational landscape. This has also
been suggested by reported NMR studies on hexaacylated endotoxin bound to wild­
type and F126A mutant MD-2, which indicate that re-orientation of the aromatic side
chain of Phe126 is induced by binding of hexaacylated endotoxin, preceding
interaction with TLR4.77 Multimeric complexes are available with natural agonist
binder LPS (PDB-ID: 3FXI, human TLR4/MD-2), and with lipid IVa (PDB-ID: 3VQ1, mouse
TLR4/MD-2)/ In this way, lipid IVa acts as an “accidental” agonist or antagonist
depending on the species dual binder, able to activate the TLR4 immune response in
mice, but to block the TLR4 system in humans. As an agonist, it is able to bridge
between the two phosphate binding sites of the two TLR4/MD-2 units. As a "flipped"
17
  
 
     
              
     
     
 
   
   
 
 
   
           
       
        
       
     
       
     
       

 
1. INTRODUCTION
antagonist (the glucosamine backbone is in opposite orientation than LPS) it is buried 
more deeply into the cavity of MD-2 (4-5 Å) and thus can only connect to one
phosphate binding site. Eritoran is not able to bridge between the two TLR4/MD-2 
subunits of any of the analyzed species.
Figure 1.8. Multimer complex composed of two copies of heterodimers of the TLR4/MD-2/LPS 
complex organized symmetrically (PDB-ID: 3FXI).Box at the bottom shows the standard naming
for each β-strand of MD-2.
Structure of CD14
CD14 acts as a co-receptor for the detection of LPS, and can bind LPS only in the
presence of the lipopolysaccharide-binding protein (LBP). Human (hCD14) and mouse
(mCD14) CD14 are characterized by a bent solenoid typical of leucine-rich repeat (LRR)
proteins, with a large hydrophobic pocket found on the amino-terminal side (PDB-ID:
4GLP for hCD14, and 1WWL for mCD14). Similarly to MD-2, CD14 is also characterized
by having a wide lipophilic pocket, but with fewer number of polar residues at the rim,
and it is capable of recognizing other microbial and cellular molecular determinants, in
addition to LPS, such as lipopeptides which are the PAMP recognized by TLR2. 
18
  
 
 
     
  
  
 
      
     
       
       
      
  
 
     
        
       
         
            
                
              
             
          
       
      

 
1. INTRODUCTION
Figure 1.9. 3D structure of the amino-terminal pocket of human CD14 (PDB-ID: 4GLP). On the 
left, hCD14 in cartoon style. On the right, view in surface; highlight in grey the similar binding
pocket in comparison with MD-2 pocket.
1.2 Reported Molecular Modeling Studies of the TLR4/MD-2 System
As a result of the increasing development in computing technology,78 research
to date has allowed the exploration of the dynamics of these high size TLR4/MD-2 
system by means of MD simulations, and also binding properties of reported
TLR4/MD-2 modulators. A recent review by our group has summarized these studies.
We here give a brief overview, as follows.79 
1.2.1 Computational Studies of the TLR4/MD-2 Ectodomain
There are several reported MD simulation studies focused on the extracellular
domain of the TLR4/MD-2 complex, more specifically on its ability to recognize lipid A
and lipid IVa. Garate et al.80 reported several MD simulations of different TLR4/MD­
2/ligand complexes, concluding in to highlight the hydrophobicity of the MD-2 pocket
and its ability to close promptly in an aqueous environment, due to the flexibility of the
helix connecting MD-2 with TLR4 (helix H1). MD-2 was observed to fluctuate less due to
the presence of TLR4, reducing the number of degrees of freedom. Another interesting
conclusion is the key role that charged phosphates play in the early recognition of lipids
with the corresponding impact on the formation of heterotetramers. Plasticity of MD-2 
has also been observed by DeMarco et al. after several MD simulations performed in
19
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complex with variably-acylated lipid A molecules from Escherichia coli and Neisseria
meningitides, concluding that the level of acylation of these ligands greatly influences
the final architecture of the dimerization interface,81 and the final agonist/antagonist
conformation of the TLR4/MD-2 system. This agonist/antagonist transition has also
been studied by MD simulation by Paramo et al.82 finding that the opening of the
Phe126 switch disrupts the arrangement of nearby side chains from Leu87, Val82 and
Met85 of MD-2, in agreement with NMR studies.77 
The TLR4 ectodomain and its dimerization mechanism have also been subjected
to computational studies. MD simulations of the TLR4/MD-2/TLR4*/MD-2* comlex by
de Aguiar et al. 83 revealed pronounced conformation and structure alterations in the N­
and C-terminal domains of the TLR4 ectodomains, while MD-2 underwent structural
rearrangements and interacted with TLR4 and partner TLR4*, reinforcing the stabilizing
role of MD-2 for the TLR4 complexation. In a related work, Anwar et al. performed
interesting computational studies of the TLR4 signaling mechanism by studying the
species-specific behavior of TLR4/MD-2 in the recognition of Rhodobacter sphaeroides
lipid A (RsLA): human, murine, horse and hamster TLR4/MD-2 systems.84 The data
suggested a relationship between the flexibility of two loops (the on/off switch Phe126
loop of MD-2, from residues 123–129, and the MD-2 loop containing residues 81–89,
which are the residues interacting with the partner TLR4*), and the agonist/antagonist
activity of the ligand, thus providing a plausible explanation for the species-specific
behavior of RsLA regarding TLR4 activation.
20
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Figure 1.10. Lipid A and synthetic lipid A analogues with activity as TLR4 modulators. Activity is 
referred to hTMR4/MD-2.
Computational Strategies to Study Mutant TLR4 and MD-2 Proteins
Herein, we report three studies that used in silico-mutated TLR4/MD-2 systems
to serve different purposes; namely, to transform the mouse complex interface into
the human one by mutating the residues laying there into their human counterparts,
to estimate the influence of the mutations on the binding affinity of a ligand and to
21
  
 
      
 
              
              
       
     
         
    
       
     
        
      
          
               
            
            
             
          
       
 
        
        
            
         
       
           
      
             
   
     

 
1. INTRODUCTION
evaluate the impact of mutations on the structural shape and plasticity of the MD-2 
binding pocket.
In a 2009 study, Slivka et al.85 used Rosetta software86 to compare the binding
energy of a truncated MD-2 with the original one. MD-2 was truncated (termed MD-2-I)
to keep only the residues identified as playing a major role in maintaining the
TLR4/MD-2 heterodimer stability. The docking experiment was performed targeting
both a partial human TLR4 retrieved from the Protein Data Bank (PDB-ID: 2Z65) and a
full-length TLR4 humanized model built by mutating the residues at the TLR4/MD-2 
heterodimer interface in the mouse crystal structure (PDB-ID: 2Z64) into their human
counterparts (TLR4: F160L, G234N, K263R, D264N, T290A; MD-2: H96R, H98R). In the
first case, the affinity of MD-2-I was found higher than the one of the full-length MD-2.
When docked against the human TLR4 model, MD-2-I exhibited a lower affinity than
the full length MD-2. Altogether, these results indicate that MD-2-I is theoretically able
to bind TLR4 and might even compete with the full-length MD-2. This was confirmed by
cell assay experiments showing that the addition of compound MD-2-I abolishes their
responsiveness to LPS stimulation. Flow cytometry analyses on cells (HEK293 cell line,
transfected with all proteins involved in the TLR4 activation pathway) incubated with LPS
covalently linked to fluorescein isothiocyanate (LPS-FITC), suggest that MD-2-I impedes
TLR4/MD-2 dimerization. The SEAP assay shows that MD-2-I also alters downstream
signaling.
A 4-aminoarabinose-containing lipid A from the opportunistic bacterium
Burkholderia cenocepacia (Figure 1.10) and its aminoarabinose-deficient equivalent
were docked to hMD-2 and mMD-2.87 These docked models were used to build a full
dimer complex in order to perform 0.1-ps MD simulations. In both the human and the
murine systems, the wild-type (WT) LPS obtained a better predicted free energy of
binding than the aminoarabinose-deprived one, with both the AutoDock88 and AutoDock
VINA89 docking programs. An energy analysis was conducted to estimate the per
residue contribution to the total ligand binding energy for both WT and mutated
TLR4/MD-2/TLR4*/MD-2* complexes (D294A, R322A, S415A* and S416A*) using the
MM-ISMSA method.90 This study permitted the identification of the mutated residues
22
  
 
       
     
  
     
       
        
      
       
     
          
    
         
        
              
            
     
        
       
  
 
        
   
     
     
     
    
    
    
    

 
1. INTRODUCTION
as major contributors to the total binding energy of B. cenocepacia LPS and suggested
that the ammonium groups of Ara4N stabilize the complex by providing additional
anchorage interactions.
Recently, the critical role of residue 135 of MD-2, located deeply inside the
hydrophobic pocket, was reported by Vasl et al.91. hMD-2 has the ability to bind LPS in
the absence of TLR4, while mMD-2 is responsive to LPS only when engaged in a
complex with TLR4. Site-directed mutagenesis was used on hMD-2, to mutate Val135
to its murine alanine counterpart. This single point mutation led to a mutant V135A
hMD-2 lacking the ability of binding LPS. A series of MD simulations of the WT MD-2 
and the V135A mutant MD-2 in solution and in complex with TLR4 was performed to
study the conformational changes. In the case of the WT hMD-2, the authors reported
an abrupt decreased of the SASA and volume in the first nanoseconds of the
simulation, describing it as a hydrophobic collapse. This phenomenon was not observed
in the V135A systems, suggesting that Val135 is primordial to confer plasticity to MD-2.
This tendency was confirmed by another simulation of MD-2 in complex with three
myristic acids (as observed in some crystal structures). The V135A mutant hMD-2 
needed a much longer simulation time to adapt its shape to the three myristic acids
than the wild-type. The authors concluded that this loss of plasticity could incapacitate
hMD-2 for binding LPS.91 
1.2.2 Computational Studies on the Intracellular Domain of TLR4
The intracellular domain of the TLR4 transmembrane protein contains a 
Toll/interleukin-1 receptor homology domain, which is a common feature of all
adaptors involved in the initiation of TLR4 signaling, mediating protein-protein
interactions between the TLR4 and the signal transduction components. TLR4 has two
distinguished signaling pathways involving primarily four TIR-domain-containing
adaptors. In the first pathway, the MyD88 adapter-like (Mal) acts as a “sorting”
adaptor by recruiting the myeloid differentiation primary response gene 88 (MyD88),
the “signaling” adaptor, to the plasma membrane/ In the second pathway, the TRIF­
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1. INTRODUCTION
related adaptor molecule (TR!M) plays the role of “sorting” adaptor, which recruits
the TIR-domain-containing adapter-inducing interferon-β (TRIF), the “signaling”
adaptor, to the membrane to initiate the signal. As a major component of theses
adaptors, the TIR domain is believed to play a central role in the recruitment
24, 92 processes. 
The crystal structures of human TLR1 (PDB-ID: 1FYV) and TLR2 (PDB-ID: 1FYW)
revealed the structural basis of the TIR domain93 followed by the crystal structure of
TLR10 TIR domain (PDB-ID: 2J67)94 and the solution structure of MyD88 TIR domain
resolved by NMR (PDB-ID: 2JS7 and 2Z5V).95 Prior to that release, two homology
models of the TIR domain of MyD88 were reported. Both were built based on the TLR2
TIR domain crystal structure (PDB-ID: 1FYW) resolved by X-ray crystallography.96-97 In
2012, the crystal structure of Mal was also resolved by X-ray crystallography (PDB-ID:
3UB2).98 
The lack of structural information for the TIR domain of TLR4 has driven the
creation of models to clarify the recruitment of adaptors from a structural perspective.
Dunne et al.99 built monomer models of TLR4, Mal and MyD88 using comparative
modeling and loop refining techniques. They noted differences in the electrostatic
surface potentials suggesting that adaptor binding is driven by electrostatic
complementarity. This point was also emphasized in a study by Kubarenko et al.100 in
which they compared the surface charges of TIR domains of the crystal structure of
hTLR2 and of the models of hTLR3 and hTLR4 and noted that the surface charge
distribution of the BB loop and the αC-helix (Figure 1.11) present similarities in TLR2
and TLR4 and differ between TLR3 and TLR4. The authors considered that these
findings could explain why TLR2 and TLR4 recruit MyD88, whereas TLR3 does not. In
the computational study by Gong et al.101, it was highlighted that, whereas the BB-loop
is highly conserved among TIR-domains, the APBS electrostatic surfaces differ. The
authors hypothesized that this finding might explain the specificity and selectivity of
adaptors recruitment. An experimental study showed that a single point mutation in
the TIR domain of murine TLR4 (P712H) renders the system hyporesponsive to LPS
24
  
 
       
 
 
 
        
 
 
        
           
     
            
    
      
           
         
       
        
        
       
           
       
           
           

 

 

 
1. INTRODUCTION
stimulation. The authors noted that their data do not suggest a direct role for this
residue.
Figure 1.11. Intracellular TIR domain of TLR4. Left: 3D representation of homology model.
Right: FASTA sequence.
al.99Dunne et used a docking procedure based on hydrophobicity and
geometry. Their results suggest that Mal and MyD88 bind at two distinct binding sites
(non-overlapping): the DD- and DE-loops of Mal forming interactions with the BB-loop
and αC helix of TLR4-TIR domain and the AA- and DD-loop of MyD88 with the CD-loop
of TLR4 (Figure 1.11). The biological relevance of this binding mode was later
questioned, as it was discovered that TLR4 activation required homodimerization. In
line with that, in 2007, Miguel et al.102 reported the first 3D model of the dimer of the
TIR domain of TLR4; a dimer composed of two identical subunits, arranged in a two­
fold axis of symmetry (Figure 1.12a). Despite the observation that some loops are
differently oriented, the overall monomeric fold and the secondary structure of each
subunit are very similar to the monomer model reviewed above.99 This dimer model
outlines significant interactions between the BB-loops of each monomer. A flat, but
slightly curved surface was observed and attributed to the side facing the membrane.
The authors also reported a docking study of TRAM and Mal with the TLR4 dimeric
model in which the two adaptors bind at either sides of the dimer interface formed by
the union of the two TLR4-TIR domains, which are identical due to the symmetry. The
25
  
 
        
        
   
       
    
         
       
        
  
       
      
     
       
      
      
 
   
 
 
 
   
 
 
 

 







 

 
1. INTRODUCTION
residues of the adaptors found at the TLR4 interface are mostly located on the BB-loop
suggesting that the BB-loop of all three TIR-containing structures is of critical
importance for binding specificity and selectivity.
al.101Gong et performed a docking study based on the geometry,
hydrophobicity and electrostatic complementarity of the molecular surface reporting a
dimeric model different from the model described above (Figure 1.12b). In another
study, Basith et al.,103 used in silico approaches (homology modeling, protein-protein
docking and MD simulations) to investigate the inhibitory effect of ST2L toward TLR4
activation. ST2L (IL-33r) is a member of the Toll-like/IL-1 receptor superfamily known
to negatively regulate MyD88-dependant signaling pathway. The authors reported a
TLR4-TLR4 homodimer model102 (Figure 1.12a), and their docking study also gave a
similar binding mode for Mal (at each side of the dimer). Their results indicate that
MyD88 is recruited by Mal, and that ST2L prevents the recruitment of MyD88 by
binding at the Mal interface. Thus, according to these results, ST2L successfully
competes with MyD88 to bind at the Mal interface.
Figure 1.12. Representation of the different ways the dimer is proposed by published
computational strategies to be assembled in the literature by computational strategies. 
(a) First reported by 
Miguel et al.102 ; (b) reported by Gong et al.101, (c–e) reported by Guven-Maiorov et al.104. The 
monomer has been built by homology modeling, and the secondary structure representation
has been altered to resemble the other models. The dimers have been assembled manually, 
fitting as best as possible the schemes present in each paper, to provide an overview of the 
variety of binding poses reported so far. The dimmers shown do not have the pretention of 
being as precise as those shown in the original papers and should be considered schematic.
26
  
 
        
        
      
        
       
       
          
   
     
         
         
    
    
        
  
        
         
      
     
      
       
      
   
     
     
         
     
        
       
       

 
1. INTRODUCTION
In a later study, Bovijn et al.105 reported a homology model constructed based
on the crystal structure of the dimeric TLR10 TIR domain. This model is also in
agreement with the first model reported by Miguel et al.102. The authors proposed that
Mal and TRAM adaptors are competing for binding an extended site formed by the
reunion of two TLR4 intracellular domains. An experimental mutation study showed
that all mutations that impaired Mal binding also impaired TRAM binding,
strengthening the idea that Mal and TRAM bind to the same molecular surface. They
define the TLR4/TLR4* dimer interface as binding site II, composed of residues from
the BB-loop, DD-loop and αC (Figure 1.11). Then, they describe that the binding site for
TRAM and Mal is formed by the reunion of two site I (as defined in the study: residues
from α! αB BB and BC), which is in disagreement with the binding site proposed by
Miguel et al.102. The authors thus argue that their model is supported by experimental
data and residue conservation analysis. The binding site III is defined as being located
at the opposite direction of binding site I and might be implicated in the interferon
regulatory factor 3 (IRF-3) activation.
Singh et al.106 studied the importance of the highly conserved β-sheets among
TLRs’ TIR domain and revealed their primordial implications in the communication
network. MD simulations of 100 ns of models based on sequence similarity were
performed// They reported interactions between the backbone atoms of the first β­
sheet with the BB-loop and the third β-sheet. The authors identified four interacting 
hubs mainly constituted of hydrophobic residues/ !mong them, three are in the β­
sheets just before the BB-loop, the αC helix and the DD-loops, stressing their role in
TIR/TIR interaction. This hypothesis was further supported by analyzing the mutations
known to completely abrogate signaling. They show that mutantsIFI767-769AAA and
L815A disturb the interacting network, thus explaining the impaired TIR domain
homodimerization capacity. In a very recent paper by Guven-Maiorov et al.,104 the
authors used computational techniques to describe the architecture of the
signalosome of TLR4. They built three models of the intracellular part of the TLR4
protein (Figure 1.12c–e). These three dimer models are all unprecedented despite that
the secondary structure of the monomer is in great agreement with all of the
27
  
 
      
    
 
      
      
       
        
     
      
     
 
  
      
      
          
                
             
             
         
              
           
          
    
          
                    
         
       
       
 

 
1. INTRODUCTION
published models. Furthermore, the authors used two of their models (Figure 1.12c,d) 
to propose different binding modes for Mal.
1.2.3 Binding Mode of TLR4 Modulators
Several computational studies have been performed in order to clarify the
binding mode of TLR4/MD-2 agonist and antagonist ligands. The unveiling of the
molecular recognition process at atomic detail is one of the major challenges in
TLR4/MD-2 modulation. Molecular modeling, docking studies and MD simulations
have already provided relevant contributions about the ligand/receptor interactions
with promising impact for rational drug design.79 
Synthetic LPS mimetics
Inspired by the LPS structure, different ligands have been designed and
synthesized. One of the first compounds to enter into clinical trials was Eritoran, a
synthetic lipid A mimetic, potent TLR4 antagonist, which reached phase III clinical trials
as an antisepsis agent, but failed since the study did not meet its primary endpoint of
reduction in 28-day all-cause mortality in patients with severe sepsis.107 Eritoran is a
tetraacylated lipid A, the structural analogue of lipid A from RsLA, antagonist of human
TLR4 and agonist of TLR4 from mouse and horse. In order to analyze the species­
dependent activity of Eritoran, Scior et al.108 built homology models by means of the
SCWRL4 program.109 Afterwards, docking of Eritoran was performed with AutoDock in
order to determine the characteristics of the agonist/antagonist binding in the TLR4
structures from different species: human, mouse and horse. Some key amino acids
were identified as relevant in species-specific binding: Lys58 (that corresponds to Asn
in mouse and to Glu in horse), Lys388 (which is a Ser in mouse and a Lys in horse) and
Gln436 (which is an Arg in mouse and a Gln in horse). The different pattern of
interactions that are presented by these different residues impairs the TLR4-TLR4*
bridging role of the ligand, thus preventing the effective dimerization and the agonist
activity.
28
  
 
      
      
            
           
             
         
          
         
       
         
         
       
    
     
     
      
        
      
        
     
      
       
     
     
   
      
         
     
               
              
               

 
1. INTRODUCTION
Modifications of the chemical structure of the lipid A scaffold have served as a 
starting point for the design of novel TLR4 modulators. One modification reported by
Cighetti et al.58 was the diphosphorylation of the scaffold of lipid X (Figure 1.10), a
biosynthetic precursor of lipid A, leading to Compound 1 (Figure 1.13), which has been
found to be an antagonist in both human and mouse TLR4/MD-2. This compound was
also shown to stimulate CD14 internalization in bone-marrow-derived murine
macrophages, thus demonstrating targeting of also CD14 in a TLR4-independent
manner. In order to propose 3D models for the ligand recognition processes,
computational studies were undertaken on both CD14 and MD-2 proteins. Docking
calculations in MD-2 with AutoDock and AutoDock VINA,89 followed by MD simulations
of the resulting complexes with the Impact program,110 led to the identification of two
possible binding poses: the most stable one (in terms of predicted binding energy)
allocated both FA chains inside the MD-2 binding pocket, mimicking the lipid IVa
binding to MD-2 in the crystal structure (PDB-ID: 2E59). The MD-2/Compound 1
complex is stabilized by hydrophobic interactions between its two FA chains and
aliphatic and aromatic residues from the MD-2 pocket together with polar interactions
at the rim of MD-2, involving mainly the phosphate groups and side chains from
Ser118 and Arg96 residues and, in some cases, interactions between the amide CO or 
ester CO groups from Compound 3 and the Ser120 OH group. This result was in
agreement with NMR experiments performed by the authors that clearly showed FA
chain-protein interactions. In a few cases, calculations predicted a second docked
binding pose for Compound 1 presenting only one FA chain inside the MD-2 
hydrophobic pocket, while the second FA chain was lying over Ile124. Interestingly, in
the agonist conformation, this residue has moved towards the inside of MD-2 and
Phe126 occupies its place. This synchronism allows the agonist/antagonist switch. In
the bound/unbound equilibrium, this alternative binding pose could co-exist with the
first and most stable one. Cighetti et al.58 also combined docking and MD simulations
to propose a binding mode for Compound 1 with CD14. CD14 is also characterized by
having a wide lipophilic pocket, but with fewer polar residues at the rim. Compound 1
was predicted to bind with the saccharide moiety and the phosphate groups at the
entrance of the CD14 hydrophobic cavity and with the FA chains inside the pocket, in
29
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agreement with the CD14 binding properties observed experimentally. In addition to its
properties to prevent TLR4 signaling, Compound 1 has also been proposed as a
promising hit as TLR4 modulator because of its favorable solubility properties and for
its lack of toxicity according to the MTT tests.
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Figure 1.13. Synthetic LPS mimetics studied by computational approaches.
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Another strategy to mimic lipid A was the design of tetraacylated lipid A
mimetics based on the βGlcN (1↔1) αGlcN scaffold analogue by substituting the
β(1→6) with βα(1↔1) glycosidic linkage in order to confer rigidity to the molecule.111 
In particular, Compound DA193 (Figure 1.13) resulted in being a dose-dependent
antagonist in human and mouse, according to assays performed in HEK293 cells
transiently transfected with membrane CD14 (mCD14)/hMD-2TLR4, HEK293 cells
transfected with hMD-2TLR4 only and assays on human macrophage-like cell line (THP­
1). In order to propose an atomistic understanding of the interactions between the
ligand and the receptor, MD simulations of 11 ns were performed starting from two
possible binding orientations of the ligand into the MD-2 protein. one with the α-GlcN
ring facing the Phe126 loop and the second one with the β-GlcN facing the Phe126
loop with an energy difference similar to that found for orientations of lipid A in the
binding site of hMD-2. Dissociation constants, calculated from MD simulations of the
MD-2/DA193 complex, estimated a binding to MD-2 20-fold stronger than lipid A and
three-fold more than lipid IVa. It was concluded that the conformational rigidity of the
βα(1↔1) diglucosamine backbone of these tetraacylated lipid A mimetics ensures
strong binding to MD-2, in two possible binding poses, unlike the native lipid A
structures.
The commercial TLR4 antagonist IAXO-102 (Figure 1.13)112 has also served as
inspiration for the rational design of TLR4 modulators and probes. The cationic glycolipid
IAXO-102, a potent TLR4 antagonist targeting both MD-2 and CD14 co-receptors, has
been used as scaffold to design new potential TLR4 modulators and fluorescent labels
for the TLR4 receptor complex (membrane TLR4/MD-2 dimer and CD14). The primary
amino group of IAXO-102, not involved in direct interaction with MD-2 and CD14
receptors, has been exploited to covalently attach a fluorescein (Compound 4 and 5) or
to link two molecules of IAXO-102 through diamine and diammonium spacers,
obtaining ‘dimeric’ Compound 2 and 3 (Figure 1.13). The structure-based rational
design of compounds 2-4 was guided by the optimization of MD-2 and CD14 binding.
Compounds 4 and 5 inhibited TLR4 activation, in a concentration-dependent manner,
and signaling in HEK-Blue TLR4 cells. The fluorescent labeling of murine macrophages
32
  
 
        
       
      
 
    
     
               
            
                
            
           
           
             
        
       
        
       
        
       
       
       
       
        
        
     
         
      
        
         

 
1. INTRODUCTION
by compound 4 was inhibited by LPS and was also abrogated when cell surface
proteins were digested by trypsin, thus suggesting an interaction of fluorescent probe
4 with membrane proteins of the TLR4 receptor system (See Chapter 4).
Computational studies of natural LPSs
Rhodobacter sphaeroides lipid A (RsLA, Figure 1.10)84 has five acyl chains, with
one unsaturated and two shorter chains than Escherichia coli lipid A. It is an antagonist in
human and mouse, but an agonist in horse, although, intriguingly, the horse TLR4/MD-2 
sequence is more closely related to the human sequence than to the mouse one. To clarify
the species-specific response, a computational-aided study of the three 3D structures was
undertaken. A homology model was built for horse and hamster TLR4/MD-2, with
human and murine X-ray crystallographic structures as templates (PDB-ID: 3FXI and
2Z64) by means of MODELLER.113 The role of Arg385 had been proven in horse TLR4
complex activation by lipid IVa114 through polar interactions between the guanidinium
moiety and the phosphate group of lipid IVa. In fact, in other species, this residue is
substituted by glycine in human and hamster and by an alanine in murine. The docked
structure with AutoDock VINA of the horse TLR4/MD-2/RsLa complex closely
resembled the pose of lipid IVa in murine crystal structure of TLR4/MD-2. On the
contrary, the docked binding pose found in the hamster MD-2 was similar to the lipid
IVa pose in the crystal structure from chicken (PDB-ID: 3MU3) and human. The
difference between the species was mainly attributed to the different characteristic of
each protein. By docking studies on hMD-2 with AutoDock, it has been observed that
the longest chain of RsLPS could be accommodated in MD-2 by folding the chains itself
as has been observed with the Eritoran fatty acid chains. The polar head
(diglucosamine) is always exposed to the solvent.
Molecular modeling by Irvine et al. has also showed that the different
human/horse TLR4 responses towards RsLA is related to two different amino acids,
Gly384 and Ser441, in human TLR4 (Arg385 and Pro442 in horse).115 Residue Arg385 in
horse TLR4, although located around a 9 Å distance from the docked RsLA, could
33
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establish a long-range electrostatic interaction with a phosphate group of RsLA, while 
the Pro442 is situated near the dimerization interface with TLR4* and interacts with an
FA chain of RsLA by van der Waals interactions. This hypothesis was confirmed by 
experimental assays with transfected HEK293 cells with G384R/S441P hTLR4 with
eqMD-2 and R385G/P442S eqTLR4 with hMD-2. It was observed that the R385G/P442S
mutations in horse caused a complete loss of activity, and in human, the double mutant
G384R/P441S TLR4 was unable to activate the signaling event. Since the double
mutation did not revert the activity, other residues must be required. The docking of
RsLA in human TLR4/MD-2 shares some similarity with the Eritoran crystal structure,
such as the folding of the longest acyl chain and the polar interaction with charged
residues of MD-2. RsLPS can adopt two orientations depending on the position of 1-PO4 
(oriented towards primary TLR4 in the case of horse and towards partner TLR4* in the
case of human). This fact leads to different contacts between acyl chains of RsLPS and
the hydrophobic pocket of MD-2. Moreover, superimposition of docked RsLA with X-ray
crystallography poses of lipid A and lipid IVa showed that RsLA and lipid A acyl chains 
occupy more volume than lipid Iva, an, more importantly, the R2 chain of RsLA and lipid
A protrudes from MD-2 and establishes interactions with the partner TLR4 in contrast to
the R2 chain of lipid IVa, which is folded into the MD-2 pocket.
As mentioned above, the severe pathogen B. cenocepacia LPS has been reported
by Di Lorenzo et al. to strongly activate human TLR4/MD-2, despite the fact that its lipid A
has only five acyl chains.90 The Ara4N residues in lipid A have been shown to contribute to
TLR4-lipid A interactions, and experiments in a mouse model of LPS-induced endotoxic
shock confirmed the proinflammatory potential of B. cenocepacia penta-acylated lipid A.
A combination of docking calculations and MD simulations, together with experimental
mutagenesis of the TLR4/MD-2 interacting surfaces, suggested that the longer acyl
chains allow reaching deeper regions inside the MD-2 pocket, thus compensating the
absence of one FA chain and, at the same time, allowing the exposure of the fifth FA
chain on the surface of MD-2. This enables interactions with partner TLR4* and
promotes its dimerization. The replacement of Val82 by Phe enhanced the
inflammatory response, and it was related to the changes of van der Waals
34
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interactions into stronger CH–π interactions with the F! chain, longer than the
corresponding one on E. coli LPS. Interestingly, the presence of the positively-charged
ammonium groups in the Ara4N seems to favor the electrostatic interactions and,
consequently, the binding, whereas uncharged amino acids are critical for responses to
Bordetella pertussis lipid A, for example.116 As described in Section 1.2.1, this model for
the TLR4/MD-2/LPSBC complex was used to generate a computational mutant
TLR4/MD-2/LPSBC complex (D294A, R322A, S415A* and S416A*), which was submitted
to MD simulations and energy analysis for quantification of the per residue
contributions to the final binding energy.87 Altogether, these results provided a molecular
model for the activation of the human TLR4/MD-2 complex by penta-acylated lipid A,
which sheds some light onto the comprehension of the molecular recognition of LPS by
TLR4/MD-2.
Computational Studies of Non LPS-Like TLR4 Modulators
The species-specific discrimination of TLR4 ligands by MD-2 is exemplified by
taxanes, in particular paclitaxel (PTX; Figure 1.14), a proinflammatory murine
­TLR4/MD-2 ligand, which activates the subsequent inflammatory cytokine response.117
119 Zimmer et al. demonstrated with different experiments that the activation of TLR4
by PTX requires the mMD-2 protein, being independent from TLR4 species.120 This
requirement is due to the electrostatic potential surfaces, hydrophobicity, binding pocket
size and the conformational gating of the 123–130 amino acids loop. hMD-2 and mMD-2 
have a very large cavity volume that in principle allows lipid IVa, PTX and Eritoran to fit
inside. The computational study identified the key PTX/protein interactions
responsible of the differences in the mouse/human TLR4/MD-2 binding mode and of
the subsequent different agonist/antagonist behaviour. In the best predicted MD­
2/PTX binding poses, the benzamido group of PTX is very close to Phe126, suggesting
that a π-stacking interaction may exist between both aromatic groups. Also, the Lys125
side chain establishes a hydrophobic contact with the phenyl ring, and the phenyl
group of PTX establishes a cation-π interaction with the Lys122 side chain, which is the
only different amino acid in the MD-2 species-conserved sequence Phe119–Gly123. In
35
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hMD-2, the multiple interactions attract the Gly123–Lys130 loop to form a concave 
surface facing the docked PTX. The same loop in the mouse protein is oriented in the
reverse direction. The presence of a Glu122 instead of the Lys122 in mMD-2 leads to a
completely different binding pose, possibly due to the absence of the cation-π 
interaction.120 Other work by Resmana et al.119 proposed a similar binding mode for
paclitaxel and the analogue docetaxel, on the basis of docking performed with
AutoDock in hMD-2 (PDB-ID: 2E59). Also in this case, the most favorable docked
binding poses of both taxanes oriented the benzoyl group towards the nearby region
formed by Ile61, Phe76, Leu78, Phe119 and Phe151 of hMD-2.
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Figure 1.14. Non-LPS-like TLR4/MD-2 modulators studied by computational approaches.
A docked binding mode for a prenylated chalcone-type (xanthohumol; Figure 1.14) 
into the antagonist conformation of hMD-2 (PDB-ID: 2E59) has been proposed by Fu et
al.121. The results highlighted the importance of the H-bonds between the OH groups
present in the xanthohumol and residues Tyr102 and Arg90. Moreover, another H­
bond between the OH of the phenolic group and Glu92 was identified from the
docking studies, but this interaction was rapidly broken during the subsequent MD
37
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simulation (50 ns), leading to a final MD-2/xanthohumol complex stabilized by the
above-mentioned interactions. An analogue behavior was found for curcumin (Figure
1.14) after docking with AutoDock also in the same crystal structure of hMD-2 (PDB-ID:
2E59). The hMD-2/curcumin complex resulting from the docking was subjected to MD
simulations leading to a stable complex with equivalent interactions with Tyr102 and
Arg90. Accordingly, experimental studies with MD-2 mutants (MD-2R90A/Y102A) have
pointed to a direct binding of curcumin to MD-2 in the same binding site as LPS. This
ligand would occupy a large part of the hydrophobic pocket and form H-bonds with
residues Arg90 and Tyr102. Analogously, the H-bond with Gly92 was broken during the
simulation. In addition, MD simulations have revealed that the presence of the ligand
stabilizes the complex. In particular, MD simulations of the apo-state and bound state
of MD-2 have shown that, in the case of the apo-state, MD-2 suffers an important
conformational change, reducing the volume of the cavity entrance, in agreement with
other similar MD simulations performed on the apo MD-2, whereas the bound MD-282,
91 shows good stability.122 
Cell-based high throughput screening (HTS) allowed the identification of novel
chemical entities as potent NFκB activators as selective TLR4 ligands: substituted
pyramid[5-4-b]indole derivatives49 and 4-amino-quinazolines.123 From the former family, 
one hit compound was selected (Figure 1.14; R1 = phenyl, R2 = cyclohexyl, R3 = H). A
series of pyrimido[5,4-b]indole rings with carboxamides substituted with various alkyl,
cycloalkyl, aromatic and heteroaromatic groups was synthesized and biologically tested
in order to establish the SAR. One of the most active compounds (Figure 1.14; R1 = 
phenyl, R2 = 3,3-dimethylbutyl, R3 = H) was docked in the mouse TLR4/MD-2 system. The
ligand was predicted to bind within the LPS-binding pocket. forming H-bonds and
multiple hydrophobic interactions. This computational study supported that active
compounds appeared to bind primarily to MD-2 in the TLR4/MD-2 complex.
From the second HTS, one 4-amino-quinazoline (Figure 1.14; R = COOEt, X = H)
was identified with selective agonist activity for human TLR4/MD-2 rather than
mouse. 123. Moreover, the results from the computational study underlined the
importance of the Lys122, which happens to be a glutamic acid in mouse. This could
38
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produce an electrostatic repulsion effect with the nitro group, thus justifying the 
decreased activity in mTLR4/MD-2.123 Several analogues were synthesized to establish
the basis for SAR, confirming the relevant role of the nitro group for the TLR binding
and guiding further optimization of the lead compound.
It was shown by liquid chromatography-mass spectrometry analysis that the
compound termed sulforaphane (SFN; Figure 1.14) forms a covalent bond with the
residue Cys133 of hMD-2. Covalent docking methods were applied in an attempt to
explain the propensity of SFN to impair LPS engagement with the MD-2 hydrophobic
pocket. The authors proposed a model in which SFN, once covalently linked to Cys133,
occupies the same position as the R3” lipid chain of LPS (PDB-ID: 3FXI) and XA2 lipid
chain of lipid IVa (PDB-ID: 2E59). This model suggests that SFN sterically prevents other
LPS/lipid A from approaching or settling inside the pocket.124 The same mechanism was
reported for the caffeic acid phenethyl ester compound, using only experimental
methods.125 
A series of compounds built by functionalizing pyrazole rings was reported by
al.126Bevan et to inhibit TLR4 activation. Experimental studies indicated that two
compounds (Compounds 6 and 7; Figure 1.14) were the lead inhibitors. The results
indicate that both compounds independently bind at the surface of TLR4 where a
protruding loop of MD-2 is normally found in the crystal structure. These predicted
binding modes suggest that these compounds compete with MD-2 for binding TLR4,
thus preventing or impairing the formation of the TLR4/MD-2 complex, resulting in a
TLR4 able to carry out its innate immunity role.
Polyphenol procyanidin B1 (Figure 1.14) has been shown to be able to regulate
innate and adaptive immunity by, inter alia, impairing LPS-induced inflammatory
responses in human monocytes.127-129 In order to explain its mode of action at atomic
level, the authors undertook experimental and docking studies.130 They noted a high
degree of similarity in terms of the interactions found in the predicted binding pose
with the TLR4/MD-2 system when compared to the interactions established by LPS
with TLR4/MD-2 in the crystal structure (PDB-ID: 3FXI).
39
  
 
     
      
      
     
           
       
     
       
       
       
      
      
         
         
        
         
  
      
    
      
    
       
       
       
 
     
           
        
       

 
1. INTRODUCTION
Computational Studies of Fullerenes, Nanotubes and Dendrimers as TLR4 Ligands
Large molecules have also been subjected to computational studies to unveil
their mechanism of action as TLR4/MD-2 binders. Among them, we found interesting
examples, such as fullerenes, carbon nanotubes (CNT) and dendrimers. Several studies
have indicated a strong impact of carbon nanostructures on the immune system by
inducing pro-inflammatory activity through their recognition as pathogens by the
TLRs.131-132 Turabekova et al. have undertaken a theoretical study to analyze 5,5­
armchair SWCNT and C60 fullerene (Figure 1.14) interactions with the available X-ray
structures of TLRs homo- and hetero-dimer extracellular domains.133 The authors have
searched possible binding sites able to host such nanostructures by identifying the
most favorable pockets in terms of hydrophilicity/hydrophobicity and size. In the case
of TLR4, the MD-2 binding pocket was detected as the possible binding site. The
nanostructures were docked in the environment of the hydrophobic pocket where it
interacts with aromatic residues (Phe and Tyr side chains) through π–π interactions
and with aliphatic residues through CH–π and lipophilic interactions (Leu, Ile, !la, Val
and Pro).A pair of Lys residues from the rim were found to be accessible for
establishing π-cation bonding.
al.64On the other hand, Barata et have shown that partially glycosylated
polyamidoamine (PAMAM) dendrimer inhibits TLR4/MD-2/LPS-induced inflammation.
Molecular modeling studies indicate that the hydrophilic surface bind to the entrance
of MD-2 cavity.. Crucially, dendrimer glucosamine interferes with the electrostatic
binding between LPS and polar residues Ser118, Tyr102 and Lys91 of MD-2. It was also
determined that the bioactivity was due to their surface properties, such as the
electrostatic and polar surface, their flexibility and their density.
Computational Studies of Proteins as TLR4 Modulators
Peptide-related molecules have also been explored as putative TLR4 modulators by
computational strategies aiming to shed light onto their mechanisms of interaction.
Among them, S100A8 is a small protein expressed in neutrophils and platelets, among
40
  
 
             
        
    
       
    
          
            
             
           
      
 
      
    
           
          
         
     
             
          
             
           
          
       
     
     
          
            
            
            
      

 
1. INTRODUCTION
other cells, and it can be recognized by TLR4, as part of damage-associated molecular
patterns,134 thus activating TLR4-mediated immune response. To study how TLR4 
recognizes S100A8, a rigid body docking was performed.135 Human S100A8 crystal
structure (PDB-ID: 1MR8) was docked on mouse TLR4/MD-2 crystal structure (PDB-ID:
2Z64) using ZDOCK,136 followed by a clustering/re-ranking method. Fifty-four thousand
structures were initially generated and ranked, taking into account desolvation and
electrostatic energy and shape complementarity. The top five models were examined as
possible complex structures. In all of these models, C-terminal residues of S100A8 are
located on the interface with TLR4/MD-2, in agreement with experimental data,
suggesting that the C-terminal region plays a crucial role in TLR4/MD-2/S100A8
recognition.
Another protein, annexin A2 (AnxA2), has been demonstrated to activate
human macrophages through TLR4-mediated signaling. Annexins are calcium­
dependent proteins that are involved in cell motility, endocytosis and ion channel
formation, among others cellular processes.137 Recently, experimental data suggested that
AnxA2 binds to the TRIF/TRAM/TLR4 internalized complex, although the mechanism
remains unclear. Protein-protein docking showed how this complex is formed.138 Since
there is no crystal structure available for neither TRIF, nor the TRAM protein, 3D
structures were constructed with the SWISS-MODEL homology modeling server.139 The
TRIF model was docked on TRAM using ZDOCK program. The best predicted TRIF/TRAF
complex was then docked on mouse TLR4 (PDB-ID: 3VQ1), and finally, human AnxA2
(PDB–ID: 4HRE) was docked on this complex. The results showed that the complex is
formed through both electrostatic and hydrophobic interactions.. 
A similar approach was used with another protein, the surfactant protein A (SP­
A).140 This protein downregulates inflammation, binds to TLR4 and stops cytokine
release. A protein-protein docking of SP-A trimer on the TLR4/MD-2 complex was 
performed using GRAMM-X.141 Among the 100 poses predicted by the server and taking 
into account experimental data suggesting that SP-A mainly binds to MD-2, only three
poses were kept. To identify the interacting residues, binding hotspots were predicted
using shape specificity and biochemical contact features. Twelve residues of SP-A were
41
  
 
      
      
       
 
       
   
         
      
       
         
       
          
    
        
       
    
       
  
 
    
    
       
       
       
       
       
         
          
         

 
1. INTRODUCTION
found to interact with the TLR4/MD-2 complex. Using this information, a 20-residue
peptide (SPA4) containing the interacting residues of SP-A was synthesized, and it was
showed to bind to TLR4 and suppress an inflammatory response.
1.2.4 Virtual Screening in Toll Like Receptors
In the context of drug discovery, virtual screening (VS) techniques have already 
proved to make hit identification more goal-oriented, allowing the access to a huge
number of chemically diverse binders (from public and commercial databases) with a
relatively low-cost in terms of time and materials. This computational approach has
been subjected to extensive attention and revision over the years, from the early
perspective of being an emerging method,142 until the current time where new
challenges are faced.9, 143-147 We could say that TLRs are not standard receptors which
could be approached following classical strategies in drug design. The complexity of
the system and the characteristics of their complexation with the PAMPs make them
especially difficult to tackle following classical procedures in drug design and discovery.
This is why TLRs constitute a special case study in this context. We herein report
successful cases of VS approaches that have led to TLR modulators either with agonist
or antagonist activity.
Virtual Screening Studies in TLR2
TLR2 heterodimerization either with TLR1 or TLR6 mediates specific ligand
recognition of bacterial lipopetides.148 The X-ray crystallographic structures of both
extracellular heterodimers have been resolved assisted by homology modeling in the
past few years in complex with the triacylated65 and diacylated149 synthetic
lipopeptides Pam3CSK4 and Pam2CSK4, respectively. The crystal structure of the
TLR2/TLR1 heterodimer65 with the triacylated lipoprotein revealed that the two ester­
linked lipid chains are inserted into the large TLR2 pocket in extended conformation,
and the remaining amide-bound lipid chain is inserted into a narrow channel present in
TLR1. The binding site is mainly composed of hydrophobic residues from Leucine-rich
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1. INTRODUCTION
repeat (LRR) modules 9-12 in both receptors. The peptidic head establishes contacts
with polar groups from Phe349 from TLR2, and Gly313 and Gln316 from TLR1.
Interestingly, in the case of the (mouse) TLR2-TLR6 heterodimer co-crystalized with the
diacylated lipopeptide, the TLR2-lipid interaction and strong PPIs seem to be the prime
force for heterodimerization and signalling since TLR6 channel is shortened by the
presence of the bulky side chains from Phe343 and Phe365. A H-bond between the
Phe319 (TLR6) backbone and the first peptide bond of the lipopeptide is herein
detected.
Regarding the application of VS tool for the finding of novel TLR2 modulators,
Zhong et al.150 report the identification of a natural product-like inhibitor of TLR2/TLR1
heterodimerization (code ZINC12899676, Table 1.2) following a structure-based VS
strategy, through the docking of a collection of natural products and natural product­
like compounds from ZINC database (> 90 000 compounds) to a TLR2/1 ectodomain
model based on the TLR2/TLR1/Pam3CSK4 crystal structure (PDB-ID: 2Z7X). Flexible 
ligand docking was performed using the virtual library screening module in the ICM-
Pro program151 at the TLR2/TLR1 heterodimeric interface. The 17 best ranked solutions
according to the Full ICM Score compounds were selected for biological testing.
Among these 17 compounds, compound ZINC12899676 (Table 1.2) could decrease the
secretion of pro-inflammatory cytokines TNF-α and IL-6 in RAW 264.7 macrophages
stimulated with the most studied TLR2/TLR1 agonist, Pam3CSK4. It showed that could
reduce the secretion of TNF-α by 44% over the concentration range of 0/25 to 4 mM,
with an IC50 value of ca. 6.1 mM, and the secretion of IL-6 by 56% on the concentration
range of 0.25 to 2 mM, with an IC50 value of ca. 1.9 mM, displaying similar potency to 
the only other TLR2/TLR1 small molecule antagonist reported to date (CU-CPT22)152-153 
with no cytotoxic activity being detected. Compound ZINC12899676 also
demonstrated its ability to reduce the phagocytic activity of RAW 264.7 cells.
The mechanism of the antagonist activity exhibited by compound
ZINC12899676 is proposed to be by displacement of the synthetic lipopeptide
Pam3CSK4, as shown by docking studies where two key H-bonds were identified:..
Complementary biological and biophysical tests corroborated this possible mechanism
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1. INTRODUCTION
of action. A fluorescence polarization assay demonstrated the ability of ZINC12899676
to disrupt Pam3CSK4-mediated TLR1/TLR2 heterodimerization in a dose-dependent
manner, with an IC50 value of ca. 7.2 mM. An immunoprecipitation assay was used to
confirm the inhibitory effect on lipoprotein-induced TLR1/TLR2 heterodimerization
exhibiting similar potency to reference compound CU-CPT22. Compound
ZINC12899676 could attenuate NF-kB-luciferase reporter assay in RAW 264.7 cells with
greater potency than CU-CPT22, and in HEK293T cells transfected with pZERO-TLR1,
pCMV-Flag-TLR2 and pNF-kB-Luc, and was able to downregulate IBα and IKKα/β
phosphorylation and IBα expression in cellulo.
Other interesting results in this field are the work reported by Murgueitio et
al..154 The authors report the analysis of TLR2 monomer to predict and locate ligand
binding. A subsequent structure-based strategy was followed by centering the VS on
the lipopeptide binding site sub-pockets P1-P3. A 3D-pharmacophore model was then
constructed using LigandScout155 revealing a hotspot for H-bond acceptors. Two
hydrophobic areas, defined as HYD1 (Ile319, Phe325, and Val348) and HYD2 (Leu266,
Phe284, Phe295, Ile314, and Leu328) were also characterized. This model was
validated and used to screen a library of more than 2 800 000 commercially available
compounds from different vendors (ASINEX, Life Chemicals, Maybridge, ChemBridge,
ENAMINE HTS Collection, and SPECS) with the help of LigandScout. 150 compounds
with the highest pharmacophore fit score were docked into the TLR2 binding pocket
using GOLD156-158 and, after careful visual inspection, five of them were selected for
biological testing on a NF-kB reporter assay in the cell line HEK293-TLR2. Compound
with code MolPort-001-796-266 (Table 1.3) exhibited antagonistic activity, and the IC50 
value was measured in human monocytes obtaining µM values. Its presumed binding
mode was studied by means of docking techniques into the TLR2 binding site,
displaying key H-bond and hydrophobic interactions with residues located deep inside
the TLR2 pocket.. 
A ligand-based strategy was followed using a shape- and feature-based
similarity screening assisted by ROCS and using three reported small-molecule TLR2
signaling modulators159 and E567160 against a NCI compound library of 260 071
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1. INTRODUCTION
compounds. Five hundred hits arose from the VS and, after visual inspection, 39 were
selected for biological testing. Out of them, 4 exhibited antagonist activity (hit rate:
10%): compounds ZINC16769362 and ZINC398557 (that were identified from
compound B as query structure) and compounds ZINC1758666 and ZINC585632 (from
E567 as query) (Table 1.2).
Table 1.2. 2D Chemical structure of TLR2 modulators identified by VS techniques and
mentioned in this review. The database codes are provided. a MolPort is a supplier of
chemicals included in several VS databases (www.molport.com).
TLR2/TLR1 TLR2/TLR6
3D structure from PDB-ID: 2Z7X 3D structure from PDB-ID: 3A79
ENAMINE: Z416323354154 
ZINC: ZINC12899676150 
MolPorta: MolPort-009-315-475
TLR2-TLR1 heterodimerization inhibitor
TLR2/1 & TLR2/6 inhibitor
MolPorta: MolPort-009-737-181154 
MolPorta: Molport-001-796-266154 
TLR2/1 & TLR2/6 inhibitor with a decrease of cell 
TLR2/1 & TLR2/6 inhibitor
viability
ZINC: ZINC1676936154 MolPorta: MolPort-002-914-354154 
NCI: Plated 2007 44661 TLR2/1 & TLR2/6 inhibitor
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1. INTRODUCTION
TLR2/1 & TLR2/6 inhibitor
ZINC: ZINC398557154 
NCI: Plated 2007: 205636 C29 
MolPorta: MolPort-001-835-401 TLR2 TIR domain inhibitor161 
TLR2/1 & TLR2/6 inhibitor
ZINC: ZINC1758666154 
C29L (o-vanillin)161 
NCI: Plated 2007: 17379
TLR2 TIR domain inhibitor
TLR2/1 & TLR2/6 inhibitor
ZINC: ZINC585632154 TLR2/1 & TLR2/6 inhibitor
The same procedure was repeated using compounds A, B, ZINC16769362, and
ZINC585632 as queries, this time against the collection of more than 2 800 000
commercially available compounds used in the structure-based approach. From this
procedure, 22 compounds were selected for biological testing and three of them
displayed antagonistic activity (Z416323354, MolPort-009-737-181, and MolPort-002­
914-354, Table 1.2). Compounds were also tested for TLR2-specificity and toxicity and
the decrease of pro-inflammatory cytokine TNF-α was evaluated in human monocytes/
Additional computational docking studies of ZINC16769362, which showed the
lowest IC50, were carried out showing that the ligand is embedded into a narrow sub­
pocket at the end of the binding site thus interfering with lipopeptide binding. . The 
substitution pattern of the phenyl moiety was shown to be crucial for activity, since
compounds with other pattern of substitution were inactive, as well as the presence of
aromatic rings, as compounds with aliphatic rings were inactive. Overall, these results
46
  
 
      
    
       
       
              
        
         
     
       
           
         
         
         
    
        
      
      
        
       
         
         
       
        
      
    
  
    
        
     
  

 
1. INTRODUCTION
shown to be very promising for the identification of several novel TLR2 antagonist with
activity in the µM range by using virtual screening techniques.
Mistry et al.161 have also reported the identification of two novel small 
molecule inhibitors of TLR2 signaling by targeting a pocket within the so-called BB loop
of the TLR2 TIR domain. The TIR domain, located on the cytosolic face of all TLRs and
adaptor proteins24 (in TLR2, MyD88 and TIRAP) has been proven to be key for signaling
through the mediation of certain homotypic and heterotypic PPIs162 that triggers
downstream signaling cascades and ends in the production of pro-inflammatory
cytokines and chemokines.163 The crystal structures of human TLR2 and TLR1, as well
as the P681H mutant of the TLR2 TIR domain93 revealed that the BB loop connects
strand β-B and helix α-B and sticks out of the structure. The P681H mutation in the BB
loop has shown to preclude the recruitment MyD88 and therefore TLR2 signaling.
A pocket within this BB loop of hTLR2, formed by 10 residues (Tyr647, Cys673,
Asp678, Phe679, Ile680, Lys683, Asp687, Asp688, Asp691, and Ser692) neighboring the
highly conserved Pro681 and Gly682 pair, was selected as the target for searching new
TLR2 modulators. Flexible ligand docking of a collection of commercially available small
molecules and FDA-approved compounds (> 1 million compounds) was performed
using the DOCK algorithm164 based on the anchor-and-grow search method.165 First, a
primary docking was performed where each rotatable bond was minimized while
created without reminimizing the other bonds, with a minimization of the complete
molecule once it was built. The most favored conformation of each molecule in terms
of interaction energy was conserved. This resulted in the selection of 50 000
compounds that were subjected to a secondary docking step with an additional
simultaneous minimization step of all rotatable bonds against the crystal structure
(PDB-ID: 1FYW) and three additional conformations obtained from MD simulations of
the protein.166 
The top 1 000 compounds that exhibited the most favorable interaction 
energies, taking into account every protein conformation, led to the selection of 149
compounds and 20 FDA-approved drugs attending to chemical diversity and
physicochemical properties for biological testing in HEK293T-TLR2 transfectants.
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1. INTRODUCTION
Among them, compound C29 (Table 1.2) was able to inhibit/disrupt/block both TLR2­
TLR1 and TLR2-TLR6 signaling induced by synthetic and bacterial agonist in human cell
lines. Pam3CSK4- and Pam2CSK4-induced IL-8 mRNA was decreased by compound C29
in stably transfected HEK-hTLR2 in a dose dependent manner, as well as IL-1β gene
expression in the human monocytic cell line THP-1. Other effects were not exhibited in
other TLR agonist- of TNF-α induced signaling nor cytotoxic effects/ This behaviour was
also observed when HEK-hTLR2 and THP-1 cells were stimulated with heat-killed or live
Gram-positive and Gram-negative bacteria.
Notwithstanding, C29 only showed activity on TLR2/1 signaling pathway,
disrupting only P3C-and Staphylococcus aureus lipoteichoic acid-induced IL-1β mRN!
in murine macrophages. C29L (o-vanillin), a derivative from the imine cleavage of C29
in alkaline conditions (NaOH, 65 µM), displayed similar activity and potency in NF-B 
luciferase reporter assay in HEK293T cells and has the advantage of a better water
solubility. It was shown to be active both in vitro and in vivo. In this work, Mistry et al. 
also performed an Alanine scanning mutagenesis of every residue within the BB loop
using Y647A as a control mutation as it has been reported to play no role in TLR2
signaling.167 All 10 BB loop pocket mutants resulted crucial for TR2/1 signaling but not
for TLR2/6 signaling, were mutations C673A, I680A, K683A, and S692A were found to
not be needed for TL2/6 signaling.
Virtual Screening Studies in TLR3
Toll-like receptor 3 (TLR3) is located at the membrane of the endoplasmic
reticulum, endosomes, multivesicular bodies, and lysosomes. TLR3 forms a large
horseshoe shape that contacts with a neighboring horseshoe, yielding a dimer of two
horseshoes. The overall horseshoe-shaped structure of the ectodomain TLR3 is formed
by 23 repeating LRRs, ligand-binding domain that is composed of leucine-rich repeats
(LRRs).168 Some X-ray crystallographic structures are available from mouse (PDB-ID: 
3CIG and 3CIY) and from human (PDB-ID: 2AOZ and 1ZIW). TLR3 recognizes specifically
dsRNA, and the activation of the receptor induces the secretion of type I interferons
48
  
 
   
        
     
       
      
        
      
     
   
   
      
     
       
    
     
        
       
        
       
       
 
   
 
 
 
 
 
 

 
1. INTRODUCTION
and pro-inflammatory cytokines, like a TNF-, IL-1 and IL-6, triggering immune cell
activation and recruitment of the adaptor molecule TRIF via TIR domain interaction.169 
In contrast to other TLR ligands, dsRNA signaling occurs via MyD88-independent
pathways.170 It has also been reported to recognize synthetic analogue polyinosinic­
polycytidylic acid, Poly(I:C).171 Therefore, the TLR3/dsRNA complex constitutes an
important target in multiples infectious diseases and cancer, as it has been shown to
be implicated in several infection models like a herpes simplex encephalitis,172 West
Nile disease, phlebovirus, vaccinia and Influenza A.173-176 It has also been reported that
double-stranded DNA from necrotic cells during inflammation or viral infection
activates the signal of TLR3.177 
Cheng et al. have reported the development of small-molecule probes that
exhibited activity as competitive inhibitors of dsRNA binding to TLR3.178 The authors
performed a VS in the dsRNA binding domain of TLR3 using the ENAMINE drug
database. The docking protocol was performed into the dsRNA binding domain of
mouse TLR3 (PDB-ID: 3CIY) with Glide program. A HTVS protocol was employed for the
first docking and ranking, followed by SP protocol for the top 10 000 compounds. The
resultant top 5 000 compounds were subsequently docked using the more accurate
and computationally intensive XP mode of Glide. First top-ranked 100 compounds
were selected and re-ranked by predicted binding energy. The authors finally selected
nine hits compounds for evaluation by cell assay of TLR3 activation (ENAMINE codes
are: T5528092, T5631009, T5630975, T0519-9149, T5626448, T5643856, T5260630,
T55994342, T0505-4844, Table 1.3).
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1. INTRODUCTION
Table 1.3. 2D Chemical structure of TLR3 and TLR7 modulators identified by VS techniques and
mentioned in this review. The database codes are provided.
TLR3 TLR7
No X-ray
crystallographic structure 
available
3D structure from PDB-ID: 3CIY ­
(R) Compound 4a178 ENAMINE: T5528092178 Query 1
ZINC:
ZINC1667204179 
TLR3 inhibitor TLR3 inhibitor (Imiquimod)
179 
TLR7 inhibitor
T5631009178 ENAMINE: T5630975178 ZINC: ZINC39698179 
Query 2179 
TLR3 inhibitor TLR3 inhibitor TLR7 inhibitor
T0519-9149178 ENAMINE: T5626448178 
ZINC:
ZINC12382420179 
ZINC: ZINC36416179 
TLR3 inhibitor TLR3 inhibitor
TLR7 inhibitor
TLR7 inhibitor
ENAMINE: T5643856178 ENAMINE: T5260630178 ZINC: ZINC4756232179
TLR3 inhibitor TLR3 inhibitor TLR7 inhibitor
ENAMINE: T55994342178 
ENAMINE: T0505­
4844178 
ZINC: ZINC8686004179 
TLR3 inhibitor
TLR3 inhibitor
TLR7 inhibitor
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1. INTRODUCTION
Most of these nine hits resulted to share a structural motif: the chemical 
structure of a D-amino acid conjugated with an aromatic substituent, thus yielding a
new pharmacophore for the TLR3 binding site. To select the best ranked compounds,
they took into account different benchmarks: a) predicted binding energy and spatial
complementarity; b) reasonable chemical structures found in the dsRNA-binding site of
TLR3; c) existence of at least one H-bond between the ligand and one of the dsRNA­
recognizing residues on the TLR3 surface (e.g. His539, Asn541, and Ser571); d)
protonation state and tautomeric form of the ligand had to be acceptable.
A dsRNA, Poly(I:C) was employed to selectively activate TLR3 signaling, resulting
in the activation of nitric oxide (NO) synthase and the production of NO in RAW 264.7
macrophage cells.180 They monitored the NO level as an indicator of Poly(I:C)-induced
TLR3 activation to evaluate the inhibitory activity. Hit compounds T5626448 and
T5260630, both derivatives of D-Phe, were identified with IC50 values of 154 μM and
145 μM respectively. Different analogues were synthesized and SAR analysis was
performed. Finally, only one compound, a T5626448 derivative (compound 4a in Table
1.3), was identified as a very potent dose dependent TLR3 antagonist, with a low μM
IC50 value (3.44 ± 0/41 μM)/ However, in the case of T5260630 analogues, not
significant improvement in the activity was observed, so they only focused on the
T5626448 derivative family.
Compound 4a was also tested against homologous TLRs: TLR1/2, TLR2/6, TLR3,
TLR4 and TLR7 using TLR specific ligands, but only TLR3 inhibition was observed. Other
different biological assays were performed, finding that compound 4a did not affect
cytochrome P450 CYP3A4, CYP2D6, and CYP2C19 isoforms. Tests on RAW 264.7
macrophages were also carried out showing low toxicity, and kinase profiling showed
that 4a demonstrates negligible inhibition activity against a panel of 12 representative
kinases. Biophysical tests were also carried out, with a negative control, to
demonstrate that 4a binds to TLR3. Fluorescence anisotropy assay demonstrated that
this compound competes with dsRNA for binding to TLR3 with a Ki value of 2.96 μM. By
an ELISA assay, 4a was also demonstrated to inhibit the downstream signaling
transduction mediated by the formation of the TLR3/ds RNA complex, showing that
51
  
 
     
        
            
   
 
    
        
      
    
       
        
    
      
      
    
      
       
      
        
     
      
        
       
      
       
         
   
        
      

 
1. INTRODUCTION
this compound almost completely abolishes the TL3-mediated inflammation response
at its IC90 concentration (27 μM). Finally the inhibitory effects of TNF- by compound
4a at 10 μM were also tested with a result of 60% inhibition, agreeing with the results
observed in the NO synthase assay.
Virtual Screening Studies in TLR4
In the search of novel TLR4 modulators, Yin et al. have applied a computational
methodology to the identification of small drug-like inhibitors of TLR4/MD-2 PPIs.181 
The authors have developed a novel in silico screening methodology incorporating
molecular mechanics (MM) and implicit solvent methods181 to evaluate binding free
energies, in order to improve affinity prediction accuracy without reducing screening
speed. The ENAMINE database collection was screened against the TLR4/MD-2 
complex of the crystal structure of the human TLR4 TV3 hybrid-MD-2-Eritoran complex
(PDB-ID: 2Z65). The library was clustered to ensure the least possible computational
work, while keeping as much of the full chemical diversity of the available library as
possible. A combination of Jarvis-Patrick and Li algorithms182-183 was used; as well as
the Tanimoto similarity calculation184-187 with Daylight fingerprints in order to measure
the distance between the molecules. About 86 000 clusters were isolated. Then, the
compounds representing the cluster centroids were taken, and an additional filter that
matched the molecular volume to the biding site was applied.
Fast molecular docking for the generation of binding poses and subsequent MD
simulations were performed to rank the ligand poses according to their binding
affinities. The hits were profiled against a library of 500 representative human proteins
as a selectivity filter in order to remove the non-specific inhibitors. Finally, as a proof of
concept, the compounds were screened against both TLR4 and MD-2 to validate the
181, 188strategy. Two compounds, T5342126 and T6071187 (Table 1.4) were identified as
potential TLR4- and MD-2-specific antagonists, respectively, completely abolishing LPS­
induced activation of signaling. Their biological activity and selectivity were tested in
vitro using Akt1 and nitric oxide in RAW264.7 cells.
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1. INTRODUCTION
In another study, Gobec et al.188 performed parallel ligand-based and structure­
based virtual screenings in order to identify novel TLR4 antagonists targeting the
TLR4/MD-2 interface using the crystal structure of the human TLR4 TV3 hybrid-MD-2­
Eritoran complex (PDB-ID. 2Z65)/ For both ligand-based and structure-based virtual
screening, they used the ZINC drug-like subset (~ 11/3 million drug-like compounds)
from the ZINC database/189 
Regarding the ligand-based virtual screening, they used the OMEG! software190 
on the compound T5342126 (Table 1.4),188 a known TLR4 antagonist, to generate 5
query conformers/ ROCS software was then used to compare the database to all query
conformers/ The single best overlay hits were ranked according to the TanimotoCombo
scoring function,190 considering similarities in the molecular shape and color of atom
types/ Thereby 5 compounds were identified (ZINC51408124, ZINC464832,
ZINC26905159, ZINC32525142 and ZINC32524933, Table 1.4) and evaluated in vitro/ 
Unfortunately, these compounds were either not water soluble, or not active, or
presented cytotoxicity on HEK293 cells/
For the structure-based virtual screening, before the docking process, they
performed an enriching procedure, using ROCS software between the database and
T5342126, the query molecule, in order to reduce the number of compound and to
enrich it/ Two sets of 25 000 compounds each, were created. set 1 with the highest
shape similarities to T5342126, using ShapeTanimoto algorithm, and set 2 with both
the highest shape and color (atom type) similarities to T5342126, using the
TanimotoCombo algorithm/191 Both sets were merged and the duplicates were
removed, leading to a total of 49 600 unique compounds left/ The docking procedure
was carried out using FlexX program and the active site was defined as an area of TLR4
within 8 Å around the interacting MD-2 loop (Gly97-Leu108)/ LeadIT-implemented
pharmacophore constraints were performed then in order to keep only the compounds
that can form interactions with at least one of the polar amino-acid residues such as
Ser183 and !sp209 of TLR4, and !rg106 of MD-2/ !t the end of the implementation, 25
750 compounds had been kept, and the docking procedure was performed/ The
compounds have been finally ranked according to their best scoring conformation
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1. INTRODUCTION
using LeadIT score and 40 were selected and assessed in vitro/ !fter the first in vitro
assay, only 14 compounds were sufficiently water-soluble, up to 500 μM, and
completely non-cytotoxic at 100 μM/ Those received further biological evaluation using
HEK-BlueTM hTLR4 cells, and 3 compounds with promising antagonistic activities were
discovered. ZINC25778142, ZINC49563556 and ZINC3415865/
Table 1.4. 2D Chemical structure of TLR4 modulators identified by VS techniques and
mentioned in this review. The database codes are provided.
ENAMINE: T5342126192 ZINC: ZINC04272679193 ZINC: ZINC00611718193 
TLR4 inhibitor Predicted TLR4 inhibitor Predicted TLR4 inhibitor
ENAMINE: T6071187192 ZINC: ZINC04272561193 ZINC: ZINC48141941193 
MD-2 inhibitor Predicted TLR4 inhibitor Predicted TLR4 inhibitor
ENAMINE: T5339238
ENAMINE: T6969316
ZINC: ZINC25778142188 ZINC: ZINC09535665193 
ZINC: ZINC51408124188 
TLR4 inhibitor Predicted TLR4 inhibitor
TLR4 activity not determined 
(solubility problems)
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ENAMINE: T5458371
ZINC: ZINC70039563193 
ZINC: ZINC464832188 
ZINC: ZINC49563556188 
TLR4 inhibitor
Predicted TLR4 inhibitor
TLR4 activity not determined 
(cytotoxicity on HEK293 cells)
ENAMINE: T5315798
ENAMINE: T6417643
ZINC: ZINC3415865188 
ZINC: ZINC29450369193 ZINC: ZINC26905159188 
TLR4 inhibitor
Predicted TLR4 inhibitor Predicted TLR4 inhibitor but 
not active
ENAMINE: T6280209
ZINC: ZINC64951618193 ZINC: ZINC41124663193 ZINC: ZINC32525142188 
Predicted TLR4 inhibitor Predicted TLR4 inhibitor Predicted TLR4 inhibitor but 
not active
ENAMINE: T6279749
ZINC: ZINC64951738193 ZINC: ZINC08687988193 ZINC: ZINC32524933188 
Predicted TLR4 inhibitor Predicted TLR4 inhibitor Predicted TLR4 inhibitor but 
not active
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1. INTRODUCTION
ZINC: ZINC72278680193
Predicted TLR4 inhibitor
In other work, Sowdhamini et al.193 used homology modeling, docking, and
virtual screening techniques, in combination with known experimental data, molecular
mechanics calculation to identify novel and potential small molecule inhibitors of
TR!M-mediated TLR4 signaling/ For this purpose, they identified TLR10 TIR dimer as
the best model to build the TIR domain of TLR4 as a dimer/ Then, they modeled the C-
terminal region of the !46 poxviral protein containing the VIPER motif, using the crystal
structure of !52 poxviral protein (PDB-ID. 2VVW) as a template/ This motif is capable to
bind the TIR domain of different adaptor proteins/ !fter having obtained the two
models, they performed a two-phase docking for creating reliable models of the
complex between the TR!M TIR homology model and the VIPER peptide segment/ !
virtual screening was then, performed onto the complex/ They used the lead-like and
drug-like subsets of the ZINC database, totaling 32 million of compounds/ The ligands
2D structures were converted into their 3D structure including all possible
stereoisomers, tautomers, and ionization states under a pH range of 6-8, the hydrogens
were added and the structures were optimized and minimized in LigPrep/ The library
was preliminary screened based on !DMET properties and reactive functional groups,
using Qikprop and Lipinskis rule of five/194 The amino acid residues constituting the BB
loop (110-122) and alphaC helix (141-154) of the TLR4 TIR domain were selected for
generating the receptor grid/
Glide was used for the docking by concatenating the three protocols. HTVS, SP
and XP/ The top 10% compounds, based on the Glide score, obtained from the HTVS
step were retained for the subsequent step/ These were re-docked using the SP
module/ The XP module was used to perform a more extensive docking of the top 10%
compounds carried forward from the SP step/ Final ranking of the compounds was
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1. INTRODUCTION
based on their Glide XP Score/ The compounds having similar scaffold were then
clustered using C!NV!S195-196 resulting in a pool of 265 chemically diverse structures/
These selected compounds were submitted to induced fit docking within the Maestro
suite197-199 to restrict the flexibility only into the binding site/ For this purpose, they 
used the Glide SP protocol to generate 2 000 poses for each molecule within the
binding site/ Finally, they inspected the top 20 receptor-ligand poses for each ligand to
see if potential interaction between the binding site residues and the ligand atoms
were maintained or disrupted upon incorporating flexibility to the residues, and the
ligands with more interactions conserved throughout most of the poses were selected/
Binding free energy calculations were performed on the top two poses generated
during induced-fit docking of each compound/ These complexes between the TR!M TIR
homology model and each ligand were ranked according to this analysis and a final
structural analysis of the ligand/receptor interactions was performed, shortlisting 12
molecules (Table 1.4)/ Interestingly, compound ZINC08687988 remained firmly bound
in the pocket even after incorporating a considerable degree of conformational
flexibility during the MD simulations carried out in the complexes/ To date, no further
biological testing has been performed yet/
Virtual Screening Studies in TLR7
Toll-like receptor 7 (TLR7) is intracellularly located at the membranes of
endosomes, endoplasmic reticulum, multivesicular bodies, and lysosomes.200 Its
function is related to defense against viral infection by recognizing single-stranded RNA
(ssRNA) and small-interfering RNA (siRNA) from viruses,201-202 including human
immunodeficiency virus, influenza, and vesicular stomatitis virus.203 The host can also
utilize TLR7 to detect RNA released into endolysosomes by phagosomal bacteria.
Several synthetic ligands have also been reported to modulate TLR7, such as
imidazoquinoline derivatives (resiquimod and imiquimod), and guanine analogues.204 
Also, TLR7 recognizes guanosine- and uridine-rich ssRNA, and synthetic polyuridines
act as potent ligands.202 The development of new antagonist modulators could have
57
  
 
     
     
       
     
       
      
           
      
  
        
     
        
      
 
   
        
       
       
       
         
       
           
    
        
       
    
   
        
      
      

 
1. INTRODUCTION
important applications for the treatment of autoimmune disorders, like rheumatoid
arthritis, Sjogren’s syndrome, and systemic lupus erythematosus.14 
Since no X-ray crystallographic structure of TLR7 is available to date, in order to
identify TLR7 modulators, Gobec et al. undertook a ligand-based VS.179 ROCS was
employed to carry out the screening protocol from which six compounds with three
novel chemical scaffolds were discovered. The authors employed ZINC database and
OMEGA software to prepare the compound library. With the help of ROCS, two query
compounds were identified as TLR7 binders: query 1 (imiquimod) and query 2 (1-(4­
amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol) (Table 1.3).
Imiquimod (query 1) is a TLR7 agonist currently used for topical treatment of genital
warts caused by human papillomavirus, actinic keratosis, and superficial basal cell
carcinoma,205 and query 2 compound was developed in the last years in a systematic
SAR exploration study as the most potent imidazoquinoline with TLR7 agonist
activity.206 
From queries 1 and 2, the authors performed parallel VS studies. The results
were ranked taking into account the TanimotoCombo score, and the best results from
both VS were finally merged. The best 25 ranked compounds were selected and
submitted to biological assays, only considering soluble and available compounds.
Cytotoxicity tests were performed with HEK-BlueTM hTLR7 determined using a
propidium-iodide based staining method and none of the compounds showed
cytotoxicity at 250 μM/ In the subsequent step, the soluble compounds were assayed
for TLR7 agonist activity at 250 and 500 μM using the reporter assay but none of the
compounds showed any notable agonist activity/ Finally, to evaluate the antagonist
activity, the compounds were tested using HEK239 cell line co-transfected with hTLR7
gene using imiquimod as a control/ Six compounds were identified as antagonists at the
μM scale containing three novel chemical scaffolds. chromeno[3,4-d\imidazole-4-one,
1H-imidazo[4,5-d\pyridazine-4,7-dione, and 6-amino-9H-purine (ZINC codes 12382420,
1667204, 39698, 36416, 4756232, and 8686004, Table 1.3)/ The authors also propose a 
simple and straightforward synthesis of derivatives from the chromeno[3,4d\imidazole­
4-one scaffold which showed promising TLR7 antagonistic activities/
58
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Virtual Screening Studies in TLR8
Toll-like receptor 8 (TLR8) is an endosomal membrane receptor that recognizes
single stranded RNA (ssRNA) from viruses. TLR8207 is expressed in monocytes and
myeloid dendritic cells.208-209 TLR8 signaling pathways are mediated by MyD88; this
adaptor protein activates NF-κB, IRF-7, and p38 MAPK, resulting in the induction of
pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, IL-12, and antiviral type I
interferons. Therefore, TLR8 is a promising target in the development of vaccine
adjuvants and anticancer agents.210 The 3D structure is well-known and six X-Ray
crystallographic structures of human TLR8 in complex with six agonists are available
211-213 (PDB-ID: 3W3J, 3W3K, 3W3N, 3WN4, 4Q8Z, and 4QC0). TLR8 consists of an
extracellular domain with a horseshoe-shape containing 26 LRR modules, being the
ssRNA binding site very large and flexible. Ligand binding induces reorganization of the
pre-organized TLR8 dimer finally enabling downstream signaling processes.211 
To overcome the difficulty of targeting a flexible binding site, Pei et al.195-196 
have performed an enrichment assessment of multiple virtual screening methods, and
developed a combined strategy to improve the performance of virtual screening for
TLR8 agonists. First, they have created a knowledge-based pharmacophore (KBP) by 
merging structure-based pharmacophore and previous SAR analysis including furo[2,3­
c]pyridines, furo[2,3-c]quinoles, thiazolo[4,5-c]quinolones, 3-R-quinolone-2-amine, and
C7-methoxycarbonyl-imidazoquines. The combination of the KBP screening with ROCS
search was used to improve the efficiency of the virtual screening process. The authors
prepared a benchmarking data set merging 13 known active compounds,214-217 15 
known inactive compounds, and decoys from ZINC database.218 So finally they had 13
actives and 1302 decoys. The benchmarking data set was generated from their
recently developed MUBD-Decoymaker protocol.219 
The six TLR8 crystal structures were used to generate SB pharmacophores and
shape-based 3D similarity search queries by means of LigandScout software. Eight
pharmacophore models were derived with similar backbones in agreement with
reported SAR for TLR8 agonists: three hydrophobic centroids, two aromatic rings, one
H-bond donor, and one H-bond acceptor. The eight KBPs were used to screen the
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1. INTRODUCTION
benchmarking data set in order to select the most robust KBP. The authors selected
the so-called “Phar1” as the priority KBP and reserved it for the subsequent antagonist
verification.
In order to perform an antagonist verification data set to test the
agonist/antagonist selectivity of their selected KBP, twenty reported antagonists were
used.206 For the shape-based 3D similarity search, the authors performed ROCS queries
through the alignment of the six ligands from the six crystal structures, using
TanimotoShape and TanimotoCombo scores. Among the resulting queries, the so­
called “Query4” was taken into further analysis because of its excellent performance/
As an additional step in the protocol, a comparative study was performed with four
docking programs: AutoDock VINA, GOLD, Surflex-Dock and Glide. Cross-docking runs
were performed with 20 cognate ligands and five dimer TLR8 complexes. Average and
median RMSD values were statistically analysed to determine which program and
which crystal structure best matched VS. Taken together, GOLD was identified as the
most suitable docking program in conjunction with PDB-ID: 3W3J for the VS evaluation
of the protocol.
Finally, the selected pharmacophore “Phar1” was combined with the ROCS 
“Query4” in different ways to get to the best performance as VS strategy for TLR8
agonists. Final docking with GOLD and PDB-ID: 3W3J, led to the screening of seven
compounds, being three of them known active ligands as TLR8 agonists. The authors
conclude that this “Phar1_Q4_Gold” strategy was proved to be a promising practice
for the identification of novel TLR8 agonists. Indeed, this computational effort can be
of help for the design of efficient VS strategies in other TLRs.
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1.3 Objectives
The main objective of this Thesis is to deepen into the elucidation of the
molecular recognition processes involving TLR4/MD-2 at atomic detail by means of
computational techniques. Computational methodologies, such as MD simulations,
protein-protein docking and membrane simulations will be applied to the study of the
molecular mechanisms involved in the TLRs functionality, and in the recognition of
PAMPs, such as natural lipopolysaccharides (LPS), synthetic glycolipids and non-LPS
modulators. This knowledge will be used to help in the design and identification of
new modulators.
These studies will be carried out by addressing the following specific objectives:
- CHAPTER 3: Reported modulators of the TLR4/MD-2 system with agonist and
antagonist activity will be study, more concrete, the theoretical binding modes will be
predicted. In particular, we will focus our work in synthetic glycolipids lipid A analogues
and non LPS-like molecules. For all these reported TLR4/MD-2 modulators, there is not
binding mode proposed. It is clear that, although these molecules have a different
chemical structure, they must share a common pattern of interactions when bound to
TLR4/MD-2. We will undertake a computational study of some representative
compounds to unveil some of these patterns of interactions.
- CHAPTER 4: The cationic glycolipid IAXO-102, a potent TLR4 antagonist
targeting both MD-2 and CD14 co-receptors, will be use as scaffold to design new
potential TLR4 modulators and fluorescent labels for the TLR4 receptor complex
(membrane TLR4/MD-2 dimer and CD14). Our modelling studies will led us to the
proposal of 3D models for the interaction with CD14 and TLR4/MD-2 accounting for
their binding properties and also for their antagonistic activity.
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- CHAPTER 5: Virtual screening strategies from commercial and in-house
libraries, followed by biological assays, will be used to the identification of new
chemical entities with activity in the TLR4 complex, useful for the development of
novel TLR4 modulators with a non LPS-related structure. 
- CHAPTER 6: The computational building of the full structure of the TLR4/MD-2 
heterodimer will be addressed, simulating the TLR4/MD-2 complex in the membrane
environment. We are very much interested in the study of the dynamics of the full
TLR4 at atomic level. The analysis of the molecular dynamics simulations will led us to
understand the key interactions implicated in the molecular recognition events and in
the dimerization process of this complex.
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2. COMPUTATIONAL TECHNIQUES
2. Computational Techniques In Drug Design And In Molecular Recognition
Studies
The principal aim of computational techniques in drug design is to predict
whether a given molecule or ligand will bind to a biological target and, if so, how
strongly. This allows the computational design of novel molecules with enhanced
(predicted) affinity, and guides the synthesis in the optimization protocol. When
studying molecular recognition events, it also is important the prediction of binding
poses between small molecules and macromolecules, and/or interactions between
macromolecules (e.g., dimerization events). Docking techniques predict the possible
binding poses at a concrete binding site of the target, and provides a first estimation of
the binding energy. The estimation of the strength of the intermolecular interaction
between the ligand and its biological target is most often performed by molecular
mechanics (MM) and molecular dynamics (MD). These methods are also used to
predict the conformation of the small molecules and to model conformational changes
in the target that may occur when the small molecule binds to it. Semi-empirical, ab
initio quantum mechanics methods and density functional theory (DFT) are often used
to provide optimized parameters for the molecular mechanics calculations and also to
estimate the electronic properties (electrostatic potential, polarizability, etc.) of the
drug candidate that will influence binding affinity.
In this Thesis, diverse computational techniques have been applied to decipher
some of the basis at the atomic level regarding the mechanism of functioning and the
ligand recognition processes involving the TLR4/MD-2 system.
2.1 Docking
Molecular docking has become an important tool for drug discovery. Basically, 
the aim of molecular docking is to give a prediction of the ligand-receptor complex 
structure using computation methods. Docking can be achieved through two
interrelated steps: first, by sampling conformations of the ligand in the active site of
the protein; then, ranking these conformations via a scoring function. Ideally, sampling
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algorithms should be able to reproduce the experimental binding mode, and the
scoring function should also rank the best bound pose among all the generated
conformations.
The interaction between protein and ligand has been thought as key-lock
system. This key-lock model is easy to reproduce with a rigid docking where both
ligand and protein are treated as rigid. The global vision of this model evolved with the
advent of the induced-fit theory by Koshland, in which a mutual conformation change
of both ligand and protein occurs at the moment of the interaction.1 However, these
two theories are now better substituted by the concept of conformational ensembles. The
real three-dimensional structure will be represented by an ensemble of structures which
interconvert through dynamic processes. Thus, the study of dynamics and its impact in
conformation and molecular recognition is of paramount importance within this field. 
Karush defines this as a configurational adaptability in which the best-fitting configuration
for a biomolecule after interacting with a ligand would become selected from the whole
structural ensemble.2 Furthermore, Weber suggested that the binding with a ligand shift 
the conformational equilibrium of the receptor in favor of those conformers in the
dynamic ensemble that are most complementary to the ligand.3 
The most popular method treats only the ligand as flexible, although receptor 
flexibility is becoming incorporated in several docking programs. The flexibility of a 
protein can be included into the binding site before the docking or afterward it is
possible to generate different ensembles structures from MD simulation or from
Normal Mode Analysis (NMA). Some programs use different strategy in order to
include the flexibility in the receptor. For example, AutoDock4 program allows the
selection of some bonds of the side chain of several residues as rotatable bonds when
performing the docking of the ligand. Another strategy is to perform a conformational
search and a refinement of some side chains of selected residues or in the region of
the binding site while docking the ligand (e.g. Glide program).4-5 Obviously this
techniques have an higher computational cost than considering the receptor as rigid.6 
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2. COMPUTATIONAL TECHNIQUES
In structure-based drug design, the scoring function is one of the most
important components.7 It is important to development of an energy scoring function
that can rapidly and accurately describe the interaction between protein and ligand. 
There are three important applications of scoring functions in molecular docking:
1. The first of these is the determination of the binding mode and site of a ligand
on a protein. Given a protein target, molecular docking generates hundreds of
thousands of putative ligand binding orientations/conformations at the active site
around the protein. A scoring function is used to rank these ligand
orientations/conformations by evaluating the binding tightness of each of the putative
complexes.
2. The second application of a scoring function, which is related to the first
application, is to predict the absolute binding affinity between protein and ligand. This
is particularly important in lead optimization. Lead optimization refers to the process
to improve the tightness of binding for low-affinity hits or lead compounds that have
been identified. During this process, an accurate scoring function can greatly increase
the optimization efficiency and save costs by computationally predicting the binding
affinities between the protein and modified ligands before the much more expensive
step of ligand synthesis and experimental testing.
3. The third application, perhaps the most important one in structure-based drug
design, is to identify the potential drug hits/leads for a given protein target by
searching a large ligand database, i.e. virtual database screening. A reliable scoring
function should be able to rank known binders most highly according to their binding
scores during database screening. Given the expensive cost of experimental screening
and sometimes unavailability of high-throughput assays, virtual database screening has
played an increasingly important role in drug discovery.
All of these three applications, ligand binding mode identification, binding affinity
prediction, and virtual database screening, are related to each other.
The different categories of scoring function could be:
- Force field scoring function:
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2. COMPUTATIONAL TECHNIQUES
Force field (FF) scoring functions8 are developed based on physical atomic
interactions including van der Waals (VDW) interactions, electrostatic interactions,
and bond stretching/bending/torsional forces. Force field functions and parameters
are usually derived from both experimental data and ab initio quantum mechanical
calculations according to the principles of physics. Despite its lucid physical meaning, a
major challenge in the force field scoring functions is how to treat the solvent in ligand
binding. The scoring function is composed of two energy components of Lennard-Jones
VDW and an electrostatic term (Equation [2.1]):
ቄዽዾ ቅዽዾ ቮዽቮዾ
ቈ ቭ ዮ ዮ ቧ ቖ቗ ቧ ቛ ቦ ቨ [2.1]ቯዽዾ ቯዽዾ ዾኌቯዽዾነቯዽዾዽ ዾ 
where rij represents the distance between an atom i of the protein and an atom j of
the ligand. Aij and Bij are the van der Walls parameters, and qi and qj are the atomic
charges of the atom i and j respectively. Here, the effect of solvent is implicitly
considered by introducing a simple distance-dependent dielectric constant ε(rij) n the
Coulombic term.
- Empirical scoring function:
Empirical scoring function9-10 estimates the binding affinity of a complex on the basis of
a set of weighted energy terms. Compared to the force field scoring functions, the
empirical scoring functions are much faster in binding score calculations due to their
simple energy terms. Glide Score is one of the examples of empirical scoring function
(Equation [2.2]):
ዠቊ ቭ ዮ ቚዽዠቊዽ [2.2]
ዽ 
ΔGi represents different energy terms such as VDW energy, electrostatics, hydrogen
bond, desolvation, entropy, hydrophobicity, etc. ΔGi stands for the individual empirical
energy terms and the corresponding coefficients Wi.
- Knowledge-based scoring function:
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2. COMPUTATIONAL TECHNIQUES
Knowledge-based scoring function11-12 employs energy potentials that are derived
from the structural information embedded in experimentally determined atomic
structures:
ሊቛቯቜ [2.3]ሒቛቯቜ ቭ ቧቨዜ቗ቩቫ ቩ ቉ሊዼቛቯቜ 
In this Equation [2.3] the scoring function is dependent on the density of the
protein-ligand atom pair at the distance r (ρ(r)) in the training set, and the pair density
in a reference state (ρ*(r)) where there are no interatomic interactions at the absolute
temperature T. kB is the Boltzmann constant. 
In this thesis, three different docking protocols were used: AutoDock4,13 VINA14 and
Glide.5, 15 
2.1.1 AutoDock4
AutoDock413 combines an empirical free energy force field with a Lamarckian
Genetic Algorithm. The force field evaluates binding in two steps. The ligand and
protein start in an unbound conformation. In the first step, the intramolecular
energetics are estimated for the transition from these unbound states to the
conformation of the ligand and protein in the bound state. The second step then
evaluates the intermolecular energetics of combining the ligand and protein in their
bound conformation.
The force field includes six pair-wise evaluations (V) and an estimate of the
conformational entropy lost upon binding ዠቖዷሃሂዺ (Equation [2.4])
ዦበዦ ዦበዦ ዪበዪ ዪበዪ ቜዠቊ ቭ ቛ቙ዶሃሉሂዸ ቧ ቙ሉሂዶሃሉሂዸ ቜ ቦ ቛ቙ዶሃሉሂዸ ቧ ቙ሉሂዶሃሉሂዸ 
[2.4]
ዪበዦ ዪበዦቦ ኌ቙ዶሃሉሂዸ ቧ ቙ሉሂዶሃሉሂዸ ቦ ዠቖዷሃሂዺነ
where L refers to the “ligand” and P refers to the “protein” in a ligand-protein docking
calculation.
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2. COMPUTATIONAL TECHNIQUES
Each of the pair-wise energetic terms includes evaluations for
dispersion/repulsion, hydrogen bonding, electrostatics, and desolvation (Equation
[2.5]):
ቄዽዾ ቅዽዾ ቆዽዾ ቇዽዾ
቙ ቭ ቚሊዸዱ ዮ ቧ ቧ ቨ ቦ ቚዼዶሃሉሂዸ ዮ ቈቛቱቜ ቧ ቧ ቨቖ቗ ቛ ቖ቗ ቖቕቯዽዾ ቯዽዾ ቯዽዾ ቯዽዾዽ ዾ ዽ ዾ 
[2.5]
ሆድዶ
቏ 
ቮዽቮዾ ቛበ 
቗ሺ቏
ቜ
ቦ ቚዹሀዹዷ ዮ ቧ ቨ ቦ ቚሇሃሀ ዮኌቖዽ቙ዾ ቦ ቖዾ቙ዽነቢ ዾቛቯዽዾቜቯዽዾ
ዽ ዾ ዽ ዾ 
The weighting constants W have been optimized to calibrate the empirical free
energy based on a set of experimentally determined binding constants. The first term
is a typical 6/12 potential for dispersion/repulsion interactions. The parameters are
based on the Amber force field. The second term is a directional H-bond term based on
a 10/12 potential. The parameters C and D are assigned to give a maximal well depth
of 5 kcal/mol at 1.9Å for hydrogen bonds with oxygen and nitrogen, and a well depth
of 1 kcal/mol at 2.5Å for hydrogen bonds with sulfur. The function E(t) provides
directionality based on the angle t from ideal H-bonding geometry. The third term is a
screened Coulomb potential for electrostatics. The final term is a desolvation potential
based on the volume of atoms (V) that surround a given atom and shelter it from
solvent, weighted by a solvation parameter (S) and an exponential term with distance­
weighting factor σ=3.5Å.16 
In the final ranking and clustering-based scoring methods also the loss of
entropy (ΔSconf) associated to the binding is considered. This contribution is strictly
related to the number of rotatable bonds (Ntors) in the ligand (Equation [2.6]). 
ዠቖዷሃሂዺ ቭ ቚዷሃሂዺቑለሃሆሇ [2.6]
2.1.2 VINA
AutoDock VINA (Vina is not AutoDock) is an open-source molecular docking 
program. 14 It has no graphical interface but it is compatible with MGLTools.17 However,
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2. COMPUTATIONAL TECHNIQUES
although MGLTools needs other files, such as AutoDock and AutoGrid parameter files
(GPF, DPF) and grid map files, VINA does not need them. All it requires is the 3D
structures of the molecules to be docked and the specification of the search space
including the binding site. One limitation in VINA is that the maximum number of
predicted binding poses is limited to 20 per ligand. 
AutoDock VINA uses a hybrid scoring function (Equation [2.7]), where the
summation is over all of the pairs of atoms that can move relative to each other,
normally excluding 1–4 interactions. Each atom is assigned a type ti, and a symmetric
set of interaction functions ባለድለድዶኌሆድዶነ of the interatomic distance rij should be defined.
በ ቭ ዮ ባለድለድዶኌሆድዶነ [2.7]
ዽዕዾ 
where i and j represent two atoms and ti and tj their types and rij the interatomic
distance, excluding the 1-4 interaction. A symmetric set of interaction functions ftitj 
should be defined. Basically, this sum corresponds to the sum of intermolecular and
intramolecular contributions. Finally, the optimization algorithm used is the Iterated
Local Search global optimizer.18 
It is inspired by X-score19 and tuned using the PDBbing20-21 and extracting 
empirical information from both the conformational preferences of the receptor­
ligand complexes and the experimental affinity measurements. It is both an empirical
and a knowledge-based function. Regarding the optimization algorithm, the Iterated
Local Search global optimizer is used, and to treat ligand flexibility and optimization,
VINA uses a stochastic method with the Iterated Local Search global optimizer.18, 22 
2.1.3 GLIDE
Glide is a commercial docking program provided by Schrödinger.5, 15, 23 It uses a
hierarchical series of filters to search for possible locations of the ligand in the active­
site region of the receptor. It has a systematic method to treat ligand flexibility, with
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2. COMPUTATIONAL TECHNIQUES
an exhaustive search algorithm. The predicting binding affinity and the ranking of the
binding pose is performed using GlideScore function based on ChemScore function
(Equation [2.8]).
ዠቊዶዽሂዸ ቭ ቆሃ ቦ ቆሀዽሄሃ ዮ ባቛቯሀሆቜ 
[2.8]ቦ ቆዼዶሃሂዸ ዮ ቤቛዠቯቜብቛዠዺቜ 
ቦ ቆሁዹለድሀ ዮ ባቛቯሀሁቜ ቦ ቆሆሃለዶቋሆሃለዶ 
The Glide protocol is intuitive and relies on 4 steps: the ligands and protein
preparation, the receptor grid generation, and the docking process. Before launching
the docking step, Glide has to generate a grid that represents the shape and the
properties of the receptor, using several different sets of fields that provide
progressively more accurate scoring of ligand poses. The grid permits to dock only the
relevant region of the receptor, thus saving time calculations.
Regarding the last point, the full docking VS workflow includes 3 docking
stages: HTVS, SP (Standard Precision) and XP (eXtra Precision). The first stage performs
High Throughput Virtual Screening (HTVS) docking. It is intended for rapid screening of
very large number of ligands and has much more restricted conformational sampling
than SP docking. The second stage performs SP docking. It is appropriate for screening
ligands of unknown quality in large numbers. The third stage is the XP docking and
scoring. It is a more powerful and discriminating procedure using an implementation of
a modified and expanded version of the ChemScore scoring function, called
GlideScore5 (Equation [2.9]) and categorized as an empirical scoring function. Glide can
be used to perform virtual screening, accurate binding mode precision and
furthermore, Glide exhibits excellent docking accuracy and high enrichment across a
diverse range of receptor types.
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2. COMPUTATIONAL TECHNIQUES
ዠቊዶዽሂዸ ቭ ቆሀዽሄሃበሀዽሄሃ ዮ ባቛቯሀሆቜ 
ቦ ቆዼዶሃሂዸበሂዹሉለበሂዹሉለ ዮ ቤቛዠቯቜብቛዠዺቜ 
ቦ ቆዼዶሃሂዸበሂዹሉለበዷዼድሆዻዹዸ ዮ ቤቛዠቯቜብቛዠዺቜ 
[2.9]
ቦ ቆዼዶሃሂዸበዷዼድሆዻዹዸበዷዼድሆዻዹዸ ዮ ቤቛዠቯቜብቛዠዺቜ 
ቦ ቆሁድሌበሁዹለድሀበዽሃሂ ዮ ባቛቯሀሁቜ ቦ ቆሆሃለዶቋሆሃለዶ 
ቦ ቆሄሃሀድሆበሄዼሃዶ቙ሄሃሀድሆበሄዼሃዶ ቦ ቆዷሃሉሀቈዷሃሉሀ ቦ ቆሊዸዱቈሊዸዱ 
ቦ ተቬቩታ቞ቱቦቬቫ ቱቢቯቪተ
The lipophilic-lipophilic term and H-bonding term is same as defined in
ChemScore. But the H-bonding term is separated into different weights that depend
on whether the donor and acceptor are neutral and the other is charged, or both are
charged. The metal-ligand interaction term also usesthe same functional form as in
ChemScore but varies in three principal ways: a) this term considers only itneractions
with anionic acceptor atoms; b) it ocunts just the single best interaction when two or
more metal ligations are found; and c) the net charge on th metal ion is assessed in the
unligated apo–protein. If the net carge is positive, the preferene for anionic ligand is
incorporated into the scoring functio. Else, if net charge is neutral, the prefernce is
suppressed. The seventh term in the fucntion rewards situations in chich a polar but
non-H-bonding atom is found in a hydrophobic region.
The major components are the contributions from the Coulomb and vdW
interactions energies between the ligand and the receptor (Equation [2.10]). Another
major component is hte introduction of a solvation model and incoporation of the
solvation effects. Glide docks explicit waters into the active site for each energetically
competitive ligand pose and utilize empirical scoring terms that assess the exposure of
various groups to the explicit waters.
ቛቓቊቩቦቡቢቖበቬቯቢ ቭ ቈዷሃሉሀ ቦ ቈሊዸዱ ቦ ቈዶዽሂዸ ቦ ቈሄዹሂድሀለልዸ [2.10]
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2. COMPUTATIONAL TECHNIQUES
ቈዶዽሂዸ ቭ ቈዼልዸቕዹሂዷሀሃሇሉሆዹ ቦ ቈዼዶቕሂሂቕሁሃለዽዺ ቦ ቈዼዶቕዷዷቕሁሃለዽዺ ቦ ቈዪዣ ቦ ቈዼዶቕሄድዽሆ 
[2.11]
ቦ ቈሄዼሃዶዽዷቕሄድዽሆ 
where, Ehyd_enclosure represents hydrophobic enclosure; Ehb_nn_motif represents the special
neutral-neutral H-bond motifs; Ehb_cc_motif represents special charged H-bond motifs, EPI
pi-stacking and pi-cation interactions; and Ephobic_pair hydrophobic atom-atom pair
energy term. Ehb_pair term is same as defined in ChemScore scoring function.
ቈሄዹሂድሀለል ቭ ቈዸዹሇሃሀሊ ቦ ቈሀዽዻድሂዸቕሇለሆድዽሂ [2.12]
where Edesolv represents desolvation penalties, and Eligand_strain contac penalties
(penalizing strain energy).
2.2 Molecular Mechanics and Molecular Dynamics Simulations
Molecular mechanics (MM) uses classical mechanics to model molecular 
systems. The potential energy of all systems in molecular mechanics is calculated using
force fields. Molecular mechanics can be used to study molecule systems ranging in
size and complexity from small to large biological systems or material assemblies with
many thousands to millions of atoms.
The force field refers to the functional form and parameter sets used to
calculate the potential energy of a system of atoms. All-atom force fields provide
parameters for every type of atom in a system. Force field methods (also known as
molecular mechanics; MM) ignore the electronic motions and calculate the energy of a
system as a function of the nuclear positions only. The first assumption of these
molecular mechanics is the Born-Oppenheimer approximation; MM is based upon a
rather simple model of the interactions within a system with contributions from
processes such as the stretching of bonds, the opening and closing angles and the
rotations about single bonds.
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2. COMPUTATIONAL TECHNIQUES
The basic functional form of potential energy in MM includes bondend terms
for interactions, and nonbonded terms that describe the long-range electrostaic and
van der Waals forces, as in Equation [2.13].
[2.13]቙ቛቕቜለሃለድሀ ቭ ቙ቛቕቜዶሃሂዸዹዸ ቦ ቙ቛቕቜሂሃሂበዶሃሂዸዹዸ 
The potential energy function (Equation [2.13]) could be divided into two main
terms: bonded potential energy (Equation [2.14]) and non-bonded (Equation [2.15]):
቙ቛቕቜዶሃሂዸዹዸ ቭ ዮ ቎ዶ ቛ቟ ቧ ቟ሃቜ
቗ ቦ ዮ ቎ሰ ቛሁ ቧ ሁሃቜ
቗ 
ዶሃሂዸሇ ድሂዻሀዹሇ 
[2.14]
ቦ ዮ ቎ ቟ኔ ቦ ኦኲ኶ቛቫ ቧ ቜበ
ዸዽዼዹዸሆድሀሇ 
In the case the of the bond energy term, ቎ዶ represents the force constant, 
while ቟ and ቟ሃcorrespond to the current bond leght and the equilibrated bond lenght,
respectively.
In the case the of the angle-bending energy term, ቎ሰ is the force constant for
the system composed by the three atoms, and the ሁ and ቦ኎ are the current angle and
the angle at equilibrium, respectively. And finally in the case of the dihedral energy
term, ቎ is the force constant,  is the actual angle, and  is the phse shift determining
the position of the minima.
቙ቛቕቜሂሃሂበዶሃሂዸዹዸ ቭ ዮ 
ሂሃሂዶሃሂዸዹዸ
኎ዾዽዾ ኆቧ 
ቕኌኈኍ ዽዾ 
ቯዽዾ 
ቨ 
ቖ቗ 
ቧ ቧ 
ቕኌኈኍ ዽዾ 
ቯዽዾ 
ቨ 
ቛ 
ኊ ቦ 
ቮዽቮዾ 
ዾዞቯዽዾ 
ኒ [2.15]
ድለሃሁ ሄድዽሆሇ 
The non-bonded interactions consist of Lennard-Jones repulsion and dispersion
ቖ቗ ቛ
ዬኄኀኅ ድዶ ዬኄኀኅ ድዶ ህድህዶዾዽዾ ቩኍ ኑ ቧ ኍ ኑ ቉ as well as Coulomb electrostatics (Figure 2.1). The 12­ሆድዶ ሆድዶ ርዖሆድዶ 
6 Lennard-Jones (LJ) potential is used to describe the repulsion between two atoms (i
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2. COMPUTATIONAL TECHNIQUES
and j) in which the overlap of the electron clouds of both atoms induces dipoles
generating an attractive component.
Figure 2.1. Lennard-Jones potential for two atoms (extracted and modified from
http://atomsinmotion.com/book/chapter5/md).
The electrostatic term is calculated using Coulomb’s law for the system, this
electrostatic contribution due to the partial charges of each atom (qi and qj) in
distance-dependent manner (ቯዽዾ), taking into account the permittivity of the solvent
(ዾዞ). To study biological systems the most accurate approach would use QM
calculations, but they are very time consuming (Figure 2.2).
Figure 2.2. Representation of Coulombic electrostatic term (extracted and modified from
http://atomsinmotion.com/book/chapter5/md)
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2. COMPUTATIONAL TECHNIQUES
The various contributions ara schematically represented in Figure 2.3.
Figure 2.3. Schematic representation of the key contributions to a molecular
mechanics force field: bond stretching, angle bending, torsional terms and non­
bonded interactions.
Bond stretching: The most elementary approach is to use a Hooke’s law in
which the energy varies with the square of the displacement from the reference bond
leght ቟ሃ.
Angle bending: The angle-bending energy term is also frequently described
using a Hooke’s law or harmonic potential. The contribution of each angle is
characterized by a force constant and a reference value. Rather less is required to
distort an angle away from equilibrium than to stretch or compress a bond, and the
force constant are proportionately smaller.
Torsional terms: Most of the variation in structure and relative energies is due
to the complex interplay between the torsional and non-bonded contributions. The
exitence of barriers to rotation about chemical bonds is fundamental to understanding
the structural properties of molecules and conformational analysis. Many force fields
are used for modelling flexible molecules where the major changes in conformation
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are due to rotations about bonds; in order to simulate this it is essential that the force
field properly represents the energy profiles of such changes.
Non-bonded interactions: Independent molecules and atoms interact thourght
non-bonded foreces, which also play an importatn role in determining the structure of
individual molecular species. This non bonden interactions do not depend upon a
specific bonding relationship between atoms/ They are “through-space” interactions,
and are usually modelled as a function of some inverse power of the distance. The
non-bonden terms in a force fiel are usually considered in two groups, one comprisin
electrostatic interactions ans the other van der Waals interactions.
Molecular Dynamics Simulation
MD relies on Newton’s second law of motion, described in this equation.
ቡ቗ትዽ ቉ሌዽ
ቭ [2.16]
ቡቱ቗ ቪዽ 
where ትዽ is the position in a Cartesian representation of the particle i, ቉ሌዽ is the force
acting on such a particle with a mass of ቪዽ, and t is the time. To solve this Equation
[2.16], a Taylor series expansion is used as a propagator to simulate the system’s time
evolution. The position of the particle in step (n+1) is calculated using molecular
coordinates and velocity from (n) and (n-1). Iterations continue until sufficient time
steps (defined by the user) have been produced; the information (coordinationates
and velocity) from all the steps constitute what is called MD trajectory. A classical MD
simulation protocol is composed of four important steps:
1. The structural data coming either from an experimental NMR/X-ray or 
homology modelling are prepared. Missing hydrogen atoms were added and
protonation state of ionisable groups was computed by using Maestro Protein
Preparation Wizard. Atom types and charges were assigned according to AMBER ff10
force field.
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2. COMPUTATIONAL TECHNIQUES
2. Minimization phase with the aim of removing the bad contacts between the
solute and solvent, and a heating phase for increasing the atom velocities through
gradual scaling until the system reaches the proper temperature. Initial velocities are
generally calculated using the standard temperature-dependent Maxwell-Boltzmann
distribution.
3. The equilibration phase which consists of allowing the system to relax, where
energy, temperature, volume, pressure, and Root Men Square Deviation (RMSD) are
monitore to ensure the stability of the system.
4. And the final step, production phase, where the trajectories are collected for
further analysis.
Molecular dynamics simulation algorithms have been implemented in a
number of simulation software packages: AMBER (Assisted Model building with Energy
Refinment), CHARMM (Chemistry at Harvard Molecular Mechanics), Desmond,
ESPResSo, GROMACS, GROMOS, LAMMPS, Martini, NAMD and OPLS (Optimized
Potentials for Liquid Simulations). Based on classic mechanics and given appropriate
initial conditions, ‘in theory’ we could calculate exactly how a system of interacting
particles evolves over time, deriving any desired property of the system through
statistical mechanics.
Accurate force fields are required for molecular mechanics. AMBER (Assisted
Model building with Energy Refinment) is the most common force field used to
describe proteins, developed in 1995 by Peter Kollman’s group/ The Merck Molecular
Force Field (MMFF) and the General AMBER Force Field (GAFF) have been developed
for the descripcion of small, drug-like molecules. Also lipids can be described in silico
through force fields such as Lipid 14 force field. The AMBER force field was used for
both ligand and protein, with the gaff parameter used for the ligand and the ff10
parameter used for the protein complex. MD simulations were run using the sander
module of AMBER 14.
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2.2.1 GAFF
GAFF24 is a general force field for organic molecules, which has parameters for 
most organic and pharmaceutical molecules. This force field uses 33 basic atom types
and 22 special atom types to cover almost all the chemical space composed of H, C, N,
O, S, P, F, Cl, Br, and I. For the basic atom types, all the bond length, bond angle, and
torsional angle parameters are available or can be calculated with empirical rules.
Special atom types were introduced to describe certain chemical environments
accurately, such as conjugated single and double bonds. The charge method used in
GAFF is HF/6-31G* RESP charge. The van der Waals parameters of GAFF are as same as
those used by the traditional AMBER force field.
2.2.2 GLYCAM06
GLYCAM0625 is the most general biomolecular force filed for carbohydrates.
GLYCAM development followed the general approach employed in biomolecular force
fields of defining a single dihedral angle term for each molecular-class-specific linkage.
QM calculations were employed to compute properties that are difficult or impossible
to access experimentally, such as, bond and valence angle deformation force
constants, dihedral angle rotational barriers, and electrostatic properties. The
generality of the parameters is exemplified by the utilization of a common set of terms
for α and β carbohydrate anomers. The feature to have just one C atom type facilitates
the simulation of ring-flipping, having equilibrium between conformers with axial and
equatorial substituents at the anomeric centre. This force field can be transferable to
all carbohydrate ring conformations and sizes, also can be readily extendible to
carbohydrate derivatives and other biomolecules, including monosaccharides and
complex oligosaccharides, be rigorously assessed in terms of the relative accuracy of
its component terms, and avoid the use of 1–4 electrostatic or non-bonded scaling
factors. GLYCAM turns the 1-4 non-bonded interactions off to correctly reproduce the
rotation of the ω-angle. In a study of the ω-angle rotation (O5—C5—C6—O6) in
monosaccharides, we observed that O6 may interact with either O4 (in a 1–5 
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relationship) or O5 (in a 1–4 relationship) and the use of 1–4 scaling therefore
unbalanced these interactions leading to an inability to correctly predict rotamer
populations.
2.2.3 AMBER ffSB14
Ff14SB improve the accuracy of protein side chain and backbone parameters
from ff99SB.26 ff99SB uses the functional form and many of the parameters derived in
ff9427 and ff99,28 which are associated with the Amber software.29 Some characteristic
features of ff94 include fixed partial charges on atom centers, explicit use of all
hydrogen atoms, no specific functional form for hydrogen bonding, and dihedral
parameters fit to relative quantum-mechanical (QM) energies of alternate rotamers of
small molecules. In particular, the protein φ/ψ dihedrals have specific rotational
parameters that affect relative energies of alternate backbone conformations. The
“backbone” dihedral parameters (that can alter the secondary structure) are very 
important component of protein force fields. In AMBER, each dihedral profile is
defined by a set of four atoms. The set of atoms used to define φ and ψ for glycine is
as expected, following φ and ψ along the main chain (φ= C-N-Cα-C, ψ= N-Cα-C-N).30 
2.2.4 LIPID 14
Lipid bilayers were set up and molecular dynamics run with Amber and the
Lipid14 force field. Amber 14 includes Lipid1431 which is a modular lipid AMBER force
field, allowing the simulation of a number of lipids via the combination of different
head and tail groups, a modular lipid force for tensionless lipid phospholipid
simulations. Lipid14 includes the modular charge derivation framework developed in
Lipid1132 as well as a reparameterization of key van der Waals and dihedral angles as
performed in GAFFlipid.33 Hydrocarbon parameters have been refined, resulting in
good reproduction of thermodynamic and dynamic properties for a number of simple
carbon chains. To reproduce the experimental density and heat of vaporization of
alkanes covering a range of chain lengths, LJ and torsion parameters were modified.
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Given that both the torsion and LJ parameters affected the simulated density and heat
of vaporization, these parameters were altered simultaneously, with the
CH2−CH2−CH2−CH2 torsion being fitted to ab initio data. These modifications were
tested analyzing different parameters of a selection of hydrocarbon chains. In the case
of the lipid partial charge, standard AMBER RESP protocol was used to generate partial
charges from quantum mechanical (QM) optimized structures, using six different
orientations of a single conformation. A greater number of conformations were used
per residue, with the partial charges calculated as an average over all conformations.
The head and tail group starting structures were extracted from previous in-house
bilayer simulations. This allows one to obtain Boltzmann weighted charges, introducing
a temperature dependence. The electrostatic potential (ESP) was calculated directly
from the conformations extracted from a bilayer simulation, with no QM optimization 
performed on those structures. Charges were derived using the standard AMBER RESP
protocol.34 
The modular nature of the force field allows for many combinations of lipid
head groups and tail groups as well as rapid parameterization of further lipid types.
Several van der Waals and dihedral angle parameters have been refined to fit
experimental data and quantum energies as well as a new partial charge derivation for
the head groups and tail groups. The force field was validated on six principle lipid
bilayer types. The lipid bilayer structural features compare favorably with experimental
measures such as area per lipid, bilayer thickness, NMR order parameters, scattering
data, and lipid lateral diffusion. The interaction of other species, such as small
molecules or proteins, with lipid membranes can be studied in AMBER using the
Lipid14 force field.
2.3 Free energy of binding: MM-PBSA/MM-GBSA and MM-ISMSA
The Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) and the
Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) methods calculate
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2. COMPUTATIONAL TECHNIQUES
binding free energies for macromolecules by combining molecular mechanics
calculations and continuum solvation models.35 
The Gibbs free-energy formula is applied to calculate ዠቊ (equation [2.17]):
ዠቊ ቭ ዠቋ ቧ ቗ዠቖ [2.17]
where ዠቊ is the variation of the free energy in a system, ዠቋ the variation of
the enthalpy, ዠቖ the variation of the entropy and ቗ the tempearture of the system.
The AMBER software36 used to poduce MD simulations allow us to calculate the
absolute free energies of binding by Molecular Mechanics Generalized Born (MM­
GBSA) and Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA)
approaches. The ዠቊዶዽሂዸሂሇሃሀሊ is calculated as the difference between ዠቊ of the solvated
complex (ዠቊ ዝሇሃሀሊ ) and the sum of the ዠቊ of the solvated receptor(ዠቊ 
ዬ
ሇሃሀሊ )and ligand
቏ቛዠቊ ተቬቩታ ), taking also in consideration the ዠቊ associated to the complex in vacuum
(equation [2.18]).
ዝ ዬ ዦ ቜ [2.18]ዠቊዶዽሂዸሂሇሃሀሊ ቭ ዠቊዶዽሂዸሂሊድዷ ቦ ዠቊ ሇሃሀሊ ቧ ቛዠቊ ሇሃሀሊ ቦ ዠቊ ሇሃሀሊ 
The energy of the binding is calculated in vacuum (equation [2.19]), using
classical methods and taking into account theenrgy differences associated to bonds,
angles and dihedrals upon binding and the electrostaics and van der Waals terms 
(ዠቈ ዧዧ ) and also the conformatioanl entropy change (቗ዠቖ) computed by normal
mode analysis (NMA) on a set of conformational snapshot from MD simulation.
ቧ ቗ዠቖ [2.19]ዠቊ ዶዽሂዸሂሊድዷ ቭ ዠቈ ዧዧ
The solvent free energy (ዠቊ ሇሃሀሊ) (equation [2.20]) has two contributions, the
electrostatic (polar contribution) and non-electrostatic (non-polar) contributions. The
electrostatic contribution (ዠቊ ዪዜሡዡዜ ) of the solvation to the free energy is calculated
by solving either the Generalized Born (GB) or the Poisson-Boltzmann (PB) equation.
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2. COMPUTATIONAL TECHNIQUES
The non-electrostatic contribution (ዠቊ ይዛ) is assessed by solvent accessible surface
area (SASA).
[2.20]ዠቊ ሇሃሀሊ ቭ ዠቊ ዪዜሡዡዜ ቦ ዠቊ ይዛ 
!nother an ultrafast and accurate scoring function for protein−protein docking 
is MM-ISMSA.37 It includes a molecular mechanics (MM) part based on a 12−6
Lennard-Jones potential; an electrostatic component based on an implicit solvent
model (ISM) with individual desolvation penalties for each partner in the
protein−protein complex plus a hydrogen bonding term- and a surface area (S!)
contribution to account for the loss of water contacts upon protein−protein complex
formation.
2.4 Virtual Screening Strategies in the Search of Novel TLR4 Modulators
It is imperative to find new chemical entities as TLR modulators with drug-like
properties in order to facilitate their development as drugs. In the context of drug
discovery, virtual screening techniques have already proved to make hit identification
more goal-oriented, allowing the access to a huge number of chemically diverse
binders (from public and commercial databases) with a relatively low-cost in terms of
time and materials. This computational approach has been subjected to extensive
attention and revision over the years, from the early perspective of being an emerging
method,38 until the current time where new challenges are faced.39-44 TLRs are not
standard receptors which could be approached following classical strategies in drug
design. The complexity of the system and the characteristics of their complexation
with the PAMPs make them especially difficult to tackle following classical procedures
in drug design and discovery. This is why TLRs constitute a special case study, in this
context.
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2.4.1 Virtual Screening Protocol
General strategies for a VS protocol include several steps that are summarized
in Figure 2.3. The availability of the 3D coordinates of the target is mandatory, either
from X-ray crystallography, NMR or homology modeling. Prior knowledge about the
ligand binding site may help in the identification of proper binders although, in some
approaches, the search for novel binding pockets can be an additional interesting and
challenging element in the drug discovery process.
Figure 2.3. Summary of the VS protocols applied for the search of novel TLR modulators:
access to databases and preparation/filtering of small-molecules; docking calculations;
selection of candidates; experimental testing, and final identification of drug candidates.
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2.4.2 Database Processing and Inclusion of Decoys
Database processing constitutes a fundamental step in VS approaches. It is 
crucial to generate the proper chemical library, with the adequate geometries,
ionization states, conformations, etc. Furthermore, it is very important to discard any
molecule that will not be a good candidate in the further steps of the VS study in
relation to the particular system on hand. A good database processing will assure a 
rigorous and well-conducted virtual screening, as well as it will avoid computational
cost and identification of unsuitable drug candidates. 
To preparate the databases and inclusion of decoys are some different
software:
- LigPrep,45 a software created by Schrödinger LLC, is a collection of tools
designed to prepare high quality, all-atom 3D structures for large numbers of drug-like
molecules, starting from 2D or 3D structures. LigPrep starts by converting the input
structure files to Maestro46 format. The LigPrep process consists of a series of steps
that perform conversions, apply corrections to the structures, generate variations on
the structures, eliminate unwanted structures, and optimize the geometry. LigPrep
produces a single low-energy 3D structure with defined chiralities for each processed
input structure and it can also produce a number of structures from each starting
geometry with varying ionization states, tautomeric forms, stereoisomers, and ring
conformations. Additionally, LigPrep offers the option to eliminate molecules from the
collection to be screened using various criteria including molecular weight or quantity
and types of functional groups composing the molecule.
- AutoDockTools47 is the graphical interface implemented within the Python
Molecular Viewer to make AutoGrid and AutoDock (both are required to be used as
docking program) widely accessible tools.13, 47-48 It facilitates the formatting of input
molecule files, with a set of methods that guide the user through protonation,
calculation of charges, and specification of rotatable bonds in the ligand and the
protein. As a brief outline of the preparation process, the ligand is loaded to the
graphical interface, and ADT prepares it for AutoDock docking program. Polar
hydrogens are added, charges are calculated, and nonpolar hydrogens are merged
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with the heavier atoms to which they are attached. If the ligand file presents no
charges, ADT will compute Gasteiger charges. Then, AutoDock atom types are assigned
to each atom. Regarding the ligand preparation for the virtual screening, it is important
to treat flexibility of the ligands. For this purpose, ligand flexibility is assigned in several
steps. First, a root atom is chosen, which will act as the fixed position during
coordinate transformation in the docking simulation. To find the optimal atom, the
number of atoms in each branch is evaluated, and the root atom that minimizes the
size of the largest branch is chosen. However, the ligand flexibility can be limited. As a
limitation, each step in ADT has to be launched manually, one by one, as well as the
preparation of each ligand. However, it is possible, with simple scripts, to do it
automatically.
2.4.3 Docking Tools for VS
Molecular docking is a well-established method to investigate how a ligand
interacts with its receptor. It integrates an automated computer algorithm that
determines how a compound may bind in the active site of a target (binding mode and
ligand/receptor interactions) and that tries to predict how tightly it binds (prediction of
the binding energy), revealing the electrostatic and steric complementarity between
the protein and the ligand.49-51 
Nowadays, most of the docking programs are characterized by (i) the specific
method to treat ligand flexibility,52 which can be divided into three categories:
systematic methods (incremental construction and conformational search); random or
stochastic methods (Monte Carlo, Genetic Algorithms and Tabu search); and
simulation methods53 (molecular dynamics and energy minimization); (ii) the scoring
function,52 classified into three categories: ii.a) force field-based scoring functions,54 
where a classic force field is employed to compute the noncovalent ligand-target
interactions, such as van der Waals and electrostatic energies (they are often
augmented by a GB/SA or PB/SA term in order to account for the solvation effect); ii.b)
empirical scoring function,10 where the overall binding free energy is calculated by
adding the contributions from several energetic terms, including hydrogen bond (H­
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bond) interaction and hydrophobic interaction (the weighting factors of all terms are
calibrated from a set of known complexes with experimentally determined structures
and binding affinities); and ii.c) knowledge-based scoring functions,11-12 where the
ligand/target interactions are computed as a sum of distance-dependent statistical
potentials between the ligand and the target (only the structural information of ligand­
target complexes is needed, which is being accumulated rapidly due to structural
biology advances).
1. FLAP
The new molecular modeling tool FLAP (Fingerprints for Ligands and Proteins)
provides a common reference framework for comparing molecules, using GRID
Molecular Interaction Fields (MIFs). The MIFs describe the type, strength and direction
of the molecular interactions between two biological partners. These MIFs are then
condensed into discrete pharmacophoric points representing favorable and
unfavorable interactions using a weighted energy-based and space coverage function.
Using these discrete points, all four-point quadruplets are generated, and the resulting
pharmacophore quadruplet fingerprint describes the target of interest. In addition to
the fingerprints, the GRID MIFs are retained. The targets are then aligned by matching
quadruplets in Cartesian space and a field similarity computed using the pre-calculated
MIFs. Hence, the fingerprints are used to find matching pharmacophoric regions and
the entire fields are used to score the match. Ligands and/or proteins can be the
targets of interest.
FLAP consists of a graphical user interface, and several command-line programs which
execute the various tasks. FLAP is based on four probes only, H, O, N1, and DRY, which
respectively characterize the shape, hydrogen-bond acceptor, hydrogen-bond donor,
and hydrophobic interactions.
We used this program to perform structure-based and ligand- based virtual
screening. The aim of running structure-based VS is that the 3D structure of a receptor
binding site is known, and can be used as a target for FLAP. When performing
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alignments, the MIFs of a drug candidate are compared with the receptor MIFs. These
similarities are used to rank the potential interactions of drug candidates with the
receptor. Notice that the structure-based enrichments are in general lower than the 
ligand-based enrichments. This is most likely due to the fact that a structure-based
search uses a larger cavity definition (there is more noise). Moreover, a ligand-based
approach is based on the fact that active compounds should be chemically very similar,
biasing the search results to favor a particular chemical species. The structure-based
approach has the advantage that ligands binding different subpockets can be
identified, and should not be as closely tied to the chemotype of a ligand template. 
Virtual screening employing a Ligand-Based Approach is the best way to select
potential new candidate drugs from a library of compounds with known three­
dimensional structure but unknown activity against the biological target (the so-called
“decoys”)/ Having access to a series of compounds with known activity on a specific
biotarget, FLAP is able to align the molecules from the database (decoys) to one
specific and chosen active compound (template). It then computes the GRID based -
MIFs similarity) between decoys and the template assigning a score that can be used
to rank the most similar compounds The assumption is that the higher the similarity
with the template, the higher the probability of similar mechanism of action at the
receptor site. Once scores are produced for each molecule of the dataset, it can be
necessary to evaluate how well the known active compounds are recognized by FLAP
through the use of an Enrichment Plot or a ROC curve.
2. GLIDE
Glide is a commercial docking program provided by Schrödinger5, 15, 23 and
designed to dock only the relevant region of the receptor, thus saving time
calculations. The full docking VS workflow includes 3 docking stages: HTVS, SP
(Standard Precision) and XP (Extra Precision). The first stage performs High Throughput
Virtual Screening (HTVS) docking. It is intended for rapid screening of very large
number of ligands and has much more restricted conformational sampling than SP
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docking. The second stage performs SP docking. It is appropriate for screening ligands
of unknown quality in large numbers. The third stage is the XP docking and scoring. It is
a more powerful and discriminating procedure using an implementation of a modified
and expanded version of the ChemScore scoring function, called GlideScore5 and
categorized as an empirical scoring function. Glide can be used to perform virtual
screening, accurate binding mode precision and furthermore, Glide exhibits excellent
docking accuracy and high enrichment across a diverse range of receptor types.
2.4.4 Pan Assay Interference Compounds, PAINS
A computational tool for identifying new lead compounds for the validated
drug targets in a virtual screening is high-throughput screening. However, it has also
introduced a large number of molecules which interfere drug screening. These
compounds, they are known by the name of Pan Assay Interference Compounds,
PAINS, which interfere with the progress of drug screening in various ways, such as 
interfering with a biochemical assay, modifying the protein or aggregate-based
inhibitors. PAINS may result from the presence of functional groups that can rect with
biological molecules independent of a specific molecular recognition event. The
physical properties of some small molecules coul cause them the falsely score as a hits
in assays. So it is of vital significance to remove them. New leads are commonly
identified using in-house discovery programs, competitor monitoring, and public
sources of information, such as the current literature or databases of active molecules
etc).55-57 (ChemBl, PubChem, ChemSpider, UniChem, A number of substructural
features which can help to identify compounds that appear as frequent hitters
(promiscuous compounds) in many biochemical highthroughput screens.The
compounds identified by such substructural features are not recognized by filters 
commonly used to identify reactive compounds. Even though these substructural
features were identified using only one assay detection technology, such compounds
have been reported to be active from many different assays. In fact, these compounds
are increasingly prevalent in the literature as potential starting points for further
exploration, whereas they may not be.58 They have identified rhodanines, phenolic
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Mannich bases, hydroxyphenylhydrazones, alkylidene barbiturates, alkylidene
heterocycles, 1,2,3-aralkylpyrroles, activated benzofurazans, 2-amino-3­
carbonylthiophenes, catechols and quinones as PAINS. The most common causes of
PAINS activity are metal chelation, chemical aggregation, redox activity, compound
fluorescence, cysteine oxidation or promiscuous binding. Many PAINS have multiple
functionalities, causing different types of interference and resulting in in vitro and in
vivo activity. From the pharmaceutical industry GSK has reported filters that their
59-60 medicinal chemists use to reject molecules containing undesired functional groups. 
Also Abbott reported their ALARM NMR tool and subsequent procedures to remove or
flag potentially thiol reactive compounds.56, 61 And Eli-Lilly reported on the filters they 
use at the front end of their open-innovation platform in order to discriminate the
molecules they are interested in testing from unwanted ones. 62 In the academia,
University of Dundee published a series of SMARTs filters to remove unwanted
groups. 63 Sean Ekins et al. published a study toward the phenotypic screening of
Mycobacterium tuberculosis and subsequent findings regarding unwanted groups.64 
And also Jonathan Baell from the Monash University published his report on pan
assays interference compounds (PAINS) a list of structural features of frequent hitters
from six different and independent assays. Computational filters exist to remove
known PAINS from chemical libraries and an experienced medicinal chemist will be
quickly able to identify a PAINS-type structure.
There are two servers to remove these PAINS: PAINS-remover,
http://cbligand.org/PAINS/ and http://zinc15.docking.org/patterns/home/.
107
  
 
 
       
   
     
    
      
   
     
     
   
   
 
      
       
     
   
      
       
   
   
       
       
      
      
     
     
      
    
    
  
      
        
       
    
        
   
     
     
      
     
   
    
     
       
2. COMPUTATIONAL TECHNIQUES
Bibliography:
1. Koshland, D. E., The Key–Lock Theory and the Induced Fit Theory. Angew.
Chem. Int. Ed. 1995, 33 (23-24), 2375-2378.
2. Karush, F., Heterogeneity of the Binding Sites of Bovine Serum Albumin1. J. Am. 
Chem. Soc. 1950, 72 (6), 2705-2713.
3. Weber, G., Ligand binding and internal equilibria in proteins. Biochemistry
1972, 11 (5), 864-78.
4. Morris, G. M.; Goodsell, D. S.; Huey, R.; Olson, A. J., Distributed automated
docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput.
Aided Mol. Des. 1996, 10 (4), 293-304.
5. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; 
Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P.
S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and
assessment of docking accuracy. J. Med. Chem. 2004, 47 (7), 1739-49.
6. Lexa, K. W.; Carlson, H. A., Protein flexibility in docking and surface mapping. Q.
Rev. Biophys. 2012, 45 (3), 301-43.
7. Huang, S. Y.; Grinter, S. Z.; Zou, X., Scoring functions and their evaluation 
methods for protein-ligand docking: recent advances and future directions. Physical
chemistry chemical physics : PCCP 2010, 12 (40), 12899-908.
8. Huang, N.; Kalyanaraman, C.; Irwin, J. J.; Jacobson, M. P., Physics-based scoring
of protein-ligand complexes: enrichment of known inhibitors in large-scale virtual
screening. Journal of chemical information and modeling 2006, 46 (1), 243-53.
9. Bohm, H. J., The development of a simple empirical scoring function to estimate
the binding constant for a protein-ligand complex of known three-dimensional
structure. Journal of computer-aided molecular design 1994, 8 (3), 243-56.
10. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P., Empirical
scoring functions: I. The development of a fast empirical scoring function to estimate
the binding affinity of ligands in receptor complexes. Journal of computer-aided 
molecular design 1997, 11 (5), 425-45.
11. Verkhivker, G.; Appelt, K.; Freer, S. T.; Villafranca, J. E., Empirical free energy
calculations of ligand-protein crystallographic complexes. I. Knowledge-based ligand­
protein interaction potentials applied to the prediction of human immunodeficiency
virus 1 protease binding affinity. Protein engineering 1995, 8 (7), 677-91.
12. Gohlke, H.; Hendlich, M.; Klebe, G., Knowledge-based scoring function to
predict protein-ligand interactions. Journal of molecular biology 2000, 295 (2), 337-56.
13. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D.
S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated Docking with Selective
Receptor Flexibility. J. Comput. Chem. 2009, 30 (16), 2785-2791.
14. Trott, O.; Olson, A. J., AutoDock Vina: improving the speed and accuracy of
docking with a new scoring function, efficient optimization and multithreading. J.
Comput. Chem. 2010, 31 (2), 455-461.
15. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. 
T.; Banks, J. L., Glide: a new approach for rapid, accurate docking and scoring. 2.
Enrichment factors in database screening. J. Med. Chem. 2004, 47 (7), 1750-9.
108
  
 
   
        
  
       
     
      
 
     
  
    
      
     
    
       
     
    
     
   
    
   
     
    
   
       
   
   
    
      
      
     
   
    
     
    
    
      
     
  
  
    
  
       
    
     
     
 
2. COMPUTATIONAL TECHNIQUES
16. Stouten, P. F. W.; Frömmel, C.; Nakamura, H.; Sander, C., An Effective Solvation
Term Based on Atomic Occupancies for Use in Protein Simulations. Mol. Simul. 1993,
10 (2-6), 97-120.
17. Janeway, C. A., Approaching the asymptote? Evolution and revolution in
immunology. Cold Spring Harb. Symp. Quant. Biol. 1989, 54, 1–13.
18. Baxter, J., Local Optima Avoidance in Depot Location. J. Oper. Res. Soc. 1981, 32
(9), 815-819.
19. Wang, R.; Lai, L.; Wang, S., Further development and validation of empirical 
scoring functions for structure-based binding affinity prediction. Journal of computer-
aided molecular design 2002, 16 (1), 11-26.
20. Wang, R.; Fang, X.; Lu, Y.; Wang, S., The PDBbind database: collection of binding
affinities for protein-ligand complexes with known three-dimensional structures. J.
Med. Chem. 2004, 47 (12), 2977-80.
21. Wang, R.; Fang, X.; Lu, Y.; Yang, C. Y.; Wang, S., The PDBbind database:
methodologies and updates. J. Med. Chem. 2005, 48 (12), 4111-9.
22. Blum, C.; Blesa Aguilera, M. J.; Roli, A.; Sampels, M., Hybrid Metaheuristics: An
Emerging Approach to Optimization. Springer Publishing Company, Incorporated:
2008; p 290.
23. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; 
Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T., Extra precision glide: docking and
scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.
J. Med. Chem. 2006, 49 (21), 6177-96.
24. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A., Development
and testing of a general amber force field. J. Comput. Chem. 2004, 25 (9), 1157-74.
25. Kirschner, K. N.; Yongye, A. B.; Tschampel, S. M.; Gonzalez-Outeirino, J.; Daniels,
C. R.; Foley, B. L.; Woods, R. J., GLYCAM06: a generalizable biomolecular force field.
Carbohydrates. J. Comput. Chem. 2008, 29 (4), 622-55.
26. Maier, J. A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K. E.;
Simmerling, C., ff14SB: Improving the Accuracy of Protein Side Chain and Backbone
Parameters from ff99SB. J. Chem. Theory Comput. 2015, 11 (8), 3696-713.
27. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; 
Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A., A Second Generation Force
Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. 
Soc. 1995, 117 (19), 5179-5197.
28. Wang, J.; Cieplak, P.; Kollman, P. A., How well does a restrained electrostatic
potential (RESP) model perform in calculating conformational energies of organic and
biological molecules? J. Comput. Chem. 2000, 21 (12), 1049-1074.
29. Case, D. A.; Cheatham, T. E.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.;
Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J., The Amber biomolecular
simulation programs. J. Comput. Chem. 2005, 26 (16), 1668-88.
30. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C., 
Comparison of multiple Amber force fields and development of improved protein
backbone parameters. Proteins 2006, 65 (3), 712-25.
31. Dickson, C. J.; Madej, B. D.; Skjevik, Å. A.; Betz, R. M.; Teigen, K.; Gould, I. R.; 
Walker, R. C., Lipid14: The Amber Lipid Force Field. J. Chem. Theory Comput. 2014, 10
(2), 865-879.
109
  
 
    
    
 
      
      
    
      
    
      
   
     
       
  
   
      
    
   
 
 
    
  
       
       
 
        
   
     
   
   
    
 
      
      
 
    
    
    
   
    
    
   
  
   
     
    
2. COMPUTATIONAL TECHNIQUES
32. Skjevik, A. A.; Madej, B. D.; Walker, R. C.; Teigen, K., LIPID11: a modular
framework for lipid simulations using amber. J. Phys. Chem. B. 2012, 116 (36), 11124­
36.
33. Dickson, C. J.; Rosso, L.; Betz, R. M.; Walker, R. C.; Gould, I. R., GAFFlipid: a
General Amber Force Field for the accurate molecular dynamics simulation of
phospholipid. Soft. Matter. 2012, 8 (37), 9617-9627.
34. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A., A well-behaved
electrostatic potential based method using charge restraints for deriving atomic
charges: the RESP model. J. Phys. Chem. 1993, 97 (40), 10269-10280.
35. Hou, T.; Wang, J.; Li, Y.; Wang, W., Assessing the performance of the MM/PBSA 
and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on
molecular dynamics simulations. Journal of chemical information and modeling 2011,
51 (1), 69-82.
36. Case, D. A.; Darden, T. A.; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R.
E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Hayik, S.; Roitberg, A.;
Seabra, G.; Swails, J.; Götz, A. W.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.;
Wolf, R. M.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.;
Wang, J.; Hsieh, M.-J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Salomon-
Ferrer, R.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A.
AMBER 12, University of California, San Francisco., 2012.
37. Klett, J.; Nunez-Salgado, A.; Dos Santos, H. G.; Cortes-Cabrera, A.; Perona, A.; 
Gil-Redondo, R.; Abia, D.; Gago, F.; Morreale, A., MM-ISMSA: An Ultrafast and Accurate
Scoring Function for Protein-Protein Docking. J. Chem. Theory Comput. 2012, 8 (9),
3395-408.
38. Lyne, P. D., Structure-based virtual screening: an overview. Drug Discov. Today
2002, 7 (20), 1047-55.
39. Schneider, G., Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 
2010, 9 (4), 273-6.
40. Haga, J. H.; Ichikawa, K.; Date, S., Virtual Screening Techniques and Current
Computational Infrastructures. Curr. Pharm. Des. 2016, 22 (23), 3576-84.
41. Zhu, T.; Cao, S.; Su, P. C.; Patel, R.; Shah, D.; Chokshi, H. B.; Szukala, R.; Johnson, 
M. E.; Hevener, K. E., Hit identification and optimization in virtual screening: practical
recommendations based on a critical literature analysis. J. Med. Chem. 2013, 56 (17),
6560-72.
42. Lionta, E.; Spyrou, G.; Vassilatis, D. K.; Cournia, Z., Structure-based virtual
screening for drug discovery: principles, applications and recent advances. Curr. Top. 
Med. Chem. 2014, 14 (16), 1923-38.
43. Yan, X.; Liao, C.; Liu, Z.; Hagler, A. T.; Gu, Q.; Xu, J., Chemical Structure Similarity
Search for Ligand-based Virtual Screening: Methods and Computational Resources.
Curr. Drug Targets 2016, 17 (14), 1580-1585.
44. Sheng, C.; Dong, G.; Miao, Z.; Zhang, W.; Wang, W., State-of-the-art strategies
for targeting protein-protein interactions by small-molecule inhibitors. Chem. Soc. Rev.
2015, 44 (22), 8238-59.
45. Hennessy, E. J.; Parker, A. E.; O'Neill, A. J., Targeting of Toll-like receptors:
Emerging therapeutics? Nat. Rev. Drug Discov. 2010, 9, 293–307.
110
  
 
  
 
  
   
    
     
   
     
     
          
        
    
       
        
  
    
         
 
     
    
     
     
    
   
   
  
     
    
 
 
   
     
     
     
    
      
   
   
   
   
      
       
   
    
     
2. COMPUTATIONAL TECHNIQUES
46. Akira, S.; Takeda, K., Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4, 
499-511.
47. Takeuchi, O.; Kawai, T.; Muhlradt, P. F.; Morr, M.; Radolf, J. D.; Zychlinsky, A.;
Takeda, K.; Akira, S., Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int.
Immunol. 2001, 13 (7), 933-40.
48. Morris, G. M.; Huey, R.; Olson, A. J., Using AutoDock for ligand-receptor 
docking. Curr. Protoc. Bioinformatics 2008, Chapter 8, Unit 8.14.
49. Sousa, S. F.; Ribeiro, A. J.; Coimbra, J. T.; Neves, R. P.; Martins, S. A.; Moorthy,
N. S.; Fernandes, P. A.; Ramos, M. J., Protein-ligand docking in the new millennium--a 
retrospective of 10 years in the field. Curr. Med. Chem. 2013, 20 (18), 2296-314.
50. Moroni, E.; Paladino, A.; Colombo, G., The Dynamics of Drug Discovery. Curr.
Top. Med. Chem. 2015, 15 (20), 2043-55.
51. Spyrakis, F.; Cavasotto, C. N., Open challenges in structure-based virtual
screening: Receptor modeling, target flexibility consideration and active site water
molecules description. Arch. Biochem. Biophys. 2015, 583, 105-19.
52. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R., Principles of docking: An
overview of search algorithms and a guide to scoring functions. Proteins 2002, 47 (4),
409-443.
53. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E. W., Computational Methods in
Drug Discovery. Pharmacol. Rev. 2014, 66 (1), 334-395.
54. Genheden, S.; Ryde, U., The MM/PBSA and MM/GBSA methods to estimate
ligand-binding affinities. Expert. Opin. Drug. Discov. 2015, 10 (5), 449-61.
55. Xie, X. Q., Exploiting PubChem for Virtual Screening. Expert Opin. Drug Discov.
2010, 5 (12), 1205-1220.
56. Huth, J. R.; Song, D.; Mendoza, R. R.; Black-Schaefer, C. L.; Mack, J. C.; Dorwin, 
S. A.; Ladror, U. S.; Severin, J. M.; Walter, K. A.; Bartley, D. M.; Hajduk, P. J.,
Toxicological evaluation of thiol-reactive compounds identified using a la assay to
detect reactive molecules by nuclear magnetic resonance. Chem. Res. Toxicol. 2007, 20
(12), 1752-9.
57. http://depth-first.com/articles/2011/10/12/sixty-four-free-chemistry­
databases/ Sixty-Four Free Chemistry Databases.
58. Baell, J. B.; Holloway, G. A., New Substructure Filters for Removal of Pan Assay
Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in
Bioassays. J. Med. Chem. 2010, 53 (7), 2719-2740.
59. Nadin, A.; Hattotuwagama, C.; Churcher, I., Lead-oriented synthesis: a new
opportunity for synthetic chemistry. Angew. Chem. Int. Ed. Engl. 2012, 51 (5), 1114-22.
60. Hann, M.; Hudson, B.; Lewell, X.; Lifely, R.; Miller, L.; Ramsden, N., Strategic 
Pooling of Compounds for High-Throughput Screening. J. Chem. Inform. Comput. Sci. 
1999, 39 (5), 897-902.
61. Huth, J. R.; Mendoza, R.; Olejniczak, E. T.; Johnson, R. W.; Cothron, D. A.; Liu, Y.;
Lerner, C. G.; Chen, J.; Hajduk, P. J., ALARM NMR.  ! Rapid and Robust Experimental
Method To Detect Reactive False Positives in Biochemical Screens. J. Am. Chem. Soc. 
2005, 127 (1), 217-224.
62. Bruns, R. F.; Watson, I. A., Rules for Identifying Potentially Reactive or
Promiscuous Compounds. J. Med. Chem. 2012, 55 (22), 9763-9772.
111
  
 
  
    
     
    
 
         
    
 
2. COMPUTATIONAL TECHNIQUES
63. Brenk, R.; Schipani, A.; James, D.; Krasowski, A.; Gilbert, I. H.; Frearson, J.; 
Wyatt, P. G., Lessons learnt from assembling screening libraries for drug discovery for
neglected diseases. ChemMedChem 2008, 3 (3), 435-44.
64. Ekins, S.; Kaneko, T.; Lipinski, C. A.; Bradford, J.; Dole, K.; Spektor, A.; Gregory, 
K.; Blondeau, D.; Ernst, S.; Yang, J.; Goncharoff, N.; Hohman, M. M.; Bunin, B. A., 
Analysis and hit filtering of a very large library of compounds screened against
Mycobacterium tuberculosis. Mol. Biosyst. 2010, 6 (11), 2316-24.
112
  
 
 
 
 
  
 
 
 
 
 
 
 
 

 



 
CHAPTER 3
Computational Studies of Reported 
TLR4/MD-2 Ligands
 
   
 
 
  
       
         
      
     
        
           
           
    
       
       
     
         
       
       
        
     
         
        
          
    
        
     
 
 
 
 
  
3. TLR4 LIGANDS
3.1 Introduction
As mentioned in Chapter 1, LPSs are large glycolipids consisting of a highly
conserved lipid moiety, known as lipid A, and a polysaccharide composed of an
oligosaccharidic core (outer and inner part) and a O-specific polysaccharide. Recently, 
structural information on TLR4 has become available, providing insights on the binding
at the atomic level.1 In the X-ray crystallographic structure of TLR4/MD-2 in complex 
with potent agonist Escherichia coli LPS (PDB- ID: 3FXI), MD-2 is able to accommodate
up to five fatty acid (FA) chains of the E. coli lipid A into its large hydrophobic cavity.
The sixth chain protrudes from the MD-2 hydrophobic pocket, thus completing the
dimerization interface. The phosphate groups of the LPS are anchored to the polar
MD-2 rim, and the polysaccharide moiety establishes a network of polar interactions
with TLR4. Therefore, all of the structural components of the LPS molecule play a
fundamental role in the TLR4/MD-2 recognition and in the binding.2 
Lipid A is composed of FA chains of different lengths attached to a 1,4-β­
diphosphorylated diglucosamine backbone (Figure 3.1). The agonistic activity of lipid A
has been mainly assigned to the number (established as six), length and chemical
structure of the attached FA chains, as well as variability in the level of
phosphorylation and the number and types of substituted groups found attached to
the phosphate residues. Recent findings have pointed to the need of revisiting this
paradigm since some examples of LPS bearing a penta-acylated lipid A, together with
positively-charged residues decorating the lipid A, have been reported with
immunostimulatory ability. Therefore, these data suggest that subtle changes in lipid A
structure may profoundly impact the innate immune response from the host.
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3. TLR4 LIGANDS
Figure 3.1. Showing the contact interface of the dimerized TLR4/MD-2 complex bound to
LPS. (PDB-ID 3FXI). At the right, primary contact interface between the MD-2 in purple and
the TLR4 in green, which includes two different contact regions, the Patch A and Patch B. 
At the left the dimerization interface, remarking the channel created in the surroundings 
of Phe126.
In a previous work performed by members of our group, the study was focused
in the binding of lipid IVa,3 which is a synthetic analogue of lipid A, that is the most
outer region of the LPS used by the gram-negative bacteria to anchor the host outer
membrane during the invasion process. The main interest of studying the binding of
lipid IVa is the difference in the mechanism action of the molecule across different
species; in particular, lipid IVa is an agonist of the immune response in murine and an
antagonist in human. Lipid IVa bound conformation differs significantly when looking at
the mouse and human crystal structures by having opposite orientation in the direction
of the sugar moiety and phosphate groups. Interestingly there are certain substitutions
in the MD-2 sequence that may stabilize these two different conformations of the lipid 
IVa. The strongest interaction found out from our energy analysis is the polar interaction
between the Lys122 from MD-2 that interacts with and the O5 from the sugars and the
oxygen from the glycosidic linkage. Lys122 from the MD-2 is substituted by Glu122 in
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3. TLR4 LIGANDS
mouse that interacts with the hydroxyls from the sugar moieties. This is the main
difference found in the protein sequence that facilitates two different binding modes of
lipid IVa in terms of polar interactions; other substitutions were found, but only affecting
to hydrophobic residues which kept their hydrophobic nature. It is remarkable that, in
human, there is an interaction between Lys122 from the MD-2 and the oxygen atoms
from the sugar core of lipid IVa exactly in the same way as the Ly360 from the TLR4 is 
interacting with the lipid IVa. Another mayor difference we found that the antagonist
human conformation interaction pattern lacks of important interactions with the TLR4.
In the mouse agonist system we observed the interaction with the O5 from the sugar
moieties and oxygen atom from the glycosidic linkage with Lys360 from the TLR4, this
interaction could contribute to stabilize the agonist conformation in terms of the
global motion previously described for the maintaining the TLR4/MD-2 complex.
Small molecules pyrimido[5,4- b]indoles have shown to stimulate TLR4 and
could potentially be used as adjuvants or immune modulators.4 Synthetic analogues of
natural product Euodenine A have exhibited potent and selective agonistic activity
towards TLR4.5 It has also been reported that synthetic peptides mimic the TLR4/LPS
interactions.6 On the other hand, several small non LPS molecules with TLR4 antagonist
activity have also been developed, such as ethyl 4-oxo-4-(oxazolidin-3-yl)-butenoate
derivatives (OSL07), benzothiazole-based inhibitors, ethyl phenyl­
sulfamoylcyclohexenecarboxylate derivatives (TAK-242 or resatorvid), and β-amino
alcohol derivatives.7-10 However, no successful progress was shown in clinical phases
(for example, in the case of compound OSL07).
Due to the wide range of possible therapeutic usages of TLR4 modulators,
several approaches for their design have been exploited, leading to four general
classes of therapeutics: LPS mimetics, small molecule modulators, peptides, and
monoclonal antibodies.11 Compared with all the designed TLR4 therapeutic agents,
small molecules show interesting advantages given that LPS analogues show important
solubility and toxicity limitations,12 and peptides have poor pharmacokinetics.13 
Therefore, small molecules that do not structurally resemble to LPS represent a 
different promising and interesting alternative. A deep and extensive study of the
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3. TLR4 LIGANDS
molecular mechanisms by which these TLR4 ligands modulate TLR4 activity emerges as 
an interesting strategy to understand TLR4 pharmacodynamics, which is essential for
drug design and development processes. Also computational chemistry methodologies
appear as necessary, powerful and time-saving tools for the prediction of ligand
binding modes with the TLR4/MD-2 systems.
There is experimental evidence confirming that most of the TLR4 small
molecule modulators exert their pharmacological activity through binding to MD-2 
inner pocket. Among them we found the TLR4 agonists such as paclitaxel,14 some
opioids (remifentanil),15 and TLR4 antagonists like xanthohumol (XN),16 sulforaphane
(SFN),17 N-pyrene maleimide (NPM), dalcetrapib (JTT705), iodoacetylaminonaphtyl
sulfate (IAANS),18 curcumin,19 cinnamamides,20 and certain opioids such as naxolone.15 
However, TLR4 small molecule modulators show varied physicochemical properties,
suggesting that not all of them may bind to MD-2 pocket, which is extremely
hydrophobic. Additionally, MD-2 binding ligands may not be exerting its function by
binding uniquely to MD-2 pocket, modulating the receptor by binding to other
unknown binding sites.21 
The presence of drug binding sites other than MD-2 has been further confirmed
by experimental studies which proof that the TLR4 agonist as DiC14-amidine acts as a
protein-protein interaction (PPI) stabilizing agent, binding to the TLR4/TLR4* interface
of the activated system.22 There is also experimental evidence that this dimerization
interface is targeted by nickel ions, which activate the receptor complex.23 
Furthermore, although there is no experimental evidence for drug binding, Gobec and
coworkers and Yin and coworkers4 reported series of TLR4 modulating agents which
presumably act as PPI inhibitors by disrupting the TLR4/MD-2 interface in the
TLR4/MD-2 system.24 Other compounds, such as 4-aminoquinazolines and pyrimido-[5­
4,b]-indoles show TLR4 agonist activity through binding to the TLR4/MD-2* interface of
the TLR4/MD-2/TLR4*/MD-2 system.4, 25 The design and development of PPI stabilizing
agents and PPI inhibitors has appeared as a relatively new approach for the
achievement of drugs with different pharmacodynamic profile.26 
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3. TLR4 LIGANDS
Many of the ligands that were found to modulate TLR4 activity do not present
neither experimental nor computational studies of their binding mode: this was the
case of the heme group, 27 bryostatin-1 (bryo-1)28 and certain polyoxygenated
cholesterol ester hydroperoxides (BEP-CE),29 as these compounds were proven to
activate TLR4. Additionally, there are several compounds which are able to inhibit the
dimerization of the TLR4/MD-2 system whose binding is unknown, such as glycyrrhizin,
and isoliquiritigenin.30 Furthermore, although eudonenines require MD-2 to activate
TLR4, their binding modes have not been yet fully defined.5 Finally, the binding mode
of certain tryciclics such as imipramine, desipramine and amitriptyline is only
supported by computational studies thus there is no experimental evidence proving
their binding to MD-2.31 
Our work aimed to propose a binding mode for some reported TLR4/MD-2 
binders, and to understand, at atomic level, the main ligand-macromolecule
interactions taking place for the agonist/antagonist behaviour comparing with lipid A
and lipid IVa. 
In particular, we focused our work in simplified LPS analogues, among them
(Figure 3.2): P01 and P0312 are small molecules with two fatty acid chains containing
an ammonium group; the tetraacylated synthetic compound Eritoran32 reached phase
III in clinical trials, but failed to demonstrate sufficient efficacy in late stage human
trials, although it has recently shown promising activity in preventing influenza­
induced acute lung injury, through a TLR4 antagonism mechanism; agonist compounds
ONO-400733 (a LPS-like compound with TLR4 agonist activity through the induction of
TNF-α production in tumor cells, with no further clinical development due to the
limited water solubility), antagonist compound D133 (a synthetic lipid A analogue,
which inhibits endotoxin activation of TLR4 by precluding interaction of the endotoxin
with both CD14 and TLR4/MD-2) and the antagonists compounds A1 and A2. 
Non LPS molecules have also been developed among them (Figure 3.3): 
euodenine A,5 a natural product isolated from the leaves of Euodia asteridula, with no
LPS structure; its synthetic analogues have exhibited potent and selective agonism
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3. TLR4 LIGANDS
towards the TLR4, Paclitaxel,34 and pyrimido[5,4-b]indoles4 have shown to stimulate
TLR4 and could potentially be used as adjuvants or immune modulators.
For all these TLR4 modulators there are not binding mode proposed. It is clear
that although these molecules have a different chemical structure, they must share a
common pattern of interactions with TLR4. We have undertaken a computational
study of some representative compounds to unveil some of these patterns of
interactions. Some of them have engender an antagonistic response and other agonist
response in the TLR4 complex. These molecules were docked comfortably into the
hydrophobic pocket MD-2, thus creating a stable complex between the MD-2 and TLR4
in molecular dynamics. There is something common among them that do have this
behaviour and we are studying by molecular modelling technique.
It is interesting to note that a number of small molecules have been reported as
TLR4 modulators. Although it is plausible these molecules bind MD-2, we have to
consider that they might be targeting other sites/pockets (due to its reduced volume
and size in comparison with the “native” ligand LPS)/ Moved by this idea, we
undertook a computational analysis of the different accessible pockets of the
TLR4/MD-2 system to identify/discover new/alternative binding sites where these
small molecules could be binding.
For this, a combined approach involving binding site prediction and docking 
studies was implemented to determine primary and secondary drug binding sites for
known TLR4 ligands, and evaluate the results to deduce the underlying molecular
mechanism that reflects ligand pharmacodynamics. Our objectives here were, the
identification of possible binding pockets in different conformations of the TLR4/MD-2 
system, and the proposal of the binding modes for known TLR4 small molecule
modulators. Different new primary drug binding sites and secondary sites were found
in the TLR4/MD-2 systems, especially in protein-protein interfaces. Additionally,
regarding the specific targeted docking studies, new binding modes for the TLR4
modulation through different ligands were proposed.
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LPS-like Molecules
Figure 3.2. Chemical structures LPS-like molecules.
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Non LPS-like Molecules
Figure 3.3. Chemical structures non LPS-like molecules
3.2 Results and Discussion
3.2.1 Interaction in TLR4/MD-2 Modulators with LPS-like Structure
To evaluate putative TLR4/MD-2 binding properties of these compounds, we
undertook docking studies in the hTLR4/MD-2 system. The X-ray structure PDB-ID: 3FXI
was used for the agonist conformation. Since the X-ray structure of the hTLR4/MD-2 
complex is not available in the complex with an antagonist, we used a hybrid in house
model by superimposing MD-2 structure from PDB-ID: 2E59 in one of the MD-2 
subunits of the TLR4/MD-2 complex (PDB-ID: 3FXI, chain C) (for more details, see
Chapter 3). AutoDock4 and VINA programs were used to carry out the docking
calculations leading to similar predicted binding poses in all cases, without main
differencies in the observed ligand-TLR4/MD-2 interactions.
As in the X-ray crystallographic structures of LPS and lipid IVa in both
conformation, agonist and antagonist, the predicted binding poses for all the LPS-like 
molecules showed a general tendency to bury their fatty acid (FA) chains deeply buried
into the hydrophobic pocket of MD-2, establishing van der Waals and CH-π 
interactions with the side chains of the lipophilic residues of the MD-2 pocket, and
polar interactions between the sugars and the polar residues of MD-2 rim. The
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3. TLR4 LIGANDS
resulting docked complexes of TLR4/MD-2 with P01, P03, eritoran, D1, and ONO-4007
were submitted to MD simulations for a deeper analysis of the ligand-receptor
interactions.
3.2.1.1 LPS-like Antagonist Ligands
Studies into de binding pose of synthetic LPS-like compounds were performed
for the following ligands: P01, P03, D1, A1 and A2, together with endotoxin, eritoran
and lipid IVa35 as reference compounds.
For all the studied LPS-like compounds, docking calculations led to similar 
results in both MD-2 and TLR4/MD-2 systems. The FA chains were allocated inside the
hydrophobic MD-2 pocket, and sugar moieties were found to be accommodated in the
MD-2 rim, by establishing polar interactions. In particular, the studied LPS-like
antagonists were found to establish many hydrophobic interactions in common to
those observed for lipid IVa 35 inside MD-2: Ile32, Ile44, Ile46, Val48, Ile52, Leu61,
Ile63, Tyr65, Leu71, Leu74, Phe76, Leu78, Ile80, Val82, Ile94, Phe104, Val113, Ile117, 
Phe119, Phe121, Ile124, Val135, Leu146, Phe147, Leu149, Phe151 and Ile153. Also
common polar interactions were found in the docked poses for most of the LPS-like
antagonists, in particular with Tyr65, Arg90, Glu92, Tyr102, Ser118, Ser120, Lys122,
Tyr131, and Cys133. Additionally, D1 and A2 were found to interact with Arg264 from
TLR4.
Regarding P01 and P03,12 our results showed that most of the docking models
displayed a very rational binding mode with the FA chains toward the pocket (Figure
3.3), but they were not able to provide an unique binding mode. This result suggests
that the ligand may be fluctuating in the hydrophobic pocket while being bound to the
MD-2, and an adaptation of the MD-2 hydrophobic pocket could take place, as shown
by our calculations of the volume of the hydrophobic pocket.
For both P01 and P03, two docking calculations were done respectively, first in
the isolated MD-2 and second in the TLR4/MD-2 complex. Similar results were
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3. TLR4 LIGANDS
obtained in terms of the general orientation of the molecule as lower energy binding
modes tended to bury their FA chains inside the MD-2 pocket and the sugar moiety
located at the rim of the MD-2 establishing polar interactions. From the all docking 
obtained, the poses with lowest binding energy and having the consistent orientation
of the FA chains towards the pocket were chosen for MD simulation studies.
Figure 3.4. P01 (yellow) and P03 (orange) docking binding pose, superimposed with lipid IVa
(green) in TLR4(cyan)/MD-2(dark blue) system.
The MD simulations were performed from the resulting docked poses in the
TLR4/MD-2 complex in antagonist conformation with both ligands P01 and P03. In all
cases, from the RMSD analysis of the MD simulations (Annex Figure 3.1), it is observed
that the receptor stays stable throughout the whole of the simulation during the run
time of 50 ns. In contrast, the ligand had some significant movements that have been
identified as different regions of stability, corresponding to different conformations of
the ligand during the MD simulation. So, we have obtained minimized average
structures and studied in detail for each conformation their significant interactions. As
shown in the RMSD graph (Annex Figure 3.1) different polar interactions stabilize
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3. TLR4 LIGANDS
different conformations of the ligand, allow us to suggest different possible docking
poses of these ligands in the TLR4/MD-2 complex, with the hypothesis that there is a
period of stabilization, then, there will be polar bonds holding at that specific time.
Therefore, we studied the hydrophobic and polar interactions occurring in the parts of
the simulation where the ligand was stable identifying interactions present in all the
simulations of P01 and P03. Looking at hydrophobic contacts, we observed many
common interactions to all the docking models and average structures from these
simulations as Ile46, Ile52, Leu61, Ile63, Leu74, Phe76, Leu78, Ile80, Ile94, Phe104,
Ile117, and Val135. In the case of polar interactions only few of them were found in
the majority of the binding modes, the interaction with Tyr65 is present in all the
solutions but at the end of the MD simulation of the TLR4/MD-2/P01 simulation is 
weaker; or the interaction with Glu92, that is present again in all the proposed binding
modes but is only missing at the beginning of the MD simulation of the TLR4/MD­
2/P01 and at the end of the simulation of the TLR4/MD-2/P03. Some other remarkable
polar interactions stabilizing certain stable binding modes, i.e. interactions observed
during some moments of the MD simulation are: the interaction with Arg90 which is
formed along the MD simulation of the TLR4/MD-2/P01 or the interaction Tyr102,
which is found as a very strong interaction in all the binding modes from the docking
models proposed by AutoDock, but which is lost along all the MD simulations; the
interaction with Ser118 which is observed in some of the binding modes of P01 but not
in the ones from P03; opposite to the interaction with Ser120, which can be seen in
some of the binding modes of P03 but is more rarely seen in the P01 ones; or Lys122
or Gly123 present in only few of the P01 and P03 complexes. For example, along the
MD simulation of the MD-2 protein with P01 and P03, according to the RMSD graph of
the ligand there is a period of stabilization then there will be polar bonds holding at
that specific time, for example with Tyr102 and in other period of time with Glu92.
These results show a difference when comparing with other compounds, for example
of eritoran which shows a significant stability in its proposed binding mode and during
the MD simulation as it will be shown below, due to the big size of the ligand which
completely fills the hydrophobic pocket. 
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3. TLR4 LIGANDS
In particular for P01, we also computed the RMSD of the different parts of the
P01 molecule, as the two acyl chains (AC-1 and AC-2) and the sugar and aromatic ring
respectively (sugar scaffold) (Annex Figure 3.2). In general, one of the acyl chains, AC­
1, is more stable along the MD simulation but the other acyl chain, AC-2, and the sugar
scaffold move more along the MD. These results mean that across the MD simulation
the ligand migrates from its original docking pose to a more central position within the
MD-2 pocket. The MD simulation implemented on the P01 molecule but with the
binding pose selected from the docking (Figure 3.5) performed with the full TLR4/MD­
2 complex showed no key areas of stability across the whole simulation. Comparing
the observed polar interactions to the previous simulation, we found that Glu92 is still
present during most of the simulation, but new polar interactions were observed as
Arg90. Again to understand the main reason of the motion of the ligand we computed
the RMSD of the different parts of the P01 molecule, and the contacts over the
different stable regions of the MD, which showed that in this case AC-1 and the sugar
scaffold were fluctuating along the whole simulation but the other AC-2 was stable
along the MD.
Figure 3.5. Detail of interactions of average structure of P01 during the MD simulation
with residues of MD-2 pocket.
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3. TLR4 LIGANDS
In the case of the docking studies for P03 using MD-2 and TLR4/MD-2 systems,
we obtained several predicted binding poses. One of them was further studied by
means of MD simulation. The MD simulation of the docked P03/MD-2 showed that the
ligand was fairly stable with peaks and troughs varying from 9Å to 12Å. The polar
interactions found were Glu92, Ser120 and Gly123. When observing the RMSD of the 
P03 ligand we observe that during all the MD simulation again only one of the FA
chains was stable. The final simulation that was performed for the small antagonist
molecules was the P03 from the docked full complex being run in and MD simulation
with the full complex. The complex like all other simulations stayed stable throughout
the whole simulation. The ligand on the other hand shows some varying regions of
stability. Again in this simulation we observe that one of the FA chain remains stable
along the MD simulation, but also the sugar scaffold. The other FA chain moves away
from its initial position, reaching other conformation in which it is stable (Figure 3.6).
Figure 3.6. P03 (orange) binding pose on the top, and highlight three binding poses around the 
MD simulation with the interactions with MD-2 pocket.
So one thing to take into consideration from this result is that P01 along with
P03 are small molecules, if converted into dimers there will not be nearly as much
space available for the ligand to move around the MD-2 pocket throughout the MD
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3. TLR4 LIGANDS
simulation. Further studies were performed to unravel these questions regarding
ligand-receptor interactions with relevance for future design of novel binders (for
more details see Chapter 4).36 
In the case of eritoran, a crystallographic structure in complex with a hybrid
Insore Hagfish/Human TLR4/MD-2 complex can be found at the PDB (PDB-ID: 2Z65).
We used this initial X-ray crystallographic structure to build a hTLR4/MD-2 in
antagonist conformation using the TLR4/MD-2 model from the antagonist MD-2 (PDB­
ID: 2E59) and the agonist TLR4 (PDB-ID: 3FXI), and the lipid IVa after superimposing
the MD-2 subunit found the hybrid model (PDB-ID: 2Z65) to the MD-2 of our model.
This model was submitted to a 50 ns MD simulation under explicit water which was
found to be stable during the simulation time (Annex Figure 3.3).
The RMSD values of the ligand observed during the whole simulation allow us
to confirm that this binding mode is stable, and that the ligand is placed filling the
hydrophobic pocket. Further analysis of single residue interactions, we observed some
stable polar interactions between eritoran and Lys122, Arg90 and Tyr102, also
observed in the TLR4/MD-2/lipid IVa model, but not in many P01 or P03 binding
modes. Only the interaction with Leu54 and Thr115 disappear along he MD simulation,
but is possible to observe new interactions with Val24, Val48, Lys58, Tyr65, Ser118,
Lys132, Leu146 and Val152 (Figure 3.7 and Annex Figure 3.4).
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3. TLR4 LIGANDS
Figure 3.7. Principal interactions of eritoran (pistachio green color, average structure during
the MD simulation) with TLR4/MD-2 system.
ompound D1 from the point of view of the chemical structure is very different
from other ligands/ The succinic diamide linker with the two negatively charged groups
from the sulfate mimics the distance between the phosphates of lipid IVa/ So, the
sulfate role could represent an alternative anchorage group to design new ligands/ In
the case of D1, the F! chains establishes hydrophobic interactions in the MD-2 pocket
between the alkyl side chains from residues Ile44, Ile46, Leu61, Ile63, Tyr65, Leu71,
Leu74, Phe76, Leu78, Ile80, Val93, Ile94, Tyr102, Val113, Ile117, Phe119, Ile124, 
Tyr131, ys133, Val135, Phe147, and H-π interactions with Phe104 and Phe151 side
chains/ !dditionally, polar interactions are established with the residues at the MD-2 
rim between one of the phosphate groups and Glu92, !rg96, !sp100 and Lys122 and
some interactions with TLR4 between !sn339 and !rg264 side chains (Figure 3.8)/
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3. TLR4 LIGANDS
Figure 3.8. Principal interactions of D1 (magent) with TLR4/MD-2 system/
Overall, from docking calculations and MD simulations, we can say that the
predicted binding pose is analogue to the antagonist binding pose found for lipid IVa in
the crystallographic structure (PDB-ID: 2E59), with the FA chains deeply buried into the
lipophilic pocket of MD-2 and with polar interactions with the polar residues from the
MD-2 rim. Stability of such predicted complex was tested by means of MD simulations.
!long the MD simulation (50 ns) is possible to observe that the receptor is stable and
the ligand migrates from its original docking pose to a more central position within the
MD-2 pocket, where two F! chains (the two F! chains in the deep of the pocket)
remain stable from the beginning to the end of the simulation/ The other two fatty acid
chains are moving from the beginning position and remain stable around MD since 20
ns/ Due to the change in the ligand position, D1 goes toward the innermost part of the
MD-2 pocket/ !long the MD simulation the interactions with TLR4 (with !rg264,
!sn339, Lys341 and Lys362) are lost/ It stabilizes in the period from 20 ns to the end
(Figure 3.9)/ The interactions were analyzed monitoring the distances between the
residues from TLR4/MD-2 complex which interact with D1 along the MD simulation, 
being possible to observe the loss of interactions with TLR4 (with Arg264, Asn339,
Lys341 and Lys 362), also others interactions were lost, among them: Val82, Leu87,
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3. TLR4 LIGANDS
Val93, Arg96, Asp100 but some interactions were established with Val24, Ile32, Val48,
Ile52, Lys58, Gly59, Pro67, Thr115, Ser118, Ser120 and Leu149, due to a slight change
in the initial position of the ligand. 
Figure 3.9. MD simulation of the complex TLR4/MD-2/D1(50 ns): RMSD (Å) is represented for
the -Carbons for TLR4/MD-2 (green), TLR4 (cyan), and MD-2 (dark blue), and the heavy
atoms for the ligand D1 (red).
For selected binding pose, free energy of binding was calculated by means of
the MM-GS! method computed with Primea, obtaining. -115 kcal mol-1/ This
calculation of the free energy of binding by MM-GS! approach can be appropriate to
overcome the possible underestimation of binding energy for big hydrophobic ligands/
omparing with lipid IVa, as representative TLR4 antagonist, in the multimeric 
complex of TLR4/MD-2/antagonist from the X-ray structure, some interesting 
interactions are identified (Figure 3.10)/
Figure 3.10. omparison the contacts between D1 (from the docking and average structures
of the MD simulation) and lipid IVa with the residues from the TLR4/MD-2 antagonist system/
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3. TLR4 LIGANDS
Compounds A1 and A2 are simplification to a single sugar of the lipid A
chemical structure. A1 presents four fatty acid chains, and A2 with only two. To 
evaluate MD-2 binding properties of A1 and A2, we performed docking studies in the 
hybrid model TLR4/MD-2 in-house system, since the X-ray structure of the TLR4/MD-2 
complex is not available in the antagonist conformation. Most of the best docked
solutions correspond to binding poses for these compounds with FA chains deeply
confined inside the MD-2 hydrophobic pocket, in a way equivalent to lipid IVa.
In the case of the compound A1, the two branched FA chains establishes
hydrophobic interactions in the MD-2 pocket between the alkyl side chains from
residues Val24, Ile32, Ile44, Ile46, Val48, Ile52, Leu54, Leu61, Ile63, Leu71, Leu74,
Leu78, Ile80, Val82, Ile94, Phe104, Phe119, Phe121, Ile117, Ile124, Tyr131, ys133,
Val135, Phe147, Leu149, Ile153, and H-π interactions with Phe76, Tyr102 and Phe151
side chains/ !dditionally, polar interactions are established with the residues at the
MD-2 rim, one phosphate group participate in hydrogen bond with Ser120 and the 
second phosphate group with Lys122- also establishes polar contact with !rg90 and
Ser120, and also one of the phosphates from the ligand interact with Lys122 (Figure
3.11)/
Figure 3.11/ Interactions details of !1 with TLR4/MD-2 system/
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3. TLR4 LIGANDS
In the case of the compound A2, the three best binding poses are shown
presenting both FA chains inside the pocket, with the polar phosphate groups and the
sugar placed at the rim of MD-2, similar than lipid IVa (Annex Figure 3.5).
In all the cases, the two FA chains established hydrophobic contacts with some 
residues and CH-π interactions with Phe151 in a similar way to lipid IVa. In one case,
polar interaction was also identified in these binding poses, even with Arg264,
presenting in TLR4. Also we observed in the most cases, that the phosphates groups
participate in hydrogen bonds with Ser118 and Lys122 from the hydrophilic rim,
adopting three preferred binding poses, all of them similar to the lipid IVa. But the
interactions that all the solutions share each other were with Ile32, Ile46, Val48, Ile52,
Leu61, Ile63, Phe119, Phe121, Phe151 and Ile153. Comparing with lipid IVa all of them
establish interactions with Phe119, Ser120, Phe121, Phe151 and Ile153 (Figure 3.12).
Figure 3.12. Comparison the contacts between A1 and A2 (from the docking structures) and
lipid IVa with the residues from the TLR4/MD-2 antagonist system.
Here is showed a perspective of the TLR4 antagonist conformation with lipid
IVa and the superimposition with different antagonist LPS-like ligands (Figure 3.13): 
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3. TLR4 LIGANDS
Figure 3.13. TLR4 antagonist conformation with lipid IVa (green) superimposition with:
eritoran, D1, P01, P03, A1, A2.
3.2.1.2 LPS-like Agonist Ligands
Regarding ONO-4007, which has an agonist behavior, AutoDock and AutoDock4
Vina docked binding poses were equivalent to that observed for lipid A in the
TLR4/MD-2 complex (PDB-ID: 3FXI), and which can be considered as the agonist-like
binding mode. We selected the best binding pose to perform 50 ns of MD simulations
(Figure 3.14). At the beginning of the MD simulation, the ligand showed some drastic
movements. Visibly it can be seen that the ligand almost instantly began to move away
from the position that it originally sat in when the docking was performed, because the
chains move towards the deep of the pocket but the receptor was very stable around
the MD simulation (Figure 3.14). We also identified an alternative binding pose with
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3. TLR4 LIGANDS
one phenylalkyl chain occupying the channel and the other two chains inside the MD-2 
pocket (Figure 3.16).
Figure 3.14. Change the position of ligand ONO-4007 at the beginning of the MD simulation in 
green and during the MD simulation in dark green/ !t the bottom the superimposition with 
lipid ! (pink)/
In the docking pose, the two phenylalkyl chains buried inside the MD-2 pocket
(with hydrophobic interactions with residues Phe119, Phe126, Ile52, Tyr65), and the
alkyl chain placed in the channel, stabilizing the “on” conformation of Phe126/ The FA
chains establish hydrophobic interactions with Ile44, Ile46, Ile52, Leu54, Leu61, Ile63,
Leu71, Phe76, Leu78, Ile80, Val82, Ile117, Lys122, Gly123, Ile124, Cys133, Val135,
Leu149 and Phe151, CH-π interactions with Tyr65, Phe119, Phe121, Tyr131 and also π­
π interactions with Phe147. We also identified polar interactions between ONO-4007
and Arg90, Ser118 and Ser120 from MD-2 and Arg264, Asn339 and Lys362 from TLR4.
After the re-colocation of the ligand new interactions were established, and new
interactions, the interactions with Ile44, Ile46, Ile52, Leu61, Ile63, Tyr65, Leu71, Phe76,
Leu78, Arg90, Glu92, Ile117 Phe119, Ser120, Cys133, Val135, Phe147, Leu149 and
Phe151 were maintained. New hydrophobic interactions with Val24, Ile32, Val48,
Lys58, Leu74, Ile94, Tyr102, Phe104, Val113, Asn114, Thr115, Ile117, and Leu146 were
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3. TLR4 LIGANDS
observed. The contact with Arg264, Asn339 and Lys362 from TLR4, Leu54, Ile80, Val82,
Phe121, Lys122, Gly123, Ile124, Phe126, Tyr131, and Lys132 MD-2 were lost.
Figure 3.15. MD simulation of the complex TLR4/MD-2/ONO-4007 (50 ns): RMSD (Å) is 
represented for the -Carbons for TLR4/MD-2 (green), TLR4 (cyan), and MD-2 (purple), and
the heavy atoms for the ligand ONO-4007 (red).
For selected binding pose, free energy of binding was calculated by means of
the MM-GS! and MM-ISMS! methods, obtaining. -63 kcal mol-1 and -79 kcal mol-1
respectively/ 
Docked binding poses of the agonist ligands revealed common interactions with
lipid !, some of them are Val24, Ile32, Ile44, Ile46, Val48, Ile52, Lys58, Leu61, Ile63,
Tyr65, Phe76, Leu78, !rg90, Glu92, Ile94, Tyr102, Phe104, Val113, Thr115, Ile117,
Ser118, Phe119, Ser120, ys133, Val135, Phe147, Leu149 and Phe151 (Figure 3.16)/
Figure 3.16. Comparison the contacts between ONO-4007 (from the docking and average
structures from MD) and lipid A with the residues from the TLR4/MD-2 agonist system.
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Also in the case of the binding pose with one phenylalkyl chain occupying the 
channel and the other two chains inside the MD-2 pocket, was possible to observe
from the RMSD along the MD simulation (30 ns) that almost instantly ONO-4007
moved away from the original position, and keeping stable the complex for around 25
ns. After that time the phenylalkyl FA chain went outside of the pocket and the others
FA chains occupied the channel. The complex stayed stable throughout the whole of
the simulation and although it moves around a little no drastic changes were observed
during the run time of 30 ns (Figure 3.18).
Figure 3.17. Docking pose of ONO-4007 (grey) with TLR4/MD-2 system, but with one 
phenylalkyl chain occupying the channel/
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3. TLR4 LIGANDS
Figure 3.18. MD simulation of the complex TLR4/MD-2/ONO-4007 (30 ns): RMSD (Å)
is represented for the -Carbons for TLR4/MD-2 (green), TLR4 (cyan), and MD-2 
(purple), and the heavy atoms for the ligand ONO-4007 (red).
3.2.2 Interactions in TLR4/MD-2 Modulators With Non LPS-like Structure
Scarce small molecules have been reported to modulate TLR4/MD-2 system.
Because these ligands do not have a LPS-like chemical structure, they are very
interesting binders to be studied. Some molecules have already shown agonist activity 
such as euodenine A and others with antagonist activity such as ethyl 4-oxo-4­
(oxazolidin-3-yl)-butenoate derivatives (OSL07), benzothiazole-based inhibitors, ethyl
phenyl-sulfamoylcyclohexenecarboxylate derivatives (TAK-242 or resatorvid),
paclitaxel and β-amino alcohol derivatives. To evaluate putative TLR4/MD-2 binding
properties of these compounds, we also undertook docking studies in the agonist and
antagonist hTLR4/MD-2 system. 
3.2.2.1 Non LPS-like Antagonist Ligands 
Non-LPS-like antagonist ligands displayed common hydrophobic and polar 
interactions with lipid IVa. Ile52, Leu61, Phe76, Leu78, Ile80, Glu92, Ile94, Ile117,
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Phe119, Ser120, Phe121, ys133, Val135, Phe151 and Ile153/
Paclitaxel is a compound isolated from the bark of Taxus brevifolia, has been
discovered as a cancer chemotherapeutic agent that bound to β-tubulin and prevented
mitosis through microtubule overstabilization.37 Also paclitaxel has been shown
implication in the induction of apoptosis of cancer cells via the TLR4 innate immune
pathway.
Docking of paclitaxel on the TLR4/MD-2 complex in antagonist conformation 
(using as complex the same model as in all antagonist models) was computed. Several
low energy docking solutions were found in which the ligand was showing three
different possible binding modes, one displaying an extended conformation of the
ligand (typical in non-polar environments) and two similar to the two previously
described paclitaxel conformations, T-Taxol conformation (tubuline-bound
conformation) and polar conformation.38-39 
From the lowest binding energy docking models, a total of 14 models (2 in
extended conformation, 6 in polar conformation and 6 in T-Taxol conformation) were
selected and further studied were performed by means of MD simulation. Initially, 2 ns
of MD simulation was carried out. From these initial MD run, only two of the docking
poses shown stability, hence, longer MD simulation of 50 ns was performed to provide
reliable conformations for the TLR4/MD-2/paclitaxel complex (Annex Figure 3.6). 
In particular TLR4/MD-2/paclitaxel extended model shown mainly hydrophobic
interactions due to the high amount of hydrophobic moieties of paclitaxel, as Val24,
Ile46, Val48, Leu61, Ile63, Phe76, Leu78, Ile80, Ile92, Phe104, Phe119, Phe121, Val135,
Phe147 among others, but also some polar interactions with key residues observed in
the TLR4/MD-2/lipid-IVa model as Arg90, Glu92, Ser118 and Ser120 (Figure 3.19).
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Figure 3.19. On the left, docking pose of paclitaxel; on the top right, during the MD simulation
change the position establishing in MD-2 pocket, and on the bottom right, in dark green the 
new binding pose showing in sticks the interactions with MD-2 residues. 
Activation of paclitaxel is quite specific as its analogue
docetaxel does not have immunostimulatory activity (Figure 3.20).37, 40 
Paclitaxel Docetaxel
Figure 3.20. Chemical structures of paclitaxel and docetaxel.
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3.2.2.2 Non LPS-like Agonist Ligands
Euodenine A is one of the few small molecules reported with TLR4/MD-2 
agonist behavior. Euodenine A, a natural product, was identified as an agonist activity
of the human TLR4 receptor, this ligand does not have a LPS-like chemical structure,
and it is a very interesting binder to be studied. Other small molecules have been
reported to modulate TLR4/MD-2 system but with antagonist behavior. To provide a
model for understanding the mechanism, docking calculations with euodenine A were
undertaken into agonist (PDB-ID: 3FXI) and antagonist (PDB-ID: 2E59) hTLR4/MD-2 
proteins. We used the hybrid in-house model. Docking studies led to binding poses into
the region inside the MD-2 pocket defined by Phe119, Phe121 and Phe151. 
Figure 3.21. On the left, binding pose of euodenine A in TLR4/MD-2 system, and highlight 
interactions at atomic detail for an average structure during the MD simulation and highlight 
the Phe126 which is the agonist/antagonist conformation switch.
From the analysis of the docking poses hydrophobic interactions with Ile32, 
Ile52, Leu54, Leu78, Ile80, Thr81, Phe119, Cys133 and Ile153 were detected, H-π 
interactions were observed with Phe126, Tyr131 and Phe151, also π-π interactions
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3. TLR4 LIGANDS
with Phe121/ Polar interactions with Lys132 and Ser120 were also established (Figure 
3.21)/
Analyzing the MD simulation from the monomer around 70 ns, it can be
observed that the receptor was stable throughout the whole of the simulation and
although it moved a little, no drastic changes during the run time of 70 ns were
registered (Figure 3.22).
Figure 3.22. MD simulation of the complex TLR4/MD-2/euodenine-A (70 ns): RMSD (Å) is 
represented for the -Carbons for TLR4/MD-2 (green), TLR4 (cyan), and MD-2 (purple), and
the heavy atoms for the ligand eudenine A (red).
For selected binding pose, free energy of binding was calculated by means of
the MM-GS! and MM-ISMS! methods, obtaining. -38 kcal mol-1 and -48 kcal mol-1
respectively/ 
The analysis of the water molecules around the MD-2 was performed and it
was observed that there was always only one water molecule inside the MD-2 pocket;
in the starting geometry of the MD simulation no water molecules were present into
the pocket. Along the MD simulation a water molecule sneaked into the pocket
establishing interaction with the NH group from euodenine A amide group. It is
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3. TLR4 LIGANDS
curious because was not always the same molecule and in other cases was not
possible to observe this. The water molecule was surrounded by Leu35, Tyr36, Cys67,
Val68 and Val69.
omparing with lipid !, was possible to observe some common interactions 
(Figure 3.23)/
Figure 3.23. Comparison the contacts between euodenine A (from the docking and average
structures from MD simulation) and lipid A with the residues from the TLR4/MD-2 agonist 
system.
A in-house dimer model TLR4/MD-2/euodenine A was built (Figure 3.24), 
starting from an average structure from the MD simulation from the monomer, and we
were performed the MD simulation of the monomer. Also the dimer was submitted to
50 ns of MD simulation. The RMSD of the dimer shown high stability for the receptor
along the MD, as well as for the two euodenine A (Figure 3.25).
Figure 3.24. TLR4/MD-2 agonist in-house model, with two molecules of euodenine A inside the 
MD-2 pocket. Highlight the major LPS mimic interactions.
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3. TLR4 LIGANDS
Figure 3.25. MD simulation of the full dimer complex TLR4/MD-2/eudenine-A (50 ns): RMSD
(Å) is represented for the -Carbons for TLR4/MD-2 (green), TLR4’/MD-2’ (dark green), TLR4
(cyan), TLR4’ (dark blue), and MD-2 (purple), MD-2’ (magenta), and the heavy atoms for the
ligand eudenine A (red) and euodenine A’ (yellow)/
In terms of the protein-protein interaction, the distance between TLR4 and
TLR4’ were monitored around dimer MD, analyzing the polar interactions and
comparing them with the X-ray crystallographic structure (PD-ID. 3FXI)/ The
interactions analyzed were (TLR4-TLR4’). !sn365(TLR4)-Ser386(TLR4’), Ser386(TLR4)­
Ser386(TLR4’), !sn433(TLR4)-!sn433(TLR4’) and Gln507(TLR4)-Gln507(TLR4’)/ !ll of
them remained stable around the MD except for the case of Gln507 located in the
lower part of TLR4 (!nnex Figure 3.7)/
Also the docking of the euodenine A in the TLR4/MD-2 antagonist
conformation was performed. Two binding poses were chosen in which the ligand
occupied a more central position in the MD-2 pocket. Analyzing the MD simulation (70
ns) it was observed that the ligand moved away from the original central pose, not
getting a stable position throughout the MD simulation.
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3. TLR4 LIGANDS
3.2.3 Small Molecules
In this study, a combined approach involving binding site prediction and
docking studies was implemented to determine primary and secondary drug binding
sites for known TLR4 ligands, and evaluate the results to deduce the underlying
molecular mechanism that reflects ligand pharmacodynamics. Therefore, two main
objectives were aimed for this work: the identification of possible binding pockets in
different conformations of the TLR4/MD-2 system, and the proposal of the binding
modes for known TLR4 small molecule modulators. Different new primary drug binding
sites and secondary sites were found in the TLR4/MD-2 system, especially in protein­
protein interfaces. Additionally, regarding the specifically targeted docking studies,
new binding modes for the TLR4 modulation through different ligands are proposed.
Binding Site Prediction Studies
SiteMap. As a result of the structural differences between the receptor
structures used in this study, certain binding sites were identified in every receptor
conformation, while others were identified in only two or even one protein structure.
Identified binding sites and their scoring values can be found in Annex Table 3.1. 
MD-2 pocket was reported as a single binding site in both TLR4/MD-2 systems
(Figure 3.26a). In the dimer conformation, MD-2 pocket was identified as part of two
binding sites, named A and Q, which also display a solvent exposed surface
corresponding to part of the TLR4/MD-2 and TLR4/MD-2 interfaces, respectively.
Another binding site was predicted in the surface of MD-2, named M.
The TLR4/MD-2 interface was identified as several binding sites (Figure 3.26b). 
Interestingly, the binding region where the polar interactions of LPS occur was
identified as two different binding sites, one comprising the solvent exposed region of
binding site A and another binding site, named as L. Additionally, another binding site
was identified in all the receptor structures which was described in the TLR4/MD­
2/TLR4*/MD-2* system as three different components: B, which comprised most of
the surface of this dimerization interface for the binding site; X, a region between the
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3. TLR4 LIGANDS
LRRs of TLR4 and MD-2, and a small, narrow pocket located in the TLR4 LRRs, named as
W. 
The TLR4/TLR4* dimerization interface was reported as five different binding
sites (Figure 3.26c). Two binding sites encompassed the vast majority of this interface:
J and C comprised the lower half of the interface, while the upper half was composed
by binding sites P, U and I, being the latter two also reported in both agonist and
antagonist TLR4/MD-2 systems. Three different binding regions were identified in the
TLR4/MD-2* dimerization interface (Figure 3.26d): the solvent exposed part of Q, M
and a highly solvent exposed binding site, named as R. Other binding sites were
reported in the TLR4 LRRs (Figure 3.26e). A binding region was also detected in the
TLR4 central domain, comprising binding sites F, G, H and O. Near the TLR4 N-terminal
domain, a series of binding sites were reported (D, K, N, S and Y). Due to their location,
binding sites E (transmembrane end) and T (inner cavity) were not considered for
further studies. Additionally, another binding site was only identified in one monomer
of the TLR4/MD-2/TLR-4*/MD-2* system; named as V, the identification of this binding
site could be an artefact secondary to the removal of glycosylations in the protein
preparation process.
Figures 3.26a-26e. From left to right: binding sites at MD-2, TLR4/MD-2 interface, TLR4/TLR4* 
interface, TLR4*/MD-2 interface, and TLR LRRs. Acceptor and donor maps are shown in red
and blue, respectively; hydrophobic maps are represented in yellow. MD-2 surface is colored in
orange; TLR4 surface is colored in grey.
CASTp. Probe radius variation resulted in jobs with different characteristics). A
probe radius of value of 1.7 Å was defined as it combined analysis simplicity with
minimum loss of SiteMap binding site identification (Figures 3.27a and 3.27b). With
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3. TLR4 LIGANDS
the exceptions of binding sites that were not recognized (L, S), partly recognized in
each (V) or a determined structure (M and F), all SiteMap reported binding sites were
totally recognized by CASTp. These results were consistent with SiteMap output, given 
that binding site F was only reported in the antagonist conformation, binding sites J, P,
U and R are located in homodimerization interfaces, and M is absent in the antagonist
conformation. 
Figure 3.27a. Graphs showing the effect of probe radius variation in the number of 
recognized SiteMap binding sites (left) and the total number of identified sites (right). CASTp
jobs wherein there is a loss of identification of SiteMap binding sites are depicted in red;
adequate CASTp jobs are represented in green.
Figures 3.27b. Results of pocket identification by CASTp for the TLR4/MD-2 system in agonist 
conformation. Left: predicted pockets excluding MD-2 internal pocket; Right: MD-2 inner 
binding site (right) is reported as a huge pocket, even comprising parts of TLR-4. In this pocket, 
sites A and Q are encompassed; certainly all SiteMap binding sites are identified by CASTp.
Residues forming pockets are represented by spheres and FASTA code letters of different color 
(green: A, Q, part of W; magenta: pocket K, parts of N and M; yellow: parts of C and M; cyan: Y, 
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3. TLR4 LIGANDS
B and part of W pocket; purple: part of C; dark blue: D and X; orange: O and N; brown: I and
part of P)/ Regarding the protein structure, β-sheets and α-helices are colored in orange and
red, respectively; loops are depicted in white. *: these pockets were only partially recognized 
by CASTp.
Binding Site Rating and Evaluation
Predicted binding sites were rated regarding their scoring values and their
identification by SiteMap and CASTp in all the receptor structures. As expected, A and
Q shown the highest values for SiteScore, supporting the evidence that MD-2 pocket is
the primary binding site for the TLR4/MD-2 complex. Although binding site M shown
low scoring values, its consideration as a binding site could be of potential usefulness
due to its proximity to the external region of Q binding site. As a result of the high
scoring values of binding sites that comprise the TLR4/MD-2 interface, A, L, B and W
appear to be potential drug binding sites. Moreover, the presence of pharmacological
activity in this binding region is supported by previous studies over certain TLR4
antagonists. Regarding the TLR4/TLR4* interface, C, J and P were reported as highly 
scored binding sites. Due to their location, these binding sites are potential candidates
for the binding of PPI modulators.59, 83 Regarding the TLR4/MD-2* interface, the
notable scoring values of M and Q was not a particular surprise given that Phe126,
located in this region, plays a crucial role in the receptor activation where several TLR4
modulators have been reported to bind.58, 60
Docking Studies
Receptor-Based. The average value for all minimum binding energies
performed in docking calculations was -7.17 kcal mol-1, with a standard deviation value
of 1.45, which was indicative of the fact that there was a wide distribution of binding
energy values between different docking calculations.
When averaging all the minimum binding energies of all dockings carried out in
a determined grid box, a differential distribution of energies was observed between
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3. TLR4 LIGANDS
different grid boxes for the same receptor conformation, suggesting that ligands
displayed more favourable binding energies for specific regions in the TLR4/MD-2 
complex. Particularly, AL (-7.72 kcal mol-1 for the average of the three receptor
structures) and AQ (-7.68 kcal mol-1) grid boxes, comprising MD-2 pocket, showed the
most favourable binding energy results followed by DN (TLR4 LRRs, -7.63 kcal mol-1), C 
(TLR4 LRRs -7.59 kcal mol-1), B1W (TLR4/MD-2 interface, -7.49 kcal mol-1) and B2 
(TLR4/MD-2 interface, -7.32 kcal mol-1). KS, J, FGHO, MQR, IUP and V grid boxes
showed less favourable results (-7.29, -7.19, -7.11, -6.67, -6.46 and -5.90 kcal mol-1 , 
respectively). 
Subsequently, when averaging the minimum binding energies for a determined
grid box in a determined conformation, a differential distribution for these energies
was observed between different receptor conformations for a specific grid box. These
results suggest that certain receptor conformations allowed ligands to establish more
favourable conformations, especially in the case of grid boxes which encompass parts
of the TLR4*/TLR4* and TLR4*/MD-2 systems, suggesting the presence of ligand poses
which display interactions in the TLR4/MD-2/TLR-4*/MD-2* systems with both
TLR4/MD-2 dimers. For example, J grid box showed an energy value of -7.69 kcal mol-1 
in the TLR4/MD-2/TLR-4*/MD-2* system, while less favourable values were found in
mol-1 the agonist and antagonist TLR4/MD-2 systems (-6.91 and -6.94 kcal , 
respectively). Thus, J, C, IUP and MQR grid boxes were potentially identified as possible
binding sites for PPI modulating agents. Interestingly, a considerable decrease in
mol-1 binding energy was found for B1W grid box (-7.63, -7.47, -7.35 kcal for
antagonist, agonist TLR4/MD-2 systems and TLR4/MD-2/TLR4*/MD-2* system,
respectively), which may be reflected by the conformational change occurring in the
TLR4/MD-2 interface between agonist and antagonist conformations. When
considering the standard deviation related with the different minimum energy values
calculated for each ligand in each grid box of each structure substantial differences
was found in the calculated values, suggesting that there are regions of the TLR4 which
are more likely to bind specific ligands than others. Finally, a correlation between
certain energy values for a determined grid box of a determined conformation and
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3. TLR4 LIGANDS
SiteScore values can be found, which confirms the potential of the predictive score
obtained by SiteMap.
Results. Binding site mapping has been performed over all the surface of the
monomer and dimer TLR4/MD-2 systems in three different structures. The binding
sites reported by Sitemap have been successfully validated by CASTp. The scoring of
these binding sites generally correlates with docking results, being MD-2 pocket the
primary binding site for TLR4 small molecule modulators. Binding site prediction also
defined the existence of other well scored sites, mainly comprising the TLR4/TLR4*,
TLR4/MD-2* and TLR4/MD-2 interfaces. As some molecules have been determined to
bind to these regions of the receptor, these scoring values are consistent with
experimental evidence. Additionally, regarding docking results, binding site C, which is
a new highly scored pocket in the C-terminal domain of TLR4, appears to bind
molecules with low binding energies. Some of these TLR4 modulators could exert their
pharmacological activity by binding to this site, either stabilizing PPI interactions or by
other unknown mechanisms. Furthermore, binding site D, a pocket present in the N-
terminal domain of TLR4, appears to be an important binding site for certain TLR4
modulators. The potential of our binding site prediction studies is established, as these
two novel binding sites have never been reported in previous studies.
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Figure 3.28. Some chemical structure, given names and families of TLR4 ligands.
Additionally, evaluation of the binding energies from different TLR4 modulators
to the different predicted binding sites has permitted to propose their preferential
binding to certain areas of the TLR4/MD-2 complex. Thus, the binding site of many
natural and natural-like products with TLR4 agonist/antagonist activity has been
proposed: bryostatin-1,28 1-Dehydro-10-gingerdione,41 polyoxygenated cholesterol
ester hydroperoxides,29 6-shogaol,41 curcumin19 and euodenins5 appear to bind MD-2 
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3. TLR4 LIGANDS
selectively, while hemin likely binds both TLR4/TLR4* interface and MD-2 pocket
(Figure 3.28). Furthermore, Isoliquiritigenin30 displayed very good energy values for
regions comprising both TLR4/TLR4* and TLR4/MD-2 interfaces. However, the
hypothesis that ILG forms covalent bonds with TLR4/MD-2 cannot be rejected.
Additionally, three binding modes for GL have been proposed: this compound may be
binding to either two regions of the TLR4/TLR4* interface or MD-2 pocket. 
On the other hand, the predicted binding site of other TLR4 ligands has been in
agreement with the experimental evidences shown in previous studies. Although all of
them presented low binding energies for MD-2 pocket, several differences could be
found in certain compound series. Although tricyclic compounds31 and cinnamamides
are thought to bind MD-2 pocket, favourable binding energies were found for binding
site B, located in the TLR4/MD-2 interface (Figure 3.20). Certain opioids15 showed
remarkable favourable binding energies for binding sites C and D. Additionally, the
TLR4/TLR4* interface could be targeted by paclitaxel. Therefore, a more detailed study
of these compounds is necessary in order to assess mechanisms that may unravel their
binding modes. Other synthetic compounds, which are thought to bind the TLR4/MD-2 
interface, displayed very good binding energies for site B. Nevertheless, they also
showed favourable binding energies for MD-2 pocket. Thus, their binding mode should
be reconsidered. 
Other compounds (sulforaphane,17 helenalin, acrolein, cinnamaldehyde42-43),
showed low selectivity, as similar predicted binding energies for all the binding sites
were observed. This could be mainly due to their small sized chemical structure that
leads to predicted binding to a large variety of regions in the receptor surface. 
However, a mechanism through establishment of covalent bonds with the receptor
cannot be excluded, which would require additional computational studies to assess
this possibility. Last but not least, this study has permitted to consider that the
feasibility of MD-2 binding assays in which 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic
acid41 participates may be compromised if TLR4/MD-2 systems were used, as it has
been found that site C could be a secondary binding site for this compound. It can be
concluded that this combined computational approach has permitted to identify new
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3. TLR4 LIGANDS
receptor binding sites in the TLR4/MD-2 complex and predict plausible binding poses
to them. Ultimately, this may help in understanding the principles that govern TLR4
activity and thus the development of new TLR4/MD-2 targeting modulators.
3.2.4 Overview of Agonist and Antagonist Interaction Patterns
Agonists ligands (lipid A, euodenine A and ONO-4007) always bind to the MD-2 
region delimited for Ile32, Ile52, Leu54, Leu61, Leu78, Ile80, Val82, Arg90, Ser118,
Phe119, Ser120, Phe121, Ile124, Phe126, Cys133 and Phe151 (Figure 3.29).
Figure 3.29. Comparison the contacts between the agonist ligands (from the docking and
average structures from MD) and lipid A with the residues from the TLR4/MD-2 agonist 
system.
Antagonists ligands (lipid IVa, eritoran, P01, P03, paclitaxel, D1, A1, A2) share
the following interactions with MD-2 pocket: Ile32, Ile44, Ile46, Val48, Ile52, Leu61,
Ile63, Phe76, Leu78, Ile80, Arg90, Glu92, Ile94, Tyr102, Phe104, Ile117, Phe119,
Ser120, Phe121, Cys133, Val135, Phe147, Leu149, Phe151 and Ile153 (Figure 3.30).
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3. TLR4 LIGANDS
Figure 3.30. Comparison the contacts between the antagonists ligands (from the docking and
average structures from MD) and lipid IVa with the residues from the TLR4/MD-2 antagonist 
system.
In the case of LPS-like ligands (ONO-4007 and lipid A, among the agonists, and
lipid IVa, D1 and eritoran, among the antagonists), there is like a wall in the MD-2 
pocket where one FA chain is driven towards this region cover by Ile63 and Tyr65 from
one of the β-sheet, Val113, Thr115 and Ile117 from another β-sheet and some amino
acids residues from the bottom of the pocket like Leu71, Leu74, Ile94, Tyr102 and
Phe104. There are three residues at the bottom of the MD-2 pocket (Val135, Phe147
and Leu149), where one of the fatty acid chain from LPS-ligand always interacts. And
also around Phe126, LPS-like ligands interact with Phe121 and Ile124 (Figure 3.31).
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3. TLR4 LIGANDS
Figure 3.31. Hightlighted residues where LPS-like ligands interact. The pink spheres 
represent like a wall where one FA chain always goes towards this direction in the
pocket. In yellow spheres the deep residues where another FA chain always 
interacts. Circle red highlights the principal difference between MD-2 
agonist/antagonist conformations (Phe126).
According to our docking calculations, Paclitaxel (non-LPS ligand) does not bind
into the pocket depth, this molecule doesn’t establish interactions with the bottom of
the MD-2 pocket where are the amino acids residues: Tyr65, Pro67, Leu71, Leu74,
Val113 and Thr115. 
Euodenine A (agonist) and paclitaxel (antagonist) share common interactions
with MD-2 pocket, both interact with Ile52, Leu78, Ile80, Val82, Arg90, Ser118,
Phe119, Ser120, Phe121, Cys133, Phe151 and Ile 153, both remain at the rim of MD-2 
and they do not bind in the pocket background. The binding mode of these molecules
is similar (Figure 3.32 and 3.33). These interactions can be also observed in lipid A and
lipid IVa.
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Figure 3.32. Superimposition of the binding pose of euodenine A (pink) and paclitaxel (green)
in the TLR4/MD-2 complex. MD-2 agonist in purple and MD-2 antagonist in dark blue.
Figure 3.33. Superimposition of the average structure obtained from MD simulation of
euodenine A (light pink) and paclitaxel (dark green). MD-2 agonist conformation is shown in
purple and MD-2 antagonist in dark blue.
The plasticity of the TLR4/MD-2 complex was analyzed calculating the solvent
accesible volume on hydrophobic pockets of MD-2 by using CASTp server which
identifies and computes the molecular area and volume for cavities and pockets of a
156
   
 
 
    
         
      
        
          
       
       
      
        
  
            
   
     
         
        
 
  
     
    
 
3. TLR4 LIGANDS
given protein.44-45For this, the binding pose of the docking and the average structures
from the MD simulations were used for all the ligands; the ligand was removed and the
plasticity of the MD-2 pocket was analyzed. The data corresponding to the
hydrophobic pockets of MD-2 proteins were selected. In the case of the smallest
compounds and without LPS-like structure (euodenine A and paclitaxel) is possible to
observe that the MD-2 pocket acquires a more closed conformation and the pocket
gets a bit smaller in comparison with the LPS-like structure and more bigger ligands
(ONO-4007, D1, eritoran, P01, P03, A1 and A2). It is possible to confirm that MD-2 is
very plastic, adapting a conformation in a ligand dependent manner (Annex Table 3.2).
RMSD of the α-carbons of the loop from Leu78 to Lys89 and from Phe121 to
Gln129 (loops implicated in the dimerization interface) from all the ligands was 
calculated. It was possible to observe that MD-2 is very flexible around the MD
simulation (Figure 3.34 and 3.35). We can conclude that MD-2 is very flexible but
differences between agonist and antagonist conformation are very difficult to be
detected.
Figure 3.34. RMSD from Leu78 to Lys89 of the α-Carbons from MD-2 loops implicated in the 
dimerization interface from the agonist (left) and antagonist (right) ligands.
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Figure 3.35. RMSD from Phe121 to Gln129 α-Carbons from MD-2 loops implicated in the 
dimerization interface from the agonist (left) and antagonist (right) ligands.
Regarding the plasticity of de MD-2 pocket implicated in the dimerization
interface distances between Met85-Lys125, Leu87-Ile124 and Val82-Phe126 from MD­
2 pocket were analyzed in agonist and antagonist ligands (Figure 3.36). The distance in
this region in the edge of the MD-2 pocket remains stable along the MD in all the
cases, not being possible to see any significant differences between agonists and
antagonists (Annex Figure 3.8). Except in the case of D1, is could be possible to observe
some drastic movements since 20 ns, which is the time where D1 adopt a new position
going towards the deep of the pocket. It is possible to think that it could be due to the
size of D1, which has a bigger size than the other ligands.
Figure 3.36. Distances between Met85-Lys125, Leu87-Ile124 and Val82-Phe126 from MD-2 
pocket were analyzed in MD simulation of agonist and antagonist ligands. Agonist
conformation on the left and antagonist conformation on the right.
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3. TLR4 LIGANDS
The polar interactions between TLR4 and MD-2 were monitored around the MD
from agonists and antagonist ligands comparing with the TLR4/MD-2 monomer
structure (PDB-ID: 3FXI and 2E59). For the agonist conformation the distance
interactions monitored were (TLR4/MD-2): Ser317-Asp101, Arg264-Asp101, Arg289­
Ser98, Arg289-Asp99, Arg234-Asp100, Glu266-Ser103, Ser183-Arg106, Ser184-Arg106,
Glu135-Thr112, Arg87-Thr112 and Glu42-Arg68. For the antagonist conformation the
distance interactions monitored were (TLR4/MD-2): Asn339-Asp100, Ser317-Asp100, 
Arg234-Asp99, Arg264-Asp100, Glu266-Ser103, Asn265-Ser103, Glu135-Thr112 and
Arg87-Thr112 (Annex Figure 3.9a and 3.9b). It was not possible to observe any changes
in plasticity of MD-2 pocket. The interactions remained stable throughout the MD
simulation (Annex Figure 3.9a and 3.9b).
The number of water molecules around Phe126 and Tyr131 were detected in
the agonist and the antagonist conformation, being able to see that Phe126 in the
antagonist conformation is exposure to the solvent having around 26 water molecules,
while in the agonist conformation, has around 9 molecules of water in a 4 Å radius. In
the case of Tyr131 is not possible to observe many changes between agonist and
antagonist conformation (Annex Figure 3.10).
The electrostatic potential from MD-2 pocket was calculated for all the ligands
using APBS tool,46 a molecular solvation based in the Poisson-Boltzmann
approximation. It was not possible to observe significant differences between agonist
and antagonist conformations (Annex Figure 3.11).
The angle formed for Asp530(TLR4), Phe272(TLR4) and Pro50(MD-2) was 
calculated for all the ligands around the MD simulation (Figure 3.37), it could be said
that there were no abrupt changes throughout the MD simulations.
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3. TLR4 LIGANDS
Figure 3.37. Angle measurement in the TLR4/MD-2 system between Asp530(TLR4)­

Phe272(TLR4)-Pro50(MD-2). Agonists ligands on the left, antagonists ligands on the right.
3.3 Conclusions
Theoretical binding modes have been predicted for reported modulators of the
TLR4/MD-2 system, with agonist and antagonist activity. In particular, we focused our
work in simplified LPS analogues and non-LPS molecules have also been developed. For
all these TLR4 modulators there are not binding mode proposed. It is clear that
although these molecules have a different chemical structure, they must share a
common pattern of interactions with TLR4. We have undertaken a computational
study of some representative compounds to unveil some of these patterns of
interactions. Some of them have engendered an antagonistic response and other
agonist response in the TLR4 complex.
3.4 Materials and Methods
3.4.1 Macromolecule Preparation
In the case of the agonist conformation of the TLR4/MD-2 monomer, 3D 
coordinates from TLR4/MD-2 heterodimer were obtained from the Protein Data
Bank,47 (PDB-ID: 3FXI) and then chains A and C were extracted and considered as
TLR4/MD-2 monomer in agonist conformation. In the case of the antagonist
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3. TLR4 LIGANDS
conformation, since the full crystallographic structure of the TLR4/MD-2 complex is not
available, a in-house model was used. This model was built using the human MD-2 
protein in antagonist conformation (PDB-ID: 2E59) superimposed onto the MD-2 
subunit of the agonist full complex (PDB-ID: 3FXI chain C) through PyMOL. Then,
coordinates from the TLR4 chain of the 3FXI adjacent to the superimposed MD-2 (PDB­
ID: 3FXI chain A) and the superimposed MD-2 in antagonist conformation were
retained, forming the TLR4/MD-2 monomer in antagonist conformation. Finally, both
agonist and antagonist structures were subjected to 10.000 cycles of steepest descent
energy minimization under the OPLS_2005 force field via Maestro.48 
3.4.2 Ligand Preparation
We built the full 3D structure of the agonists and antagonists ligands, with the
help of ChemDraw® and Corina.49 Optimization of the 3D geometries was performed
using Macromodel from Maestro Suite, using steepest descent minimization under the
MMFFs force field until a convergence in energy of 0.5 kcal/mol was reached.
3.4.3 Docking Studies
Starting geometries of the ligands were docked in the agonist or antagonist
conformation of the TLR4/MD-2 complex respectively, by using AutoDock450 in the
case of all of the ligands, Vina51 for some molecules (specifically ONO 4007, D1 and
euodenine A) and also Glide52-55 (in the case of euodenine A to compare the results
obtained with AutoDock4 and Vina).
For the docking studies performed with AutoDock4, the TLR4/MD-2 system was 
prepared with the help of AutodockTools by assigning Kollman charges and setting the
grid as follows. For the TLR4/MD-2 in agonist conformation, the grid point spacing was 
set at 0.375 Å, the center of the grid box were in the midst of Leu78, Val135, Cys133
and Ile80 residues from MD-2 pocket and number of grid points in x, y, z was 88, 96,
86. For the TLR4/MD-2 in antagonist conformation, the grid point spacing was set at
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3. TLR4 LIGANDS
0.375 Å, the center of the grid box was close to Glu92 and number of grid points in x, y, 
z was 84, 96, 74.
Ligand was also prepared with the help of AutodockTools, retaining the charges
obtained from the optimization process.
All docking calculations with AutoDock4 were performed using the Lamarckian
genetic algorithm,56 number of individuals in population 150, maximum number of
energy evaluations 2500000-5000000, maximum number of generations 27000,
number of top individuals to survive to next generation 1, rate of gene mutation 0.02,
rate of crossover 0.8, window size 10, Alpha parameter of Cauchy distribution 0.0, Beta
parameter Cauchy distribution 1.0, run 200. Disposition of the ligand was defined as
random changes in the torsion angles, location and overall orientation of the molecule.
In the docking studies with Vina the following boxes were used: the TLR4/MD-2 
system in agonist conformation, the grid point spacing was set at 1 Å, the center of the
grid box were in the midst of Leu78, Val135, Cys133 and Ile80, and number of grid
points in x, y, z was 33, 36, 33. For the antagonist conformation, the grid point spacing
was set at 1 Å, the center of the grid box was close to Glu92 residue from MD-2 
pocket, and number of grid points in x, y, z was 32, 36, 28. For all of them, the
maximum number of binding modes to generate was 50, and the exhaustiveness of
the global search (roughly proportional to time) was increased to 20.
And docking calculations with Glide were performed using the grid points in x, 
y, z 58, 47, and 45, and the lengths of the inner box for agonist protein conformation
were: 10 Å, 10 Å, 10 Å (x, y, z) and for the outer box: 30 Å, 30 Å, 30 Å (x, y, z). Epik state
penalties for docking were used, and the non-polar part of the ligand potential were
soften by scaling the van der Waals radii of ligand atoms with small partial charges. To
do so, the scaling was 0.8, and the partial charge cutoff was 0.15. Standard Precision
(SP) was performed and 200 docking poses per ligand was set. The Dock flexibility
method was used for SP docking allowing us to penalize non-planar conformation for
amide bonds. A post-docking minimization was also performed, as well as constraints
for the docking stage.
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3. TLR4 LIGANDS
3.4.4 Molecular Dynamic Simulations
Molecular dynamic simulation was carried out for the some of the complexes 
obtained from the docking studies, i.e. eritoran, P01, P03, paclitaxel, euodenine A, 
ONO-4007 and D1. The AMBER force field was used for both ligand and protein, with
the ff10 parameter used for the TLR4/MD-2complex, and the gaff parameter were
applied for the ligand with the help of antechamber. Then counter ions were added to
the systems as to neutralize it (9 Na+ atoms), and then they were solvated by using
TIP3P waters in a cubic box with a 10 Å distance around the TLR4/MD-2 complex.
Minimization was performed using Sander and MD simulations were run using the
pmemd, which are distributed within the AMBER 12 package.57 A 1 fs integration step
and the shake algorithm on every hydrogen-containing bond.58 The smooth particle
mesh Ewald method59 was used to represent the electrostatic attractions in the system
while each simulation was under periodic boundary conditions, and the grid spacing
was 1 Å. Initial annealing of the system occurred steadily and lightly from 100 K to 300
K over 25 ps. The temperature was then kept constant at 300 K during 50 ps with
progressive energy minimizations and also a solute restraint. The solute restraints
were gradually released, which was closely followed by a 20 ps heating period which
went from 100 K to 300 K, once completed the restraints were removed. Each of the
simulations lasted 50 ns. The systems then advanced in an isothermal-isobaric
ensemble.
3.4.5 Average Structures
Average structures were extracted from molecular dynamics simulations of the
ligands with ptraj of AmberTools 13. All the average structures were minimized with
5000 steps of steepest descent minimization with position restrain (force constant of
Å-2 10 kcal mol-1 ) for all nonhydrogen atoms, plus 5000 steps of steepest descent
minimization with no restrains.
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3. TLR4 LIGANDS
3.4.6 Plasticity of the TLR4/MD-2 Complex
Solvent accesible volume was calculated on hydrophobic pockets of MD-2 by
using CASTp server.45 CASTp server identifies and computes the molecular area and
volume for cavities and pockets of a given protein. The data corresponding to the
hydrophobic pockets of MD-2 proteins were selected.
3.4.7 Binding Site Prediction Studies
Two different programs based in different algorithms were used to predict and
score potential drug binding sites: SiteMap60 and CASTp.44 
SiteMap. Binding sites were predicted and scored for the mol2 files prepared
receptor structures. SiteMap default parameters for the identification of site points
were used. Requiring at least 15 site points per reported site, a maximum value of 30
sites per run was determined. Calculations were performed in a standard grid, using a
restrictive definition of hydrophobicity. Maps were cropped at 4 Å from nearest site
point. Results were visualized using Maestro. Site point groups were saved in xyz
format.
CASTp. On a first approach, a probe radius input parameter was fixed. For this 
purpose, different jobs using the TLR4/MD-2 system and varying the probe radius were
submitted to CASTp server. The correspondent calculations were retrieved, loaded and
visualized using Pymol. SiteMap results were contrasted with CASTp results using the
xyz exports. SiteMap sites that were either located next to the membrane domain or
forming cavities inside TLR4 were not used for this evaluation. For each job, the
number of pockets which were entirely recognized by CASTp was plotted against the
number of reported pockets. Once a determined probe radius was fixed, two different
jobs for the TLR4/MD-2/TLR4*/MD-2* and antagonist TLR4/MD-2 systems were
submitted to CASTp server. Results were again visualized and compared with SiteMap
results. Two different parameters were used to rank binding sites: detection of the
binding site by CASTp in the different receptor structures and SiteScore.
164
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3.5 Annex III
a) b) 
c) d)
Annex Figure 3.1. a) MD simulation of MD-2/P01 (50 ns): RMSD (Å) is represented for the -
Carbons for MD-2 (dark blue) and the heavy atoms for the ligand P01 (red), b) MD simulation
of TLR4/MD-2/P01 (50 ns): RMSD (Å) is represented for the -Carbons for TLR4/MD-2 (green) 
and the heavy atoms for the ligand P01 (red), c) MD simulation of MD-2/P03 (50 ns): RMSD (Å) 
is represented for the -Carbons for MD-2 (dark blue) and the heavy atoms for the ligand P03
(red), d) MD simulation of TLR4/MD-2/P03 (50 ns): RMSD (Å) is represented for the -Carbons 
for TLR4/MD-2 (green) and the heavy atoms for the ligand P03 (red).
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a) b)
c) d) 
Annex Figure 3.2. RMSD of the positions of the atoms belonging to the P01 ligand. Black acyl 
chain 1, red acyl chain 2 and green sugar moiety.   a) P01 docking in MD-2 and simulation in full
complex. b) P01 docking in TLR4/MD-2 and simulation in “MD-2 only”/ c) P03 docking in
TLR4/MD-2 and simulation in full complex. d) P03 docking in TLR4/MD-2 and simulation in 
“MD-2 only”/
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3. TLR4 LIGANDS
Annex Figure 3.3. MD simulation of the complex TLR4/MD-2/Eritoran (50 ns): RMSD (Å) is 
represented for the -Carbons for TLR4/MD-2 (green), TLR4 (cyan), and MD-2 (dark blue), and
the heavy atoms for the ligand Eritoran (red).
Annex Figure 3.4. Contacts between Eritoran ligand and the residues from the TLR4/MD-2 
present in two different average structures of the MD simulation.
Annex Figure 3.5. Three binding poses (orange, magenta and pink) of compound A2 in
TLR4/MD-2 system.
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Annex Figure 3.6. MD simulation of the complex TLR4/MD-2/paclitaxel (50 ns): RMSD (Å) is 
represented for the -Carbons for TLR4/MD-2 (green), TLR4 (cyan), and MD-2 (dark blue), and
the heavy atoms for the ligand paclitaxel (red).
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!nnex Figure 3.7. Distances between TLR4-TLR4’ residues around dimer MD simulation of the
euodenine ! in the full complex/
Annex Table 3.1. Identified SiteMap binding sites in all the receptor structures, with 
their correspondent SiteScore and Dscore values, and their location in the TLR4/MD-2 
complex.
inding site
name
dimerization
state
onformation SiteScore Dscore Location
!, Q homodimer agonist 1,228 1,34 MD-2 pocket
!, Q heterodimer antagonist 1,205 1,302 MD-2 pocket
!, Q heterodimer agonist 1,147 1,229 MD-2 pocket
! homodimer agonist 1,126 1,2 MD-2 pocket
Q homodimer agonist 1,073 1,118 MD-2 pocket
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3. TLR4 LIGANDS
, W, X homodimer agonist 1,023 1,048
TLR4/MD-2 
heterodimerizatio
n interface and
TLR4
, X heterodimer antagonist 1,018 1,035
TLR4/MD-2 
heterodimerizatio
n interface and
TLR4
, X homodimer agonist 1,012 1,039
TLR4/MD-2 
heterodimerizatio
n interface and
TLR4
, W, X heterodimer agonist 1,01 1,041
TLR4/MD-2 
heterodimerizatio
n interface and
TLR4
,  homodimer agonist 1,009 0,959 TLR4*
T homodimer agonist 0,983 0,968
TLR4 (internal
cavity)
J homodimer agonist 0,981 0,937
TLR4/TLR4
homodimerization
interface
L homodimer agonist 0,971 0,842
TLR4/MD-2 
heterodimerizatio
n interface
P, I homodimer agonist 0,969 0,897
TLR4/TLR4
homodimerization
interface
F, G, H homodimer agonist 0,922 0,933 TLR4
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3. TLR4 LIGANDS
F, G, H, O homodimer agonist 0,91 0,954 TLR4
 heterodimer agonist 0,886 0,892 TLR4
E homodimer agonist 0,841 0,84
TLR4 (near
transmembrane
domain)
 heterodimer antagonist 0,838 0,84 TLR4
G, H heterodimer agonist 0,838 0,875 TLR4
E homodimer agonist 0,835 0,845
TLR4 (near
transmembrane
domain)
D heterodimer antagonist 0,835 0,844 TLR4
W homodimer agonist 0,827 0,817 TLR4
L homodimer agonist 0,786 0,543
TLR4/MD-2 
heterodimerizatio
n interface
W homodimer agonist 0,78 0,741 TLR-4
U homodimer agonist 0,778 0,747
TLR4/TLR4
homodimerization
interface
V homodimer agonist 0,777 0,695 TLR-4
E heterodimer agonist 0,77 0,775
TLR4 (near
transmembrane
domain)
D homodimer agonist 0,762 0,744 TLR4
E heterodimer antagonist 0,747 0,735
TLR4 (near
transmembrane
domain)
D heterodimer agonist 0,738 0,718 TLR4
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3. TLR4 LIGANDS
D homodimer agonist 0,705 0,674 TLR4
L heterodimer agonist 0,703 0,474
TLR4/MD-2 
heterodimerizatio
n interface
M homodimer agonist 0,686 0,595
MD-2 (external 
binding site)*
M homodimer agonist 0,676 0,58
MD-2 (external 
binding site)*
F, G heterodimer antagonist 0,668 0,659 TLR4
I heterodimer antagonist 0,649 0,366 TLR4
I heterodimer agonist 0,64 0,476 TLR4
G, H heterodimer antagonist 0,627 0,586 TLR4
M heterodimer agonist 0,623 0,51
MD-2 (external 
binding site)
O homodimer agonist 0,62 0,516 TLR4
X homodimer agonist 0,614 0,566 TLR4
R homodimer agonist 0,58 0,524
TLR4/MD-2 
homodimerization
interface
K, Y heterodimer antagonist 0,577 0,504 TLR4
N heterodimer agonist 0,552 0,471 TLR4
S, Y homodimer agonist 0,547 0,491 TLR4
O heterodimer agonist 0,543 0,455 TLR4
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!nnex Table 3.2/ Calculated SASA and volume of MD-2 pockets by CASTp for the binding
poses and average structure during the MD simulations of the different ligands.
LIGAND
Euodenine A
Nº 
ATOM
61
ONO-4007
D1
Eritoran
142
238
213
Paclitaxel 113
DOCKING/AVERAGE
SASA (Å2)
docking: 617.650
average 42-238: 635.431
average 1152-1662: 393.377
average 3837-4249: 334.191
docking: 667.810
average 1500-2500: 739.338
docking: 781.697
average 3000-4000 819.913
docking: 613.745
average 1560-1943: 771.575
average 2015-2150: 591.068
EXT-sol2-clust6_docking 635.865
EXT-sol2-clust6_average 591.347
EXT-sol2-clust7_docking 645.843
EXT-sol2-clust7_average 622.278
POLAR_sol1_clust30_docking 660.009
POLAR_sol1_clust30_average 557.977
POLAR_sol1_clust1_docking 660.004
POLAR_sol1_clust1_av300-1000 653.755
T-TAXOL_docking 660.016
T-TAXOL_average 830.141
Docking 660.009
Volume 
(Å3)
602.904
495.813
309.073
261.028
715.539
837.885
1007.779
781.971
670.638
988.573
659.075
681.513
525.086
721.360
638.440
690.237
470.107
690.231
717.826
690.214
1005.880
690.237P01 113
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FullComplex_av300-390
FullComplex_av1210-1300
FullComplex_av2340-2420
docking
MD2only_av100-250
MD2only_av1200-2000
MD2only_av2130-2230
P03 104 docking
FullComplex_av1560-1943
FullComplex_av2016-2150
docking
MD2only_av130-250
MD2only_av500-850
A1 193 docking
115 docking_SOL1
docking_SOL2
docking_SOL3
605.486
498.415
459.895
539.230
831.267
518.032
668.878
660.009
572.964
708.288
539.221
733.237
678.205
699.866
699.866
699.866
699.866
497.741
379.840
318.623
527.605
860.676
358.442
575.479
690.237
439.545
595.026
527.594
536.505
647.867
798.737
798.737
798.737
798.737
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Annex Figure 3.8. Distances between Met85­
Lys125, Leu87-Ile124 and Val82-Phe126 from
the loops in MD-2 pocket in agonist and
antagonist MD simulations of the ligands.
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Ligand: Euodenine A
Ligand: ONO-4007
Annex Figure 3.9a. Polar interactions monitorized between TLR4 and MD-2 residues from
Euodenine A and ONO-4007 MD simulation.
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Ligand: D1
Ligand: Eritoran
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Ligand: P01
Annex Figure 3.9b. Polar interactions monitorized between TLR4 and MD-2 residues from D1, 
Eritoran and P01 MD simulation.
Average of the water Average of the
ANTAGONISTS Time (ns) molecules around water molecules
Phe126 around Tyr131
P01_FullComplex 50 24.724 6.544
P01_MD2Only 50 23.248 10.208
P03_FullComplex 50 26.062 8.432
P03_MD2Only 50 26.906 10.038
D1 50 26.102 8.56
Eritoran 50 18.5 6.586
TAXOL-EXT-clust6 30 26.7733 7.59333
TAXOL-EXT-clust7 30 28.4333 14.1933
TAXOL-POLAR-clust1 50 26.552 13.804
TAXOL-POLAR-clust30 30 25.4933 6.36
TAXOL-TTAXOL 30 28.2133 9.08667
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Average of the water Average of the
AGONISTS Time (ns) molecules around water molecules
Phe126 around Tyr131
Euodenine A 70 9.84286 10.0271
ONO 4007 50 8.954 7.994
Annex Figure 3.10. Evaluation of the number of water molecules around Phe126 and Tyr131
in a radius of 4 Å from the center of mass of the both residues. The average of the water 
molecules was taken from the MD simulation starting from the docked binding poses.
APBS from MD-2 pocket:
Ligand Euodenine A
docking average 42-238 average 1152-1662 average 3837-4249
Ligand ONO-4007
docking average 1500-2500
Ligand Eritoran
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3. TLR4 LIGANDS
docking average 1560-1943 average 2015-2150
Ligand D1
docking average
Ligand P01
docking average 100-250 average 1200-2000 average 2130-2230
Ligand P03
docking average 130-250 average 500-850
Ligand A1 Ligand A2
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docking docking
Annex Figure 3.11. Electrostatic potential of MD-2 in Pymol plotted on the solvent accessible 
surface. The surface colors are clamped at red (-) or blue (+).
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CHAPTER 4
Glycolipid-Based TLR4 Modulators and 
Fluorescent Probes:
Rational Design, Synthesis and Biological 
Properties
  
  
 
  
      
    
   
    
       
     
     
      
     
       
     
     
        
        
  
     
      
        
     
        
       
     
         
     
       
     
         
      
       
4. TLR4 MODULATORS AND PROBES
4.1 Introduction
As it has been mentioned in the Introduction, the induction of
inflammatory responses by endotoxin is achieved by the coordinated and
sequential action of four principal endotoxin-binding proteins: the
lipopolysaccharide-binding protein (LBP), the cluster differentiation antigen CD14,
the myeloid differentiation protein (MD-2), and TLR4.1 CD14-dependent or
independent TLR4 activation by endogenous factors (danger or damage­
associated molecular patterns, DAMPs) such as heat-shock proteins, fibronectin,
and oxidized phospholipids has been recently related to a wide array of
inflammatory disorders, including neuroinflammation and neurological diseases,
such as amyotrophic lateral sclerosis (ALS),2 neuropathic pain,3 and !lzheimer’s
disease (AD).4 Consensus is growing that TLR-directed compounds will provide in
the near future new specific drugs against a wide array of diseases still lacking
specific pharmacological treatment,5 and the EU is now strongly committed to
support academic and industrial research focused on TLR modulation by small
molecules and antibodies.
Small molecules able to interact with membrane CD14 and TLR4/MD-2 
dimer are not only new hit for drug development, but also potential templates to
develop selective chemical probes allowing in vitro and in vivo imaging of innate
immune receptors and ligand/receptor co-localization studies. The portion of LPS
that binds to the CD14 and MD-2 receptors is lipid A. Even though lipid A chemical
structure varies in different bacterial species, it is generally composed by a
hydrophilic domain formed by a glucosamine disaccharide bearing two phosphate
groups and a hydrophobic domain formed by linear and branched fatty acid lipid
chains attached to the disaccharide core through ester or amide bonds.6-7 The
lipid A structure can be mimicked by synthetic glycolipids bearing anionic
phosphates. Synthetic TLR4 activators (agonists)8 and inhibitors (antagonists)9-10 
have been developed with a variety of clinical and pharmacological applications.11 
Although the negative charges on phosphate are important for the
interaction of lipid A and its synthetic analogs with the CD14 and MD-2 
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4. TLR4 MODULATORS AND PROBES
receptors,12 it has been recently found that also cationic lipids with positively
charged head groups are active in modulating TLR4 activity as agonists or
antagonists.13 While the mechanism of action of other cationic lipids seems to be
mainly based on interaction with LPS and stabilization or solubilization of insoluble
LPS aggregates, specific interaction with MD-2 and CD14 co-receptors was clearly 
14-16 demonstrated for cationic glycolipids developed by our group. These
compounds are active in inhibiting TLR4-dependent cytokine production in cells 
and in blocking TLR4 activation by LPS15 and endogenous17 stimulation in animal
models. Size-exclusion chromatography revealed that incubation of soluble CD14
(sCD14) with these compounds inhibited the transfer of lipooligosaccharides (LOS)
from CD14 to TLR4/MD-2.14 Evaluation of transfer of LOS from monomeric sCD14
to His6-tagged CD14 or MD-2 by co-capture to metal chelating resin clearly
showed that the cationic lipids derived from D-glucose or benzylamine inhibit the
transfer of LOS from sCD14 to CD14-His6, but not the transfer of LOS from sCD14
to MD-2. Finally, saturation transfer difference (STD) NMR data demonstrated
direct binding of the cationic lipids to CD14, through acyl chains mainly.14 
Altogether, these data suggest therefore that the cationic lipid tails insert into the
hydrophobic pocket of CD14 and compete with LPS or LOS lipid chains. In fact, the
wideness of MD-2 pocket leaves space to accommodate extra units of LPS-like
ligands with two fatty acid chains such as IAXO-102 ligand.
With this starting background, we undertook the computer-assisted,
structure-based rational design, the synthesis, and a preliminary evaluation of
biological activity of compounds 4.1-4.4 (Figure 4.1). Labeling properties of
fluorescent compound 4.1 were studied in murine macrophages. The synthesis
and biological evaluation of the compounds were performed at the laboratory of
Prof. Peri at the University Milano-Bicocca. All the experimental details can be 
found elsewhere.18 
Compounds 4.1 and 4.2 are derived from the glycolipid IAXO-102
previously developed by Francesco Peri’s group from Milano (Italy) and now
commercially available (Adipogen, www.adipogen.com). Compound 4.1 has a
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4. TLR4 MODULATORS AND PROBES
fluorescein unit directly linked to the glucose C-6, while fluorescein is linked to the
sugar through a glutaryl-diaminoethyl-thiourea linker in compound 4.2 (Figure
4.1). Compounds 4.3 and 4.4 are composed by two glycolipid units with the same
structure of IAXO-102 connected through, respectively, C4 diamino and di­
ammonium linkers (Figure 4.1).
Figure 4.1. Glycolipid derivatives of IAXO-102: fluorescent probes 4.1 and 4.2, dimeric
derivatives 4.3 and 4.4, and control compound 4.5.
The use of permanently charged ammonium groups in compound 4.4, 
instead of pH-sensitive amines of 4.3, is aimed at improving water solubility of
these molecules and at the same time optimizing charge interactions with CD14
and MD-2 receptors. Compound 4.5, a water-soluble fluorescein derivative, was
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4. TLR4 MODULATORS AND PROBES
also synthesized to be used as a negative control for fluorescence labeling studies 
on cells.
4.2 Results
Structures of CD14 and MD-2 Binding Pockets
Structurally, both human and mouse CD14 (hCD14 and mCD14) are 
characterized by a bent solenoid typical of leucine-rich repeat (LRR) proteins, with
a large hydrophobic pocket found on the amino-terminal side (PDB-ID: 4GLP for
hCD14, and 1WWL for mCD14). In the TLR4/MD-2 complex, MD-2 protein is 
responsible for LPS binding and it is characterized by a wide lipophilic pocket that
hosts the fatty acid chains from LPS. Our calculations showed that both hCD14 and
hMD-2 pockets share a similar topology in terms of solvent accessible surface area
(SASA) and volume (Figure 4.2 and Table 4.1). However, CD14 possesses fewer
polar residues in the rim and it is capable of recognizing other microbial and
cellular molecular determinants, in addition to LPS.9 Therefore, despite being very
similar in lipophilicity, SASA, and volume, the pockets differ in the polarity of the
rim, allowing MD-2 to be more selective than CD14 in the recognition of LPS.
Figure 4.2. Binding pockets identified by CASTp26 in hCD14 (left, PDB-ID: 4GLP) and hMD­
2 (right, PDB-ID: 2E59).
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4. TLR4 MODULATORS AND PROBES
Rational Design of IAXO-102-derived Fluorescent Probes 4.1 and 4.2
Based on IAXO-102 structure (Figure 4.1), we aimed to develop small­
molecule fluorescent probes for endotoxin receptors, able to bind to CD14 and
TLR4/MD-2 complex. Then, we designed compounds 4.1 and 4.2 (Figure 4.1) 
where IAXO-102 is chemically linked to fluorescein through a thiourea 0-atoms
linker (compound 4.1) or a glutaryl-diaminoethyl 9-atoms linker (compound 4.2).
The C-6 position of the glucose moiety in IAXO-102 has been selected as
attachment point for fluorescein because it is apart from lipid chains that directly
interact with hCD14 and MD-2 receptors, according to NMR binding studies on
IAXO-102.14 
To estimate its CD14 binding properties, designed compounds 4.1 and 4.2
were submitted to docking studies using the X-ray crystal structure of hCD14
(PDB-ID: 4GLP), focusing on the amino-terminal pocket, that presumably binds
acylated ligands including LPS. As the 3D structure of CD14-bound ligands are not
available, and given that the crystallographic structure for CD14 (PDB-ID: 4GLP) 
adopts a closed conformation of the pocket, thus preventing an efficient
exploration by docking, we first undertook a normal mode analysis (NMA) of the
protein to represent motions and conformational changes. Finally, docking
calculations were performed in three different conformations of hCD14 obtained
by NMA (see Experimental Section), thus approaching a flexible protein docking
protocol. Calculations predicted binding poses for compounds 4.1 and 4.2, with a
general tendency to bury their fatty acid chains inside the hydrophobic pocket,
with the sugar pyranose ring remaining toward the external portion (Table 4.2).
Only, 2% of the docking results (performed in the three different structures from
NMA) predicted fluorescein moiety inserted inside the CD14 pocket with one or
two FA chain outside the pocket, and always with unfavorable theoretical binding
energy. These results are in agreement with the binding modes proposed for
other TLR4 modulators interacting with hCD14.19 Our calculations have predicted
that the thiourea linker and the fluorescein moiety establish polar interactions
with the hydrophilic rim, without adopting any preferred binding pose. This
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heterogeneity can be observed in the docked poses shown in Figure 4.3. These
results would not be incompatible with the fluorescein tag dangling from the
CD14 into the solvent. Similar docking results were obtained for mCD14 (Figure
4.4). Selected docked poses from the most populated clusters were submitted to
minimization and analysis of the free energy of binding using the MM-GBSA
approach (see Experimental Section).
Figure 4.3. Rational design of compounds 4.1 and 4.2. Docked poses for compound 4.1 (left,
lateral, and top views) and compound 4.2 (right, lateral, and top views) binding to hCD14 (PDB­
ID: 4GLP). Fluorescein remains at the hCD14 rim and the IAXO-102 scaffold binds into the hCD14
pocket. Fatty acid chains are buried inside the hydrophobic pocket. Three different 
conformations of hCD14 from NMA are superimposed.
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4. TLR4 MODULATORS AND PROBES
Figure 4.4. Docked poses for compound 4.2 binding to mCD14 (PDB-ID: 1WWL). 
Fluorescein remains at the mCD14 rim and the IAXO-102 scaffold binds into the mCD14
pocket (on the left). Fatty acid chains are buried inside the hydrophobic pocket (on the 
right).
To evaluate putative MD-2 binding properties of compounds 4.1 and 4.2, 
we also undertook docking studies in the hTLR4/MD-2 system. As the X-ray
structure of the hTLR4/MD-2 is not available in complex with an antagonist, we
used a hybrid model built by us from PDB-IDs 3FXI and 2E59 (see Experimental
Section). Similarly to CD14, the calculations predicted binding poses with FA
chains buried inside the MD-2 hydrophobic pocket (Table 4.2). These results are in
agreement with the antagonist binding pose found for lipid IVa, a precursor of
lipid A, in the crystallographic structure (PDB-ID: 2E59). In the case of compounds
4.1 and 4.2, the thiourea linker and the fluorescein moiety resulted outside MD-2,
adopting different orientations (Figure 4.5) and establishing transient polar
interactions with MD-2 residues Arg90, Glu92, Lys122, and Tyr102. In the case of
compound 4.2, the longer linker allows the fluorescein moiety to reach the TLR4
region delimited by Asn361, Lys362, Gly363, and Arg264. In a dynamic
environment, it is likely the fluorescein tag may fluctuate into the solvent.
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A B 
Figure 4.5. Rational design of compounds 4.1 and 4.2. Docked poses for compound 4.1
(A) and compound 4.2 (B) binding to TLR4/MD-2 (hybrid model from PDB-ID 2E59) 
showing three preferred binding poses.
Rational Design of IAXO-102 derivatives 4.3 and 4.4
Previous computational and NMR studies performed by our group showed
that LPS-like compounds bearing two FA chains are able to bind MD-2, inserting
both chains inside the pocket, by adopting different biding poses.19 In fact, the
wideness of MD-2 pocket leaves room to accommodate the ligand while leaving 
enough empty space to host a second ligand molecule. Duplication of the
structure of IAXO-102 would still allow both ammonium groups to remain at the
rim of MD-2, while allowing the four FA chains to go inside the pocket, following a 
dimer-based design strategy already used for TLR4 ligands.20-21 Thus, different
dimeric structures were designed and docked to CD14 and TLR4/MD-2 (data not
shown), finally leading to the selection of molecules 4.3 and 4.4.
Predicted binding poses of compounds 4.3 and 4.4 on the hTLR4/MD-2 
receptor complex showed a general tendency to bury their fatty acid chains inside
the hydrophobic pocket of MD-2, similarly to lipid A and lipid IVa, and to place the
sugar moieties in the rim of MD-2, establishing polar interactions. Selected docked
poses from the most populated clusters were submitted to analysis of the free
energy of binding using the MM-GBSA approach (Table 4.2). The computed energy 
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values were reasonably good when compared with the antagonist lipid IVa, whose
binding energy was also computed as reference value (Table 4.2).
Analysis of the docked poses in the hTLR4/MD-2 system for both
compounds 4.3 and 4.4 showed that the FA chains establish lipophilic interactions
with the alkyl and aromatic residues building the inside of MD-2 pocket, mainly
Ile44, Ile46, Ile52, Leu61, Ile63, Tyr65, Leu78, Ile94, Ile117, Phe121, Ile124, Val135,
Phe147, and Ile153. In addition, CH–π interactions were observed for both
compounds between the ligand aliphatic chains and Phe76, Phe104, and Phe151
side chains. No CH–π interactions were observed involving the sugar CH groups.
For the analysis of the lipophilic interactions, distances of FA chains of compounds
4.3 and 4.4 with residues alkyl chains were measured (distance to compound 4.3 / 
distance to compound 4.4): Ile44 (3.2 Å / 3.4 Å), Ile46 (3.6 Å / 3.5 Å), Ile52 (2.9 Å /
3.5 Å), Leu61 (4 Å / 3.6 Å), Ile63 (3.2 Å / 3.7 Å), Tyr65 (3.4 Å / 3.6 Å), Leu78 (3.7 Å /
3.6 Å), Ile94 (3.4 Å / 3.1 Å), Ile117 (3.3 Å / 3.4 Å), Phe121 (3.4 Å / 3.2 Å), Ile124
(3.3 Å / 3.6 Å), Val135 (3.3 Å / 3.3 Å), Phe147 (3.6 Å / 3.4 Å) and Ile153 (3.2 Å / 3.5
Å). Distance for CH-π interactions were also measured with Phe76 (3.2 Å / 3.1 Å), 
Phe104 (3.6 Å / 3.3 Å) and Phe151 (4.1 Å / 4.6 Å).
Both compounds also showed a similar pattern of polar interactions.
Several hydrogen bonds can be identified between hydroxyl groups from both
glucose moieties (glucoses A and B in Figure 4.6). Distances in the docked
TLR4/MD-2 ligand complex are (compound 4.3/compound 4.4): Arg90 side chain
and O3 from glucose A (2.6 Å/1.9 Å), Glu92 side chain and O4 from glucose A (2.2
Å /2.2 Å), and Arg96 side chain and O5 from glucose B (3.8 Å /3.1 Å). The
ammonium group from glucose B is in the close vicinity of Glu92 side chain
(distance of 4.5 Å /4.7 Å), establishing a favorable electrostatic interaction for
both compounds. In the case of compound 4.3, the presence of polar hydrogen
atoms leads us to suggest the possible formation of a hydrogen bond. Overall, the
reasonably good predicted binding properties prompted us to synthesize and test
both compounds.18 
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Figure 4.6. Rational 
design of compounds
4.3 (top) and 4.4
(bottom). Docked
poses for compounds 
4.3 and 4.4 binding to
TLR4/MD-2.
Superimposed lipid IVa 
(magenta) is shown as 
reference in the global 
views (left, top, and
bottom). Details of
some ligand–receptor 
interactions are shown 
(right, top, and
bottom).
4.3 Discussion
The TLR4 antagonist IAXO-102 has proven to serve as inspiration for 
rational design of new glycolipid-based TLR4 inhibitors: compounds 4.1 and 4.2
are fluorescein labeled analogs of the parent molecule; compounds 4.3 and 4.4 
are homodimers based on another dimeric version of TLR4 antagonist already
described by our group. 20 Molecular modeling studies have assisted in the
structure based design of new molecules and in the rationalization of the putative
binding modes for the three molecules 4.1-4.4, showing that the primary amino
group at of IAXO-102 is not directly involved in the binding to CD14 and TLR4/MD­
2 receptors, while FA chains are inserted in the lipophilic pockets of the receptors.
The primary amino group has been covalently attached to a fluorescent tag
through a long short 0-atom or a long 9-atoms linker (molecules 4.1 and 4.2) or 
used to link two glucose molecules through di-amine and di-ammonium spacers
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4. TLR4 MODULATORS AND PROBES
(molecules 4.2 and 4.3). All compounds proved to inhibit in a concentration­
dependent manner TLR4 activation and signaling in HEK-BlueTM cells expressing
hTLR4, compounds 4.1 and 4.2 being more active than 4.3 and 4.4. In preliminary
confocal microscopy experiments,18 compound 4.1 was able to fluorescently label
the surface of murine macrophages, and labeling was abrogated when cells were
pre-treated with LPS or with trypsin. This would suggest a selective interaction of 
compound 4.1 with LPS-binding proteins CD14 and MD-2 of the TLR4 receptor 
system. The reference fluorescein ethanolamine did not bind to cells in the same
experimental conditions, thus suggesting again that compound 4.1 interact with
LPS-binding proteins on the macrophage surface.
We still do not completely exclude some non-specific interactions of
compounds 4.1 and 4.2 with cell membrane, including insertion into membrane
bilayer, and we are further investigating this property for these and other
compounds of the IAXO series. We are also investigating why the presence of the
9-atoms linker makes compound 4.2 much less efficient than 4.1 in fluorescence
labeling of cells.
Homodimers 4.3 and 4.4 with increased hydrophobic part inhibited LPS­
stimulated TLR4 signal in cells very weakly.18 Both these compounds have very 
poor solubility in aqueous solutions with tendency to form aggregates.
Experimentally was found that critical micellar concentration (CMC) for compound
4.3 and 4.4 are, respectively, 18.1 and 29.7 µM using an established fluorescence
technique based on pyrene.22 Both compounds present quite low CMC values, if
compared to other cationic glycolipids active as TLR4 modulators.23 The low value 
of CMC could account for the weak TLR4 activity of these compounds.
In the concentration range used for biological characterization (10–200
µM), these molecules form aggregates, so that activity on TLR4 receptor system is
due to very few residual monomers able to interact with CD14 and MD-2 
receptors. While being active in cells, fluorescent compounds 4.1 and 4.2 failed to
inhibit LPS-induced cytokine production in vivo. In fact, calculated logP values for
compounds 4.1 and 4.2 (9.89 and 9.78, respectively)
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4. TLR4 MODULATORS AND PROBES
(http://www.molinspiration.com) indicate a high predicted lipophilicity,
accounting for poor solubility and unfavorable distribution properties that could
explain the lack of in vivo activity. Given that the physico-chemical properties can
be tuned, the very low toxicity on cells of compounds 4.1 and 4.2 is however an
important prerequisite for drug development. Another interesting result from this
study is the possibility to chemically label with fluorophores TLR4 antagonists
preserving their TLR4 activity. Overall, these findings suggest that molecules 4.1
and 4.2 could be promising hits for the development of TLR4/MD-2 modulators
and probes.
4.4 Materials and Methods
Building of Ligands
3D co-ordinates of the compounds 4.1-4.4 were built in Corina24 from the
SMILES code. Optimization of the ligands was performed with MMFFs force field
using MacroModel.25 Two fragments from compounds 4.2 were built and
optimized with MMFFs force field: the glycolipid moiety F1 and the fluorescein
moiety plus the linker F2 (Figure 4.7). Fluorescein moiety was modeled according
to the protonation state at experimental conditions. 3D co-ordinates of human
CD14 protein (PDB-ID: 4GLP) and mouse CD14 (PDB-ID: 1WWL) were refined and
optimized under the Protein Preparation Wizard module of Maestro,25 using
AMBER force field. In the case of human CD14, three geometries resulting from
the normal mode analysis (NMA) were considered for docking purposes as
described below. For the building of the human TLR4/MD-2 system, we used the
(hetero) monomer from crystallographic TLR4/MD-2/LPS heterodimer (PDB-ID: 
3FXI, agonist conformation), by replacement of the MD-2 protein by the human
MD-2 in antagonist conformation (from PDB-ID: 2E59) by superimposition of the
Cα trace. Ligand was deleted, missing hydrogens were added, and protonation
state of ionizable groups was computed using the Protein Preparation Wizard
module of Maestro. This structure was submitted to 100000 steps of steepest
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4. TLR4 MODULATORS AND PROBES
descent minimization with MacroModel,25 optimized with AMBER force field, and
finally used as TLR4/MD-2 macromolecule for the docking calculations.
Figure 4.7. Preparation of the macromolecules: fragments F1 and F2 of molecule 4.2.
SASA and Volume Calculations
Solvent accessible surface area (SASA) and solvent accessible volume were 
calculated on hydrophobic pockets of CD14 (PDB-ID: 4GLP) and MD-2 (PDB-ID:
2E59) using CASTp server.26 CASTp server identifies and computes the molecular
area and volume for cavities and pockets of a given protein. In our case, we
selected the data corresponding to the hydrophobic pockets of both CD14 and
MD-2 proteins (Table 4.1).
Table 4.1. Calculated SASA and volume of 
hCD14 (PDB-ID: 4GLP) and hMD-2 (PDB-ID:
2E59) pockets by CASTp.
Molecule SASA (Å2) Volume (Å3)
hCD14 623 607
hMD-2 591 621
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4. TLR4 MODULATORS AND PROBES
Normal Mode Analysis
To compute the low frequency normal modes of CD14, the elastic network
model was used with help of the Webinterface ElNemo.27 We focused our
attention on the sequence ranging from Glu26 to Leu135 that corresponds to the
binding pocket, and normal mode 4 was found to account for the opening/closing
of the pocket. From the trajectory corresponding to this normal mode, we
selected three structures to be used for docking purposes: the one corresponding
to the crystallographic structure (CD14-a), the one corresponding to the last
structure of the displacement in one of the directions of the normal mode (CD14­
b), and the last located structure in the opposite direction (CD14-c). The three
structures were submitted to 100 000 steps of steepest descent minimization with
MacroModel25 and optimized with AMBER force field, before being used for
docking calculations.
Docking Calculations
Docking calculations were performed by means of AUTODOCK 4.2..28 
Analysis was performed with the help of AUTODOCKTools. For CD14 as
macromolecule, only the sequence ranging from Ala3 to Leu130 was considered
for docking purposes and three geometries were considered: CD14-a, CD14-b, and
CD14-c (as reported above). The grid point spacing was set at 0.375 Å, with a 
number of grid points in xyz of 78, 72, 84 for hCD14, and 66, 72, 88 for mCD14.
Due to the big size of compound 4.2, and subsequently the high number of
degrees of freedom, when performing docking on the hTLR4/MD-2 receptor, the
docking was performed in two steps. First, fragment F1 (Figure 4.7) was docked
into the hTLR4/MD-2 model using a box with 48, 76, 56 grid points in xyz, and with
a spacing set at 0.375 Å. Best docked pose (with the FA chains inside the pocket
and favorable binding energy) was selected for the second step. Second, fragment
F2 (Figure 4.2) was docked starting from the macromolecule containing the best
docked solution for F1, using a new box for the TLR4/MD-2/F1 system, with a grid
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4. TLR4 MODULATORS AND PROBES
point spacing set at 0.375 Å , and a number of grid points in xyz of 38, 38, 36.
From the best docked solutions for F2, inside the TLR4/MD-2/F1 system, a full
geometry for compound 4.2 was built considering appropriate relative fragments
orientations, allowing a reasonable F1-F2 connection. Thus, resulting geometry for
compound 4.2 was minimized (10 000 cycles of steepest descent minimization
with AMBER force field as implemented in Maestro) and subsequently docked into
TLR4/MD-2 system. The grid point spacing was set at 0.375 Å, and the number of
grid points in xyz was 84, 96, 74. For all cases, the docking protocol was as follows.
All allowed torsional bonds were considered rotatable, and Lamarckian algorithm
was used (number of individuals in population 150, run 200). Results are shown in
Table 4.2. For compounds 4.1, 4.3, and 4.4, the docking was performed directly
into TLR4/MD-2 system. The grid point spacing of the box was set at 0.375 Å, and
the number of grid points in xyz was 84, 96, 74.
Table 4.2. Results from the docking calculations of compounds 4.1, 4.2, 4.3
and 4.4 in macromolecules CD14 and TLR4/MD-2 by means of AutoDock. 
Binding energy from MM-GBSA analysis of selected docking poses is 
provided.
Compound Macromolecule
Selected
docked
solution
MM-GBSA binding
energy (kcal mol -1)
4.1 hTLR4/MD-2 pose 1 -123.25
4.1
hCD14-a
pose 1
pose 2
pose 3
-74.40
-120.20
-110.93
hCD14-b
pose 1
pose 2
-94.97
-107.51
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4. TLR4 MODULATORS AND PROBES
pose 3 -96.33
pose 1 -95.04
hCD14-c pose 2 -63.33
pose 3 -51.37
4.1 mCD14 pose 1 -134.80
4.2 hTLR4/MD-2 pose 1 -112.1
pose 2 -82.2
pose 3 -129.5
4.2 hCD14-a pose 1 -24.7
hCD14-b pose 1 -115.1
hCD14-c pose 1 -102.3
pose 2 -90.6
4.2 mCD14 pose 1 -106.0
pose 2 -98.4
4.3 hTLR4/MD-2 pose 1 -142.1
pose 2 -142.0
pose 3 -146.9
4.4 hTLR4/MD-2 pose 1 -136.2
pose 2 -153.4
pose 3 -130.1
Lipid IVa hTLR4/MD-2 pose 1 -201.9
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4. TLR4 MODULATORS AND PROBES
MM-GBSA Calculations
For selected binding poses, free energy of binding was calculated by means
of the MM-GBSA method computed with Prime. In our hands, AUTODOCK scoring
function has proved to be an efficient tool to predict binding for LPS and LPS-like
ligands. Additional calculation of the free energy of binding by MM-GBSA
approach can be appropriate to overcome the possible underestimation of
binding energy for big hydrophobic ligands (Table 4.2).
4.5 Annex IV
Experimental Section
Synthesis of the compounds
The compounds were synthesized at the Prof. Peri´s laboratory following the
route shown in Scheme 4.1. Details can be found elsewhere.18 
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Scheme 4.1. Reactions and conditions: (a) TFA, CH2Cl2, 25 °C, 1 h, 98%; FITC, CH2Cl2, 25 °C,
3.5 h, 92%; (b) Glutaric anhydride, dry pyridine, 25 °C, 2 h, 87%; (c) N-Boc­
ethylenediamine, DIC, HOBt, DIPEA, dry DMF, 40 °C, 40 h, 67%; (d) TFA, CH2Cl2, 25 °C, 1.5 
h, 73%; (e) FITC, CH2Cl2, 25 °C, 2.5 h, 50%; (f) LiAlH4, dry THF, dry CH2Cl2, 50 °C, 4 h, 78%;
(g) CH3I, Na2CO3, dry DMF, 40 °C, 24 h, 73%; (h) NH2(CH2)2OH, THF, 40 °C, 10 h, 76%.
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4. TLR4 MODULATORS AND PROBES
Biological Characterization
Biological characterization was performed at the Prof. Peri´s lab. Complete details
can be found elsewhere.18 
HEK-Blue TLR4 Assay
HEK-Blue-TLR4 cells (InvivoGen, Toulouse, France) and parental cell line 
HEK-Blue Null 2 (InvivoGen) were cultured according to manufacturer’s
instructions. Briefly, cells were cultured in DMEM high glucose medium
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 19 penicillin/
streptomycin, 19 Normocin (InvivoGen), and 19 HEK-Blue Selection (InvivoGen). 
Cells were detached by the use of a cell scraper, and the cell concentration was 
estimated using Trypan Blue (Sigma-Aldrich, St Louis, MO, USA). The cells were
diluted in DMEM high glucose medium supplemented as described before and
seeded in multiwall plate at a density of 2 x 104 cells/well in 200 µl. After 14 h
incubation (37 °C, 5% CO2, 95% humidity), supernatants were removed, cell
monolayers were washed with warm PBS without Ca2+ and Mg2+ and treated with
increasing concentrations of synthetic compounds dissolved in DMSO-ethanol
(1:1) and diluted in DMEM. After 30 min, the cells were stimulated with 100
ng/mL LPS from Escherichia coli (E. coli) O55:B5 (Sigma-Aldrich) and incubated 14
h at 37 °C, 5% CO2, and 95% humidity. As a control, the cells were treated with or
without LPS (100 ng/mL) alone. Then, the supernatants were collected, and 50 lL
of each sample was added to 100 µl PBS, pH 8, and 0.84 mM
paranitrophenylphosphate (pNPP) for a final concentration of 0.8 mM pNPP.
Plates were incubated for 2-4 h in the dark at 25 °C, and then, the plate reading
was assessed using a spectrophotometer at 405 nm (LT 4000, Labtech). The
results were normalized with positive control (LPS alone) and expressed as the
mean of percentage ± SD of at least three independent experiments.
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4. TLR4 MODULATORS AND PROBES
Activity on HEK-BlueTM Cells
The ability of molecules 4.1-4.4 to interfere with LPS-stimulated TLR4
activation in HEK-Blue hTLR4 cell model was investigated. HEK293 cell line is stably
transfected with human TLR4, MD-2, and CD14 genes. In addition, HEK-BlueTM 
cells stably express a secreted alkaline phosphatase (sAP) produced upon
activation of NF-kB. LPS binding activates TLR4 and NF-kB, leading to sAP
secretion, which is detected by an alkaline phosphatase substrate in cell culture
media. In this assay, cells were pretreated with increasing concentrations of
compounds 4.1-4.4 and then stimulated with E. coli LPS (100 ng/mL, Figure 4.8).
Fluorescent probes 4.1 and 4.2 inhibited TLR4 activation in a dose­
dependent way. Compounds 4.1 and 4.2 had IC50 of the same order of magnitude
(about 25 and 10 µM, respectively). Compounds 4.3 and 4.4 too induced an
inhibition of the TLR4 pathway, but with lower potencies (IC50 262 and 173 µM,
respectively). Reference compound 4.5 (fluorescein-ethanol) turned out to be
totally inactive in inhibiting TLR4 activation in HEK-Blue cells.
Figure 4.8. Dose-dependent inhibition by compounds 4.1, 4.2 (left) and 4.3, 4.4 (right) of 
LPS-stimulated TLR4 activation. HEK-Blue cells were treated with increasing
concentrations of synthetic molecules and then stimulated with LPS. TLR4 activation is 
monitored as sAP production. The TLR4 inhibition of compound IAXO-102 at 25 µM
concentration has been inserted as a reference. nt = HEK-Blue cells treated with 0.25%
DMSO–ethanol in DMEM. The results are normalized to activation by LPS alone and
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4. TLR4 MODULATORS AND PROBES
expressed as the mean of percentage ±SD of three independent experiments.
As a negative control, compounds 4.1-4.4 were tested in Null cell line 
(InvivoGen), transfected with the same plasmids as HEK-Blue cells but without
TLR4, MD-2, and CD14 genes, and no effect was observed. All compounds were
tested by MTT assay and showed no or very low toxicity in the concentration
range used for biological characterization (Figure 4.9).
Figure 4.9. Cell viability assay (MTT assay) on compounds 4.1-4.4.
Labeling of Murine Macrophages by Fluorescent Probe 4.1
It was hence explored if compound 4.1 can be used as a fluorescent probe 
in cells naturally expressing TLR4, MD-2, and CD14. RAW264.7 murine
macrophages were treated with 10 µM compound 4.1 and with fluorescein­
ethanol 4.5 as a negative control. Confocal microscopy images of the two slides
showed that only the fluorescent probe 4.1 bound the cells (Figure 4.10A), while
the negative control 4.5 was completely removed during the washing steps with
cold PBS. Selectivity of compound 4.1 for membrane bound TLR4/MD-2 and CD14
endotoxin receptors was tested with a competition assay toward the natural
ligand (LPS). Cells were treated with LPS (E. coli 055:B5, 100 ng/mL), then
incubated with compound 4.1 (10 µM), and analyzed in confocal microscopy. As 
expected, no fluorescence was detected suggesting that LPS and compound 4.1
compete for the binding with hCD14 and TLR4/MD-2 complex.
209
  
 
  
    
   
 
   
 
      
        
      
     
            
     
          
        
      
       
       
        
           
 
4. TLR4 MODULATORS AND PROBES
Figure 4.10. Labeling of membrane TLR4 receptor complex on RAW264.7 cells. (A)
Confocal micrographs show fluorescence when cells were treated with 10 µM compound
4.1. (B) FACS analysis of RAW264.7 cells. Red: no compound, blue: compound 4.1, green: 
control compound 4.5, mustard: trypsin + compound 4.1; light green: LPS-FITC.
To investigate which part of the observed fluorescence was caused by non­
specific interaction of the lipophilic part of molecule 1 with cell membrane,
RAW264.7 cells were pretreated with trypsin to hydrolyze the extracellular
membrane protein components, included endotoxin receptors. Cells were treated
at 37 °C for 10 min with 200 µL trypsin and then were incubated with compound
4.1. Very little fluorescence was observed on cells surfaces. The same samples
described in Figure 4.10A were analyzed with a cytofluorimetric analysis (Figure
4.10B) to confirm the selectivity of compound 4.1 interaction with the TLR4 
receptor system on the whole cellular population. RAW264.7 cells population
treated with compound 4.1 (10 µM) shows a remarkable shift toward higher
fluorescence content, similar to that observed when cells were treated with
fluorescent LPS, while, when exposed to control compound 4.5 (10 µM) or 
pretreated with trypsin before the addition of 4.1, limited or no increase in
fluorescence was observed. 
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4. TLR4 MODULATORS AND PROBES
Compound 4.2 showed a similar behavior than 4.1 as fluorescent probe, but with
a very low efficiency in cell labeling.
In Vivo Cytokines Production
As fluorescent compounds 4.1 and 4.2 were the most active in inhibiting 
TLR4 activation and signaling in HEK-cells, their inhibitory potential was tested in
vivo in C57/Bl6 mice, estimating the production of IL-6 and TNF-α cytokines
(Figure 4.11). Unfortunately, the activity found in human cells was not observed in
mice, as both compounds did not show significant inhibition of LPS-stimulated
cytokine production.
Figure 4.11. In vivo activity of compounds 4.1 and 4.2. C57/Bl6 mice were injected ip with 
synthetic molecules (2 x 10 -7 mol/mouse), followed 1 h later by ip injection of LPS (1 x 10 -9 
mol/mouse). Three hours later, sera were collected and TNF-α and IL-6 concentrations 
were determined by ELISA assay.
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5. VIRTUAL SCREENING ON TLR4
5.1 Introduction
Identification of drug-like molecules with potential therapeutic applications for
the treatment of TLR-related diseases has attracted considerable interest due to their
clinical potential. TLR modulators have the potential to be used with different
biomedical applications, especially in the field of infection,1 inflammation2 and
autoimmune diseases,3 and also in cancer 4-5 and in central nervous system (CNS) 
disorders such as Alzheimer´s disease.6 However, just few candidates are currently
under clinical development due to the difficulty to find molecules with appropriate
physic-chemical properties and low toxicity.7 Therefore, it is imperative to find new
chemical entities, and not necessary with LPS-like structure, as TLR modulators with
drug-like properties in order to facilitate their development as drugs. There are some
small molecules, described in Chapter 3, that exemplify this possibility. For example,
some pyrimido[5,4-b]indoles that have shown to stimulate TLR4 and could potentially
be used as adjuvants or immune modulators;8 synthetic analogues of natural product
euodenine A have exhibited potent and selective agonist towards TLR4;9 and synthetic
peptides to mimic the TLR4/LPS interaction have also been reported.10 Also several
small non LPS-like molecules with TLR4 antagonist activity have been developed, such
as ethyl 4-oxo-4-(oxazolidin-3-yl)-butenoate derivatives (OSL07),11 benzothiazole­
based inhibitors,12 ethyl phenyl-sulfamoylcyclohexenecarboxylate derivatives (TAK-242
or resatorvid),13 and β-amino alcohol derivatives.14 
In the context of drug discovery, virtual screening (VS) techniques have already 
proved to make hit identification more goal-oriented, allowing the access to a huge
number of chemically diverse binders (from public and commercial databases) with a
relatively low-cost in terms of time and materials. This computational approach has
been subjected to extensive attention and revision over the years, from the early
perspective of being an emerging method,15 until the current time where new
challenges are faced.16-21 We could say that TLRs are not standard receptors which
could be approached following classical strategies in drug design. The complexity of
the system and the characteristics of their complexation with the pathogen associated
molecular patterns (PAMPs) make them especially difficult to tackle following classical
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5. VIRTUAL SCREENING ON TLR4
procedures in drug design and discovery. This is why TLRs constitute a special case
study in this context. These VS approaches constitute a current strategy in drug design
for the identification of novel chemical entities with a given binding ability.22 
Specifically, on the field of TLR4 research, VS studies have been recently
reported leading to novel ligands with drug-like properties, trying to overcome the
solubility problems associated with LPS mimetics (see Chapter 1). Among these works,
Joce et al.23 have developed a novel in silico screening methodology including
molecular mechanics and implicit solvent methods to incorporate the evaluation of
binding free energies and have screened the Enamine database collection.24 The
resulting clusters were filtered by selecting the representative compounds that were
submitted to fast molecular docking for the generation of binding poses and
subsequent MD simulations to rank the ligand poses according to their predicted
binding affinities. Final filtering led to the identification of compounds T5342126 and
T6071187 (Figure 5.1) as small drug-like inhibitors of the TLR4/MD-2 protein-protein
interactions. Their biological activity and selectivity were tested in vitro, and their
TLR4/MD-2 antagonist activity was confirmed. In another study, Švajger et al.25 
performed parallel ligand-based and structure-based virtual screenings in order to
identify novel TLR4 antagonists targeting the TLR4/MD-2 interface, by using the ZINC
drug-like subset (~11.3 million drug-like compounds) from the ZINC database.26 The
identified ligands after ligand-based VS resulted in being either insoluble in water, or
inactive, or presented cytotoxicity on HEK293 cells. However, the structure-based VS
identified 40 putative TLR4/MD-2 ligands that were assessed in vitro. After the first
assays, only 14 compounds were sufficiently water-soluble and completely non­
cytotoxic at 100 μM; These compounds received further biological evaluation, and
finally, three compounds with promising antagonistic activities were discovered:
ZINC25778142, ZINC49563556 and ZINC3415865 (Figure 5.1).
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5. VIRTUAL SCREENING ON TLR4
Figure 5.1. Novel TLR4/MD-2 modulators identified by VS approaches.
On the other hand, despite the huge effort of spent time and money on
research and development, the number of new drugs brought to market drastically
decreases each year.27 Significant investments by pharmaceutical companies for
optimizing the drug discovery pipeline have been undertaken, and new techniques
such as structure-based drug design, combinatorial chemistry and high throughput
screening (HTS) techniques have emerged. However, the impact of these innovations
has not been as important as it was expected both in short and long term.28 Drug
repositioning (also known as drug repurposing, drug redirecting, or drug reprofiling) is
a process of discovering new uses outside the scope of the original medical indication
for existing drugs. Before 2004, no traces of this process have been found in the
literature,29 but it has gained an increasing attention within the international drug
development community over the last few years, and represents a new promising
direction.30-35 
Different terms are used to describe drug repositioning, but all mean a way to
find new indications for existing drugs or potential drug candidates, including those in
clinical development where mechanism-of-action is relevant to multiple diseases:
drugs that have failed to demonstrate efficacy for a particular indication during Phase
219
     
 
 
        
       
      
          
    
      
       
       
  
      
 
        
 
        
        
   
    
      
        
  
    
        
      
    
       
         
  
5. VIRTUAL SCREENING ON TLR4
II or Phase III trials but with no major safety concerns; drugs that have been
discontinued for commercial reasons; marketed drugs for which patents are close to
expiry; and drugs candidates from academic institutions and public sector laboratories
that have not been fully pursued yet, are also took into account. In this way, drug
repositioning represents unique translational opportunities, and is believed to offer
great benefits over the de novo drug discovery, reducing the development risks and
timeline to potentially 3-12 years,35 substantially increasing the probability of success 
to brought drugs into market due to existing knowledge about the drugs, and
providing relatively inexpensive solutions as therapies for rare and neglected
diseases36-39 that frequently offer limited potential revenue to pharmaceutical
companies.
Before the advancements in computational modeling that have led to rational
drug repurposing, successful repurposing examples as sildenafil (Viagra®), acetyl
salicylic acid (Aspirin®),40 and thalidomide41-42 have been due to serendipity. However, 
recent research has shown that bioinformatics-based approaches have the potential to
offer insights into the complex relationships among drugs, targets and diseases for
successful repositioning. Given the availability of X-ray crystallographic structures of a 
number of proteins and identified functional binding sites, and also the advent of
molecular docking for the prediction of the free energy of binding of a ligand and its
positioning within a defined binding pocket, “computational drug repositioning” is a 
promising and efficient tool for discovering new uses from existing drugs and holds the
great potential for precision medicine in the age of big data. 
In this work, we aimed to identify novel TLR4 modulators with non LPS-like 
structure by means of computational virtual screening. We have followed a virtual
screening protocol, and used different commercial and in-house databases. We also
present the application of computer-aided drug repositioning in the search of novel
TLR4 modulators.
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5. VIRTUAL SCREENING ON TLR4
5.2 Results and Discussion
Considering the uncertainty (not yet known) in the binding modes of the 
reported small molecules with TLR4 activity, and tacking into account that there are
plausible pockets of TLR4/MD-2 as binding sites (See Chapter 5), the VS can be
considered an effective approach to identify new molecular entities as putative TLR4
binders. 
Receptors
Presently, there are several available 3D structures of TLR4, as hetero/homo­
dimers, and in complex with some ligands (agonists and antagonists) and/or co­
receptors.43 In the case of the agonist conformation of the hTLR4/MD-2 monomer
complex, 3D coordinates from TLR4/MD-2 heterodimer were obtained from the PDB
(PDB-ID: 3FXI).44 In the case of the antagonist conformation, since the full
crystallographic structure of the hTLR4/MD-2 complex is not available, a model built by
us was used. This model was built using the human MD-2 protein in antagonist
conformation (PDB-ID: 2E59)45 superimposed onto the MD-2 subunit of the agonist full
complex (PDB-ID: 3FXI chain C) through PyMOL (see Chapter 2). Also in order to
consider different antagonist conformations of TLR4, we used PDB-ID: 2E56 (only in
the case of SPECS and Log P 1000 databases).
Databases
Database processing constitutes a fundamental step in VS approaches. It is 
crucial to generate the proper chemical library, with the adequate geometries,
ionization states, conformations, etc. Furthermore, it is very important to discard any
molecule that will not be a good candidate in the further steps of the VS study in
relation to the particular system on hand. A good database processing will assure a 
rigorous and well-conducted virtual screening, as well as it will avoid computational
cost and identification of unsuitable drug candidates. 
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5. VIRTUAL SCREENING ON TLR4
Different commercial, public and in-house databases have been used: Log P 
1000, SPECS and ZINC as commercial databases, and as in-house databases, a diversity
collection of compounds from laboratories of Prof. Péter Mátyus (PM) from
Semmelweis University (Budapest), Prof. Jose Carlos Menéndez46 (JCM) from
Complutense University of Madrid, Prof. J. R. Pedro (JRP),47-60 and Prof. A. Marco
(AM)61-66 from the University of Valencia.
Commercial databases:
ZINC15 (ZINC Is Not Commercial 2015)26, 67 is a public access database and tool
set, developed to enable ready access to compounds for virtual screening, ligand
discovery, pharmacophore screens, benchmarking, and force field development.
Nowadays ZINC15 database contains over 120 million purchasable compounds. For the
purpose of this work, we were only interested in the approved compounds which
represented, that time, a total of 2.459 structures categorized under the substance
subset called WORLD that is standing for approved drugs in major jurisdictions,
including the FDA. Being a computational drug repositioning study, the compounds
present in the ZINC15 database were filtered by clinically approved drugs. Thus 2 459
from the WORLD subset over 100 million compounds in total were kept for the
repurposing study. These compounds were submitted to a preparation process and the
number of compounds increased from 2 459 to 2 949. 
Log P 1000 dataset68 a small diverse subset of the ZIN database;26, 69 The 
subset was obtained by a similarity search based on 128 molecular VolSurf+
descriptors70 covering biologically relevant properties such as shape, surface, volume,
molecular weight, polar surface area, hydrogen bonding capacity, lipophilicity and
solubility; This was followed by an additional elimination of permanently charged
compounds and compounds with a molecular weight lower than 150 Da, resulting in a
diverse set of drug-like compounds;
SPES dataset is a database of commercially available drug-like compounds;71-72 
Due to the large number of compounds (almost 300;000) and computational
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5. VIRTUAL SCREENING ON TLR4
limitations, a reduction of the final screening set was necessary; The MOE software73 
was used to perform a cluster analysis on which a diverse subset was created;
Therefore the fingerprint of each molecule was calculated in form of a bit-packed
version of the molecular access system (M!S) structural keys (IT_M!S),74 
encoding 166 unique features; The Tanimoto coefficient was used as a measure of
similarity between fingerprints;75-77 ! similarity of 85% was used for the cluster search;
This resulted in a reduced diverse subset of SPES comprising 23;774 compounds that
were used for screening;
In-house databases:
We selected in-house collections with a wide range of chemical structures from
different collaborators expert in different types of chemistry. It is important to
mention that these chemical libraries are available to perform the biological assay, in
the case of these compounds give very good results in the VS studies.
First, we used the diversity collection of heterocyclic compounds, based on
their interesting structural characteristics, from Prof. Mátyus from Semmelweis
University with around 1964 molecules, a second in-house dataset with quinoline,
quinazoline and acridine structures from Prof. Menéndez from Complutense University
of Madrid, with 68 compounds, and a third in-house collection of 25 and 85
compounds from Prof. Pedro and Prof. Marco (Universidad de Valencia) respectively,
including pyrroles, indoles, naptholes, heterocyclic derivatives from Prof. Pedro and
analogues of natural products colchicine and pironetin from Prof. Marco library. All of
them had the available samples to be tested in case there were successfully screened.
On the other hand, given that paclitaxel had shown antagonistic activity in
human TLR4, while agonistic activity in mouse TLR4, showing the species-specific
ligand recognition by MD-2, we were prompted to include tubuline binders in our VS
approach. Prof. Marco from the University of Valencia is a well-recognized synthetic
chemist specialized in the synthesis of natural products analogues, being analogues to
tubuline binders among them. The binding of paclitaxel to TLR4 had been
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5. VIRTUAL SCREENING ON TLR4
demonstrated, however not the induction of the cytokine response. Based on these
reported results, we included other tubulin binders and related compounds as putative
TLR4 ligands in order to discover novel TLR4 modulators. We chose a family of
compounds analogue to natural products colchicine and pironetin (Figure 5.2).
Regarding their antitumoral activity, and their ability to bind to tubulin components
and microtubules, paclitaxel is a tubulin-interacting drug that stabilizes microtubules,
while colchicine causes disruption of microtubules, and pironetin derivates bind to α­
tubulin, inhibiting tubulin assembly. These opposite effects are due to the different
tubulin sites with which they interact. We also included compounds derived from
stilbene, like resveratrol since they are studied for their antimitotic properties and
their antitumor activity, all of them from Prof. Marco´s laboratory from the University
of Valencia. 
Figure 5.2. Colchicine, pironetin and euodenine A structures.
Filtering
In order to prepare the databases for the VS, different tautomers were
considered according physiological pH leading to the corresponding increase in the
total number of screened compounds (see Materials and Methods). Finally, in this
study, a database composed by around five hundred thousand compounds was built,
including known binders (data from the literature) and decoys.
We have considered the following filters:
1- Lipophilicity of the molecules: a maximum logP of 6 were considered, taking
into account that the natural LPS and reported synthetic glycolipids have a logP
very high: 29.14 ± 0.83, 14.35±0.73 and 13.53±0.47 for lipid IVa, P01 and ONO­
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5. VIRTUAL SCREENING ON TLR4
4007 respectively. This limit is a reasonable margin above the value of 5 
according to Lipinski´s rules (oral bioavailability).
2- Molecular weight (MW): we considered a wide range between 300 and 700 Da
given the MW of glycolipids targeting TLR4, with a reasonable margin above the
value of 500 according to Lipinski´s rules.
3- pH: only possible tautomers at physiological pH were considered within a range
of 7± 0.5.
4- Prediction of favourable binding from at least two docking programs and in two
different conformations of TLR4.
Protocols - Docking programs for virtual screening (SBVS and LBVS)
Molecular docking screening was performed against the different databases 
based on both, the agonist conformation of hTLR4/MD-2 complex from PDB-ID: 3FXI,
and our modeled antagonist conformation of hTLR4/MD-2 complex. Ligand Based
(LBVS) and Structure Based (SBVS) VS were carried following the protocols showed in
the Figure 5.3.
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Log	P	1000	
595	compounds	
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2012	compounds	
3	compounds	
556	compounds	
WORD	
2459	compounds	
PM	
1964	compounds	
SBVS:	Glide,	AD4,	VINA	
23	compounds	
18	compounds	
16	compounds	
32	compounds	
	
1	compound	
2	compounds	
5	compounds	
8	compounds	
8	compounds	
3	compounds	
	
COMMERCIAL	DATABASES	 IN-HOUSE	DATABASES	
JC	
68	compounds	
JRP	and	AM		
25	and	85	
7	POSSIBLE	ANTAGONISTS	
SPECS	
23774	compounds	
	
Re-Docking:	
Glide	
Biological	assays	
HEK	Blue	
Selected	compounds		
27	compounds	
Prepare	Databases:	2D	->	3D	->Fisiological	pH	state->	Minimiza on	
Filters:	logP=4-6,	MW=300-700	Da		
Re-Docking:	
FLAP	
Figure 5.3. Flow chart of VS protocol.
Structure-Based Virtual Screening (SBVS) with FLAP
The investigated compounds from Log P 1000, SPECS datasets are drug-like
molecules and not glycolipids like the known binders lipid A, lipid IVa or eritoran. The
lipid chains in those glycolipids contain a vast number of free bonds which would
increase the docking time exponentially. An additional complication would probably
arise from the circumstance that most scoring functions are calibrated on drug-like
molecules and would likely have difficulties evaluating the interactions correctly,
especially in the entropic term, due to the many degrees of freedom and the large
hydrophobic surface.78 
The literature defines three categories of compounds that may inhibit MD-2.79 
The first class consists of inhibitors that compete with LPS for the binding in the 
hydrophobic pocket but without being able to trigger the final dimerization; Paclitaxel
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5. VIRTUAL SCREENING ON TLR4
is one example for this class of inhibitors.80-81 Molecules of the second category bind
covalently to the residue Cys133; compound JTT705 is one example.82 The final class of
inhibitors does not enter the hydrophobic pocket completely but binds in the opening
region of the cavity and prevent LPS from entering the pocket; representatives of this
category are compounds JSH, curcumin, xanthohumol and isoxanthohumol (Figure
5.4).83-85 The majority of the side chains of the residues form the MD-2 pocket are
hydrophobics (Leu, Ile, Phe and Val), but the rim of the cavity, on the other hand,
contains almost no hydrophobic residues. The surface contains many positively and
negatively charged amino acids which are important for the interaction between TLR4
and MD-2.
FL!P’s SBVS method was used to perform target based VS on the TLR4/MD-2 
receptor with SPECS and Log P 1000 databases. As a benchmark, the method was 
applied initially to the set of known active compounds. The result is shown in Table 5.1
with the ligands ranked according to their Glob-Sum score. This score is a global 
similarity score calculated by summing the four single contributions: shape (H), 
hydrogen-bond acceptor (N1), hydrophobic (DRY), and hydrogen-donor acceptor (O)
descriptors; Glob-Sum is the global sum of all four energy values. Note that the scores
of the single contributions are derived from the individual best conformation for this
type of score, which might be different, while the Glob-Sum score comes from the one
conformation for which the sum of scores is maximal.
Table 5.1. Known antagonists of MD-2, ranked descending by Glob-Sum score obtained from
SBVS.
Antagonist
Paclitaxel
JSH
Curcumin
1D10G
Glob-Sum
3.245
2.714
2.695
2.669
Antagonist
6-shogaol
Isoxanthohumol
Isoquiritigenine
Cinnamaldehyde
Glob-Sum
2.498
2.465
2.239
2.179
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CAPE 2.621 C34 2.136
Xanthohumol 2.611 OSL7 1.799
JTT705 2.513 Sulforaphane 1.707
Since the Glob-Sum score does not reflect any experimental binding affinity, the
results of the known ligands allow having an idea at which value a screened ligand can
be considered as a potential hit. The highest score was obtained by paclitaxel (Glob-
Sum=3.245) which was then used as a cutoff value for the screened unknown ligands.
From Log P 1000 and SPECS libraries, 26 and 2012 compounds were obtained,
respectively, having a score equal to or higher than 3.245. The highest contribution to
the global score is given by the hydrophobic score which can easily be explained by the
high hydrophobicity of the target pocket and the screening model that is obtained
from it.
Structure-Based Virtual Screening (SBVS) with Glide, Autodock and VINA
WORD database from ZINC and in-house databases (PM, JCM, JRP and AM) 
were docked into both agonist and antagonist protein conformations, using three
docking programs, Glide, AutoDock and VINA, to avoid the limitation of one scoring
function. The receptor grid was set up in order to fully contain the E. coli LPS, allowing
small molecules to interact with the entire MD-2 pocket, as well as its rim and its
entrance (see Materials and Methods). During the docking process, all the ligands were
kept to facilitate visual inspections, comparisons and selections between the three
docking programs. 50 poses per ligand were generated with AutoDock, 20 poses per
ligand with VINA (which is the maximum for the program), and only one pose per
ligand was generated with Glide, using HTVS, SP and XP protocols in order to also
facilitate the comparisons, choosing Glide as the main docking software. Either with
Glide, AutoDock or VINA, the scoring results for all the compounds were consistent
and correlated to each other. However, the correlation between AutoDock and VINA is
stronger than between Glide and AutoDock or VINA. For the docking program
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validation analysis, either with, Glide, AutoDock or VINA, the scoring results for all the
compounds were consistent and correlated to each other. However, the correlation
between AutoDock and VINA is stronger than between Glide and AutoDock or VINA.
The docked compounds, as well as all their corresponding predicted binding poses,
were visually analyzed to detect any computational errors. The docking scores and the
delta docking scores, defined by the average score of all the poses from one ligand for
each docking program were analyzed. Among all the compounds, according to each
scoring function, only the top 25% from each docking program, has been kept for the
next analysis step. Among the databases, 23, 18, 16 and 32 compounds were selected
respectively, being ranked at the top 25% for at least two docking programs at the
same time and for one or both conformations, prioritizing a correlation with Glide,
were kept for visual cluster rank analysis. 
Molecular docking using Glide
The molecules were subjected to a grid-based ligand docking with energetics
(Glide, Schrodinger, version 6.9)86-88 using the Virtual Screening Workflow protocol
(See Materials and Methods). Regarding the docking step parameters, Epik state
penalties for docking were used, and the non-polar part of the ligand potential were
soften by scaling the van der Waals radii of ligand atoms with small partial charges.
The full workflow includes three docking stages, each step differing from the preceding
step in the amount of time taken to dock each molecule and the scoring system used
to evaluate each pose. The first stage performs HTVS (High Throughput Virtual
Screening) docking. The ligands that are retained are then passed to the next stage,
which performs SP (Standard Precision) docking. The survivors of this stage are passed
onto the third stage, which performs XP (eXtra Precision) docking, a more powerful
and discriminating procedure. The Dock flexibility method was used for HTVS, SP and
XP dockings allowing us to penalize non-planar conformation for amide bonds. A post­
docking minimization was also performed, as well as constraints for the docking
stages. One pose per compound state was generated and 100 % of the best
compounds that passed the HTVS, SP and XP docking have been kept. For HTVS and SP
229
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docking, all states have been retained, but only the best scoring state for the XP
docking.
Molecular docking using AutoDock and VINA.
Docking was also performed independently with both VINA89 and AutoDock.90 
In AutoDock the Lamarckian evolutionary algorithm was chosen and all parameters
were kept default except for the number of genetic algorithm (GA) runs which was set
to 50 to sample more docked poses. VINA (Vina Is Not AutoDock) uses an Iterated
Local Search global optimizer91-92 based on Broyden–Fletcher–Goldfarb–Shanno (BFGS) 
algorithm which approximates Newton's method and the number of docking poses
was set to 20, which is the maximum for the program. TLR4/MD-2 receptors were kept
rigid and the ligands were set partially flexible (i.e. maximum of 32 dihedral angles) for
AutoDock and totally flexible for VINA. 
Docking program validation analysis
Either with Glide, AutoDock or VINA, the scoring results for all the compounds
were consistent and correlated to each other. However, the correlation between
AutoDock and VINA is stronger than between Glide and AutoDock or VINA.
Molecular docking data analysis: score and cluster ranks
The all the docked compounds, as well as all their corresponding predicted
binding poses, were visually analyzed to detect any computational errors. The docking
scores and the delta docking scores, defined by the average score of all the poses from
one ligand for each docking program were analyzed. Among all the compounds,
according to each scoring function, only the top 10 % in the case of WORD and PM 
databases, and 20% from JCM, JRP and AM databases from each docking program, that
is to say 89 compounds has been kept for the next analysis step, re-docking with
Autodock and Glide.
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Among them, 89 compounds being ranked at the top for at least two docking 
programs at the same time and for one or both conformations, prioritizing a
correlation with Glide, were kept for visual cluster rank analysis. 
LBVS identified potential hit candidates to inhibit TLR4/MD-2 
In the case of the commercial databases, we have performed LBVS. It was the
first step of the search for TLR4/MD-2 inhibitors. Even though several inhibitors of the
TLR4/MD-2 complex acting on MD-2 were found in the literature, only a minority
shows promising characteristics to become an available drug. Eritoran for example
showed promising results in phase I and II clinical trials, but in phase II failed in
showing better properties than existing treatments for sepsis.93 
The FL!P LVS method uses the common reference framework to align a set of
candidate molecules to the template binder, to find the optimal overlap according to
the GRID MIFs; The similarity between the fields is quantified by the Tanimoto
coefficient; In the output table the user can see the individual scores obtained by the
single MIF contributions (Glob-Prod), as well as a global score representing the sum
(Glob-Sum); for each compound; 
In this work, for the LVS with FL!P, a set of known active antagonists of MD-2 
was built based on a literature search (Figure 5.4); The two datasets Log P 1000 and
SPES were screened on each known active separately and ranked by their obtained
Glob-Sum scores;
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Figure 5.4. Known antagonists of the MD-2 reported in the literature.
LBVS was here performed individually by using the 14 known ligands as 
templates for the screening. The best ranked results are shown in Table 5.2. The 2D
representations of the compounds of Log P 1000 and SPECS can be found in Annex
Figure 5.1 and 5.2, respectively. The similarity between template and test molecule of
the single contributions is a value between 0 (no similarity) and 1 (high similarity). The
four single contributions are shape (H), hydrogen-bond acceptor (O), hydrogen-bond
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donor (N1) and hydrophobic (DRY) potential. The global score value that was used as 
result for the screening analysis is the Glob-Sum which is the global sum of all four
energy values.94 Note that the scores of the single contributions are derived from the
individual best conformation for this type of score, which might be different, while the
Glob-Sum score comes from the one conformation for which the sum of scores is
maximal. 
Table 5.2. Best ranked compounds of Log P 1000 (blue) and SPECS (white) set for each known 
ligand (black).
Template Compound Glob-
Sum
H N1 DRY O
6-shogaol 152 1.326 0.663 0.508 0.224 0.239
481 1.742 0.598 0.271 0.254 0.702
Xanthohumol 568 1.269 0.699 0.283 0.340 0.124
19907 1.912 0.703 0.368 0.508 0.359
Paclitaxel 383 0.847 0.505 0.175 0.134 0.337
20513 1.022 0.565 0.171 0.105 0.321
1D10G 368 1.152 0.579 0.203 0.181 0.310
20700 1.857 0.654 0.306 0.260 0.734
JSH 492 1.165 0.598 0.359 0.229 0.144
21315 1.421 0.515 0.371 0.304 0.329
Isoliquiritigenine 42 1.181 0.637 0.364 0.195 0.010
120 1.706 0.750 0.431 0.343 0.294
Isoxanthohumaol 138 1.054 0.638 0.234 0.308 0.010
28 1.493 0.634 0.430 0.304 0.305
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5. VIRTUAL SCREENING ON TLR4
CAPE 575 1.149 0.625 0.242 0.181 0.243
22298 1.528 0.587 0.230 0.159 0.700
Curcumin 548 1.041 0.631 0.242 0.204 0.010
23010 1.562 0.519 0.264 0.173 0.623
Sulforaphane 46 1.104 0.650 0.361 0.166 0.000
3203 1.184 0.684 0.296 0.000 0.000
Cinnamaldehyde 40 1.489 0.684 0.581 0.383 0.000
23599 1.500 0.580 0.673 0.273 0.000
OSL7 35 1.007 0.648 0.295 0.128 0.000
1171 1.285 0.702 0.445 0.191 0.000
C34 187 1.142 0.506 0.205 0.137 0.512
10959 1.428 0.560 0.216 0.102 0.903
JTT705 439 1.033 0.539 0.391 0.188 0.010
14650 1.127 0.592 0.347 0.188 0.000
Table 5.2 shows that for each of the known actives the best scoring SPECS
compound scored higher than the best scoring one from the Log P 1000 database. This
could be explained by the sole fact that the SPECS set contain a much higher number
of compounds than Log P 1000. Consequently the probability is higher to find a good
scoring compound.
Regarding the single contributions of the four similarities, the shape similarity
(H) seems to have the highest impact on the global score in most of the cases. In four
cases (6-shogaol, CAPE, Curcumin, C34) the hydrogen-bond acceptor and in one case
the hydrogen-bond donor (N1) similarity made the biggest contribution to the global
score. All five compounds are from the SPECS set. The reason why the influence of
hydrophobic (DRY) similarity is comparatively low might be the relatively small size of
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5. VIRTUAL SCREENING ON TLR4
the compounds. While strong hydrogen-bond similarities can be derived from single
donor or acceptor atoms, the hydrophobic potential needs larger apolar surfaces to
show a strong impact.
RE-docking with FLAP and GLIDE
To better understand the interactions of the potential inhibitors retrieved by
LBVS and SBVS with TLR4/MD-2, a molecular re-docking approach was carried out. In
order to narrow down the number of compounds to dock, only molecules were
selected which obtained a good score in the LB and the SBVS approaches. 
In SBVS, in total, 2038 compounds (26 from Log P 1000 and 2012 from SPECS)
obtained a score higher than the cutoff value of 3.245. Since an analogous cutoff value
was not available for the LBVS approach, the same number of compounds was chosen
here, i.e. the top ranked 26 and 2012 compounds from Log P 1000 and SPECS,
respectively. Of the Log P 1000 set 3 common compounds were found in the top ranks
of both LBVS and SBVS, while SPECS shared 556 top-ranked compounds. This total
number of 559 compounds still seemed large, considering the time-consuming FLAP
docking program. For this reason only the top 100 highest scoring ligands were taken
for the docking. This selection procedure was found to be in agreement with examples
from the literature.95-98 
In the case of SBVS with Glide, AD4 and VINA:
Among them, 23 compounds from ZINC database, 18 from PM, 16 from JCM
and 32 from JRP and AM, being ranked at the top 25% for at least two docking
programs at the same time and for one or both conformations, prioritizing a
correlation with Glide, were kept for visual cluster rank analysis. 
Visually analyzing each most probable cluster for each molecule in the three
docking programs, 5 compounds from WORD database have proven to outperform all
the others: compounds 146, 157, 177, 208 and 212; 8 compounds from PM (PM1097,
PM1811, PM1779, PM567, PM1090, PM810, PM1758 and PM1200), 8 from JCM
(MS14, MS20, MS21, MS32, MS35, MS40, MS45, MS49) and 3 from JRC and AM
235
     
 
 
      
       
         
      
    
    
       
    
 
          
      
         
    
       
        
     
      
 
    
 
   
  
 
5. VIRTUAL SCREENING ON TLR4
(JRP07, JRp07p and JRP10). This analysis was based on the ligand/receptor
interactions identified by visual inspection for each compound. Each of the most
probable clusters in AutoDock and VINA were found to be relatively similar to the best
pose calculated by Glide. For a deeper pose interactions analysis with Glide, a re­
docking process was performed. The results obtained by the docking of the known
compounds allowed setting a cutoff value. For the screening scores obtained by
docking, only the ones with a score equal to or higher than the cutoff value were
retained for further biological analysis.
Discussion : Identification of key residues that interact with the screened ligands
Three ligands of the combined Log P 1000 and the SPECS datasets that were
obtained by docking had an S-score equal to or higher than the threshold of 1.074,
obtained by the best-scoring known inhibitor sulforaphane. The compounds, their 2D
description and the respective scores are listed in Table 5.3. The highest scoring
compound is ID-5382 from the Log P 1000 set, with an S-score of 1.231. The two
compounds of the SPECS set AG-690/11203225 and AF-399/15128553 obtained a
score of 1.114 and 1.074 respectively.
Table 5.3. 2D description and the respective scores from ID-5382, AG-690/11203225 and AF­
399/15128553.
Compound S-score Structure
ID-5382 1.231
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AG-690/11203225 1.114
AF-399/15128553 1.074
Compound ID-5382 is in close contact with the hydrophobic residues Ile46,
Leu61, Leu78, Phe121, Ile124, Val135 and Phe151. Compound AG-690/11203225
interacts with the residues Ile52, Phe76, Leu78, Ile80, Val82, Glu92, Phe121, Ile124,
Val135 and Ile153. Finally, the hydrophobic partners of AF-399/15128553 are Ile46,
Leu61, Ile80, Val82, Leu87, Phe121, Ile124, Tyr131 and Phe151.
The two amino acids are able to build salt bridges with the compounds ID-5382
and AG-690/11203225 due to their sulfonyl group. This would explain why the polar
score is significantly higher for these two ligands than for compound AF-399/15128553
which possesses no sulfonyl groups. The latter one only forms hydrogen-bonds
between Arg90 and Lys122 and its nitrogen located in the pentacycle. Interactions with
Cys133, as the ones reported in the literature99 could not be observed. As already 
discussed, is the simulation of covalent bonds not possible in FLAP docking. 
From J. R. Pedro and A. Sanz-Marco databases the most of the compounds,
stablishing stacking interactions with Phe76 and the CH-π interactions observed are
with the side chain of Cys133, Phe151, Phe104 and Leu61. Other interactions observed
are hydrophobic with the residues Val24, Ile32, Ile44, Val48, Ile52, Leu78, Ile80, Ile94,
Ile117, Phe119, Val135 and Ile153.
From P. Matyus databases, the majority of the compounds stablish π-π with
Phe104 and Phe151, also CH-π interactions with Phe76 and Phe121; Other interactions
observed are hydrophobic with Ile32, Ile52, Leu61, Ile117, Val135, leu149 and Ile153.
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And from J. C. Menendez databases the principal interactions observed are: π-π 
interactions with Phe76 and Phe151, and also hydrophobix interactions with Ile32,
Ile52, Leu61, Leu63, Ile94 and Val135.
In all the cases the docked ligand is located at the entry of the hydrophobic
cavity of TLR4/MD-2 in a similar pose. The principle interactions are hydrophobic and
polar ones. All the compounds show polar interactions with Arg90 and Lys122. The
hydrophobic interactions, however, are more wide spread and not with the same set
of amino acids for all the compounds. Arg90 is assumed to participate in interactions
with sulforaphane, JTT705, isoxanthohumol, isoliquiritigenin, CAPE and JSH. Lys122
interacts with OSL07 and cinnamaldehyde. Some of the identified side chains are also
participating in the interaction with known ligands. Ile80 for example interacts with
xanthohumol, JSH, OSL07, cinnamaldehyde and 6-shogaol. The side chains Phe121 and
Ile124 interact with all known ligands. Hydrophobic interactions with the ligand are
basically with aromatic cycles. 
Regarding drug repurposing results, the analysis revealed 5 compounds
outperforming the remaining ones: compounds 56, 146, 177, 179 and 208. 
Surprisingly, compared to the previous analysis done only with the best Glide pose,
compounds 157 and 212 did not show good results in the last analysis. Indeed, having
a more wide number of poses in Glide permitted to see, for these two compounds,
that the first pose was not part of the most probable cluster, or any cluster at all, for
both conformations. Moreover, it has been shown that the most probable clusters for
these two compounds were ranked in a low energy position, and with a medium total
percentage of interaction against the main residues. Compound 208, previously
revealed in the first analysis, having a good cluster position, was reported to have
medium total percentage of interaction against the main residues. Compound 56
revealed having similar problem as compounds 157 and 212. However, the most
probable cluster was ranked in a good position. Compounds 56, 157, 208 and 212
were kept as a query for future structure similarity search.
In ascending order of potential prediction, compounds 146, 177 and 179
outperformed all the compounds. Compounds 146 and 177, already revealed by the
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first cluster analysis, have shown having in each pose, interactions with almost all the
main residues. Moreover, in about 50% of the poses, they were able to make 2
hydrogen bonds at the same time, and in about 70% of the poses, able to make 2 salt
bridge interactions simultaneously. Regarding compound 179, it was predicted having
the highest affinity potential with all the main residues. It interacts with all the main
residues with high affinity, making in 80% of the poses, up to 3 hydrogen bonding and
a salt bridge in 50% of the poses. Compounds 146, 177 and 179 were also kept as
queries for future structure similarity search. 
Regarding compound 146, it is known as Diphenoxylate. It is a meperidine
congener used as an antidiarrheal, usually in combination with atropine. At high doses,
it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is
used similarly. It has little or no analgesic activity. According to DrugBank
(www.drugbank.ca), it is categorized as: analgesics, opioid, antidiarrheals,
antiperistaltic agents, alimentary tract and metabolism, antidiarrheals, intestinal anti­
Inflammatory/anti-infective agents, and antipropulsives. Because TLR pathways can be
related to inflammatory and microbial pathologies, it can be conceivable that
Diphenoxylate could have a certain affinity for TLR4. It has also been shown that
NF-κ-B,100 Diphenoxylate can regulate a protein present downstream in the TLR 
pathway. Moreover, some studies have proven the binding between morphine and
TLR4,101-103 that could suggest also a conceivable effect of Diphenoxylate to TLR4.
Compound 177 is known as Ono-Rs 411 or Pranlukast. It is a cysteinyl
leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused,
principally in asthmatics, by an allergic reaction to accidentally or inadvertently
encountered allergens. It is classified as: anti-asthmatic agents, respiratory system,
drugs for obstructive airway diseases, leukotriene receptor antagonists, cytochrome P­
450 CYP2C9 inhibitors, cytochrome P-450 CYP2C9 inducers, and CYP3A4 inhibitors.
Besides, some studies have shown that Pranlukast can inhibit NF-κ-B activation,104-105 a 
protein present downstream in the TLR activation pathway. It has also been shown
that it indirectly induces cytoplasmic membrane depolarization of Gram-negative
239
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bacteria, promoting E. coli outer membrane detachment,106 which some are
recognized by TLR4.
Compound 179 is known as Vemurafenib, a V600 mutant BRAF enzyme
inhibitor for the treatment of late-stage melanoma.107 Vemurafenib inhibits the active
form of the kinase,108-109 firmly anchoring itself in the ATP-binding site. By inhibiting
only the active form of the kinase, it selectively inhibits the proliferation of cells with
unregulated BRAF, normally those that cause cancer. It is classified as: antineoplastic
agents, protein kinase inhibitors, antineoplastic and immunomodulating agents,
cytochrome P-450 CYP1A2 inhibitors, cytochrome P-450 CYP1A2 inducers, CYP2D6
inducers, CYP2D6 inducers (strong), and CYP3A4 inhibitors. Up to date, it has been
shown that TLR4 and its signaling pathway promote the migration of human
melanoma cells,110-111 but no studies showing an effect from Vemurafenib to TLR4
have been done yet.
All hit structures show a very common scaffold and binding pattern: two
hydrophobic moieties separated by a polar linker. The larger hydrophobic part
occupies the hydrophobic MD-2 cavity, while the smaller one is placed in the same
hydrophobic side region where also one of the lipid A alkyl chains is located in the
bound X-ray structure. Key interactions are those stablished with residues Arg90,
capable of making salt bridges and hydrogen bonds, Phe121, able to make strong
hydrophobic interactions, and situated closely to Phe126, and Tyr131, also able to
make hydrogen bonds. These interactions were common for all the compounds, and
conferred them a strong predicted binding energy. The polar linker seems to be
interacting with two of the positively charged amino acids Arg90 and Lys122 at the
entry region of the pocket which have already been described in the literature to
interact with known active compounds. The literature reports a covalent interaction
between Cys133 of MD-2 and some of the known actives. This observation could be
reproduced with some of the known actives. The identified screening hits, however,
represent an interesting scaffold for a new class of possible inhibitors for the
TLR4/MD-2 complex.
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Activity on HEK293 Cells Transfected with hTLR4/MD-2.
Then biological testing has been performed in HEK-Blue hTLR4 cells to assess 
the potential of the compounds as agonist or antagonist molecules. Indeed, with
molecular docking, it is only possible to predict the binding and the affinity of a
molecule for a biological or chemical entity, but it is not possible, or it is very complex
and not accurate, to predict the activity of a compound without doing biological
assays. Further, if the biological testing reveals to show an activity for the compounds,
several strategies will be followed starting by screening wider libraries using structure
similarity search, creating pharmacophores, then a new docking protocol using the
brand-new compounds.
The ability of molecules to interfere with LPS-triggered TLR4 activation in HEK-
Blue hTLR4 cells model was investigated. This HEK293 cell line is stably transfected
with human TLR4, MD-2, and CD14 genes. In addition, Hek-BlueTM cells stably express a
secreted Alkaline Phosphatase (SEAP) produced upon activation of NF-kβ; LPS binding
activates TLR4 and NF-kB leading to SEAP secretion, which is detected by an alkaline
phosphatase substrate in cell culture media (Figure 5.5).  
Figure 5.5. Cell-based colorimetric assay for the detection of biological active endotoxin.
In this assay, HEK293 cells transfected with human CD14 and TLR4/MD-2 were
treated with increasing concentrations of synthetic molecules and then stimulated
with LPS (LPS, 100 ng/ml). TLR4 activation is monitored as SEAP production. The results
are normalized to activation by LPS alone and expressed as the mean of percentage ±
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SD of three independent experiments. Compounds B (ID-5382), F (MS21), H (MS32), I
(MS35), X (PM1090) and Z (PM1200) inhibited TLR4 activation in a dose-dependent
way (Figure 5.6). As a negative control, compounds were tested in Null cell line
(InvivoGen), transfected with the same plasmids as HEK-Blue but without TLR4, MD-2,
and CD14 genes, and no effect was observed. The toxicities of all compounds are being
assaying by MTT assay and no inhibitory effects on cell viability has being observed in
the concentration range used for biological characterization.
Figure 5.6. Results are expressed in % of TLR4 activation. Positive control (LPS 20ng/mL) 
represents 100% of activation. Dose-dependent inhbiton of LPS-stimulated TLR4 activation by
compounds.
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We finally obtained the following possible antagonsit compounds:
LogP LogP
Compound Structure
ChemSketch Molinspiration
ID-5382
5.3 (exp)
(B)
MS21 (F) 5.89+/- 0.40 6.331
MS32 (H) 4.20+/- 0.83 6.434
MS35 (I)
4.68+/-0.84 6.728
PM1090
(X)
5.70+/- 0.89 6.063
PM1200
6.29+/- 0.45 6.116
(Z)
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5.3 Conclusions
In this work, we have applied virtual screening and computational repositioning
strategies for the finding of novel TLR4 modulators. The computational protocol has
made use of different conformations of TLR4/MD-2 system, and a deep
ligand/receptor analysis, including ligand-based and structure-based virtual screening,
leading to a robust approach for the final identification of 7 possible antagonist
compounds: Compounds B (ID-5382), F (MS21), H (MS32), I (MS35), X (PM1090) and Z
(PM1200) inhibited TLR4 activation in a dose-dependent way as putative of TLR
modulators. The identified screening hits, however, represent interesting scaffolds for
a new class of possible inhibitors for the TLR4/MD-2 complex.
5.4 Materials and Methods
Computational Methods
Library Preparation
Importation. All the databases were saved as a SD File and imported in Maestro
software (Schrodinger, version 10.4),112 which is an all-purpose molecular modeling
environment. During the importation process, the chirality and the atom type of each
compound has been checked.
Ligand Preparation using LigPrep. LigPrep (Shrodinger, version 3.6)113 is a program
specialized in preparing all-atom 3D structure of drug like molecules, was used for
many purposes: to refine the geometry of the ligands imported from the databases; to
generate accurate, energy minimized 3D molecular structures; to expand tautomeric,
ring conformation, and stereoisomers in order to produce broad chemical and
structural diversity from each input structure and to predict protonation states. The 3D
structures were minimized using OPLS 2005;114 to generate ionization states, Epik115-117 
was used, in order to simulate the physiological pH. In many cases, the compounds 
contain water molecules or ions, these extra molecules were removed with Desalt
option. The generating tautomer options were also used in order to generate up to 8
tautomers per input structure. Regarding the setting stereoisomer options, the choice
244
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of retaining the specified chiralities to keep this information from the input file and
fixed these chiralities for the entire calculation has been made. The number of
stereoisomers generated was limited up to 32 per ligand. From a 2D structure, it is not
immediately obvious which ring conformations give the lowest energy or are preferred
for binding to an active site. Therefore it was decided to generate one low energy ring
conformation per ligand with LigPrep. The final output was in Maestro format to keep
the total information calculated for all the compounds. For the virtual screening, the
compounds were selected according to their molecular weight and their lipophilicity,
between 300 Da and 700 Da, and between 4 and 6 respectively, using the property
calculation tool from the Maestro software. 
Protein Preparation
In the case of the agonist conformation of the TLR4/MD-2 monomer, 3D 
coordinates from TLR4/MD-2 heterodimer were obtained from the PDB (PDB-ID:
3FXI).44 By contrast, in the case of the antagonist conformation, since the full
crystallographic structure of the TLR4/MD-2 complex is not available, a model built by
us was used. This model was built using the human MD-2 protein in antagonist
conformation (PDB-ID: 2E59)45 superimposed onto the MD-2 subunit of the agonist full
complex (PDB-ID: 3FXI chain C) through PyMOL. Then, coordinates from the TLR4 chain
of the 3FXI adjacent to the superimposed MD-2 (PDB-ID: 3FXI chain A) and the
superimposed MD-2 in antagonist conformation were retained, forming the TLR4/MD­
2 monomer in antagonist conformation. Finally, both agonist and antagonist the
structures were subjected to 10.000 cycles of steepest descent energy minimization
under the Amber force field via Maestro (see Chapter 3). Also PDB-ID: 2E56 were used
to consider different antagonist conformation of MD-2.
Receptor Grid Preparation
Glide. For preparing the receptor grids for the two protein conformations, Glide
software (Schrodinger, version 6.9) was used.86-88 All the parameters from the software
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were kept at their default values. We only determined where the scoring grids will be
positioned and their sizes. The coordinates of the box were set up to fully contain E.
coli LPS. Glide software uses two "boxes" that can be parametrized to organize the
calculation: the inner box, which can be monitored in the advanced panel, and where
the ligand center is allowed to move within that box during the site point search; and
the outer box, which is the box within all the ligand atoms must be contained. Its size is
function of the inner box, and the inner box has to be included within the outer box. 
For the inner box, the center was set up at residue serine 120 and the lengths of the
boxes for both protein conformations were the following ones: 33 Å in X, 40 Å in Y and
35 Å in Z. For the outer box, 10 Å has been chosen, that is to say 10 Å bigger than the
inner box (43 Å in X, 50 Å in Y and 45 Å in Z).
AutoDock, FLAP and VINA. As the receptor grids were already set up with
Glide, the same grids have been chosen for the softwares. Glide coordinates were kept
for VINA, but were converted in AutoDock coordinates using scaling calculation tool. In
the case of FLAP, The pockets of MD-2 were identified and defined by FLAP's pocket
search algorithm.
Docking
Structure ased Virtual Screening (SVS) with FL!P
The FL!P software explicitly distinguishes between the so called SBVS method
and docking;118-119 While in FL!P docking is primarily used for pose prediction and a
more precise quantification of binding energies, SVS is a tool for large-scale virtual
screenings; Even though docking is often used as a structure based virtual screening
technique,120 the term SBVS will hereafter refer only to FL!P’s correspondent screening
program; 
The SVS program first creates MIFs of the receptor’s binding site; During
screening, the MIFs of the ligand are compared with those of the binding site; Time
consuming calculations describing each atom-atom interaction are not needed here; 
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One downside of this method is that there is no energetic penalty for atom clashing
with the target; In some scenarios however, this might even be an advantage, since it
overcomes the rigidity of the target to some extent; 
The SVS in FL!P was performed on the 3D structure of the human co-receptor
MD-2; The structure was obtained from the PD (PD code: 2E56)45 and the MOE
software was used to prepare the protein by removing water molecules, adding
hydrogens and missing atoms and side chains;73 The optimized structure was loaded
into FL!P and the Search for pockets function was used to define the binding area; The
results are then treated in analogy to the LVS approach;
SVS with Glide
The molecules were subjected to a grid-based ligand docking with energetics
(Glide, Schrodinger, version 6.9)86-88 using the Virtual Screening Workflow protocol. It
is designed to run an entire sequence of jobs for screening large collections of
compounds against one or more targets. However, as the compounds and the grids
had already been prepared, in this case, only the docking steps of the program have
been used. The compound files and the receptor grid files were imported into the 
Virtual Screening Workflow program. Regarding the docking step parameters, Epik
state penalties for docking were used, and the non-polar part of the ligand potential
were soften by scaling the Van der Waals radii of ligand atoms with small partial
charges. To do so, the scaling factor was 0.80, and the partial charge cutoff was 0.15.
The full workflow includes three docking stages, each step differing from the preceding
step in the amount of time taken to dock each molecule and the scoring system used
to evaluate each pose. The first stage performs HTVS (High Throughput Virtual
Screening) docking. The ligands that are retained are then passed to the next stage,
which performs SP (Standard Precision) docking. The survivors of this stage are passed
onto the third stage, which performs XP (eXtra Precision) docking, a more powerful
and discriminating procedure.
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The Dock flexibility method was used for HTVS, SP and XP dockings allowing us to
penalize non-planar conformation for amide bonds. A post-docking minimization was
also performed, as well as constraints for the docking stages. One pose per compound
state was generated and 100 % of the best compounds that passed the HTVS, SP and
XP docking have been kept. For HTVS and SP docking, all states have been retained,
but only the best scoring state for the XP docking.
Ligand re-docking using Glide
The shortlisted molecules were submitted to a re-docking procedure using
Glide. All the parameters were kept as mentioned in the docking paragraph using
Glide, except for the docking poses which were set to 50 per molecule.
Molecular re-docking using FLAP
The FLAP software implements a fragmentation-based docking algorithm,
called FLAPdock, which works as follows. MIFs are calculated for the target binding 
site, in a similar manner to the SBVS approach but with more points to describe the
site in more detail (Reference manual for FLAP 2.0, © 2014 Molecular Discovery Ltd). A
set of ligand conformations is generated using a stochastic search and a customized
implementation of the MM3 force field121 with a cutoff of 30 kcal mol-1 to remove high
energy and duplicate conformations respectively. The ligands are then split into
fragments with only 1-3 rotatable bonds. For each fragment conformation, GRID MIFs
are calculated. The first fragment is docked into the binding site and the best scoring
solutions, according to the global S-Score, are retained for the next iteration. In the
next step, the next fragment, is attached to the first one and scored in the same way.
The S-Score is a scoring function that includes terms from the GRID MIF similarities
(Hydrogen-bonding and hydrophobic interactions as well as shape matching), Lennard-
Jones and electrostatic interactions. It was validated, amongst other targets, on those
of the Astex and DUD datasets.119, 122-123 In each iteration the best scoring solutions are
kept and filtered by RMS clustering. Once the reconstruction of the ligand has finished,
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the final pose can be optionally optimized by minimization and the final score is
recalculated. The benefit of FLAPdock towards the SBVS method lies in the more
detailed chemical interactions that are considered for docking and the respect of steric
clashes that are not regarded in the SBVS method. In order to obtain score reference
values, a set of known MD-2 inhibitors was docked, followed by the docking of
compounds from the Log P 1000 and the SPECS dataset.
Biological characterization
HEK-Blue TLR4 assay. HEK-Blue-TLR4 cells (InvivoGen, Toulouse, France) and
parental cell line HEK-Blue Null 2 (InvivoGen) were HEK-Blue cells were used to test the
agonist or antagonist effect of different compounds. This cell line expresses TLR4, MD­
2 and CD14 and do not express any other TLR. The activation of TLR4 leads to the
expression of SEAP, a protease that enzimatically hydrolyze a molecule present in the
media. The amount of hydrolized molecule can be mesured using colorimetric
methods. These cells were cultured according to manufacturer’s instructions; riefly,
cells were cultured in DMEM high glucose medium supplemented with 10% fetal
bovine serum (FBS), 1% glutamine, 1% penicillin/ streptomycin, 1X Normocin
(InvivoGen). Experiments were performed when 70-80% of confluence was reached.
Cells were detached by the use of PBS, tapping the flask and the cell concentration was
estimated using. Four different compound concentrations were used: 0.1, 1, 5 and 10
μg/mL; 20 μL of compound dilution were added in a 96-well plate, in triplicate (3 wells 
for each concentration), seeded in multiwall plate at a density of 2 x 104 cells/well in
200 µl. LPS was used as positive control (20ng/mL final concentration) and PBS 1x was
used as negative control. Cells were detached using 4mL of PBS and 140.000 cell/mL
solution was prepared using Detections Media. 180 µL of this solution were added into
each well (25.000 cells/well). After a 30 min incubation, 20 µL of LPS solution were
added in each well (final LPS concentration: 20ng/mL) (LPS was diluted in PBS as well).
Plates were incubated for 16 h in the dark at 37 °C, 95% of humidity and 5% of CO2 and
then, the plate reading was assessed using a spectrophotometer at 620 nm. The
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results were normalized with positive control (LPS alone) and expressed as the mean
of percentage ± SD of at least three independent experiments.
5.5 Annex V
Annex Figure 5.1. Top scoring compounds obtained by LBVS on th Log P 1000 database
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Annex Figure 5.2. Top scoring compounds obtained by LBVS on the SPECS database.
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Table 5.1. 2D Chemical structure of predicted TLR4 modulators identified by
computational drug repurposing, and kept for future structure similarity search.
Compound
number
ZINC ID
Usual/Commercial
name
2D structure
146 3830716 Diphenoxylate
157 1493878 Sorafenib
177 15919406 Ono-Rs 411
179 52509366 Zelboraf
208 53073961 Antrafenine
212 19685790 Lercanidipine
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Table 5.2. 2D Chemical structure from PM databases obtained from SBVS. 
Number Compound Structure
1 PM1097_p_R/1097
2 PM1811
3 PM1779
4 PM567S ó R
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5 PM1090
6 PM810
7 PM1758
8 PM1200
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Table 5.2. 2D Chemical structure from JCM
databases obtained from SBVS. 
Number Compound Structure
1 MS_35/35p
2 MS_29
3 MS_40
4 MS_34
5 MS_31
6 MS_22
7 MS_45
8 MS_21
9 MS_32
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10 MS_26
11 MS_14
12 MS_49
13 MS_37
14 MS_46
15 MS_20
Final compounds:
Quinoline family: MS-14, MS-20
Quinazoline family: MS-40, MS-45, MS-49
Acridine family: MS-32 and MS-21
MS-35, MS-29=MS-22, MS-26, MS-31, MS-34, MS-37
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Table 5.3. 2D Chemical structure from J. R. Pedro and A. Sanz-Marco databases obtained from SBVS. 
Name Structure Name Structure
JRP07 !M15
JRP10 !M18
JRP18 !M19
!M20 !M54
momo 
!M21 !M57
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!M20 !M58
AM59
!M22 !M62
!M23 !M65
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!M24 !M66
!M25 !M72
!M40 !M16
!M41 JRP01
259
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5. VIRTUAL SCREENING ON TLR4
!M42 !M08
!M48 !M14
!M53 !M71
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6. MD SIMULATIONS MEMBRANES WITH TLR4
6.1 Introduction
Cell membranes, also known as the plasma membrane or cytoplasmic 
membrane, consists in a lipid bilayer with ions, channels and proteins embedded, and
separate the cell interior from the outside environment (Figure 6.1).1 The membrane
has important implications for many cellular processes, e.g., protein trafficking and
aggregation, membrane fusion, and signal transduction. Lipids are the main
components of lipid bilayers and play an important role in many cell signaling and
physiological processes. Changes in expression levels of individual lipid species have
been implicated in many diseases including: cancers, diabetes, !lzheimer’s disease,
HIV entry, and aterosclerosis.2-3 
Figure 6.1. Cell envelopes of various microbial families.1 
A typical plasma membrane requires a lipid organization,4 which is formed by
hundreds of different lipids. All the lipid molecules in cell membranes are amphipathic, 
being phopholipids the most abundant ones, together with glycolipids and sterols.5 
The fatty chains (FA) in phospholipids and glycolipids may be saturated or unsaturated
and usually contain an even number of carbon atoms, typically between 16 and 20,
where the 16- and 18-carbon FAs the most common ones. The polar head groups are
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6. MD SIMULATIONS MEMBRANES WITH TLR4
exposed to water and nonpolar lipid tails groups go inside the membrane.6-8 The
length and the degree of unsaturation of FA chains have an effect on membrane
fluidity, preventing the FA from packing together as tightly, thus decreasing the
melting temperature (increasing the fluidity) of the membrane. In particular,
mammalian membrane is composed by phosphatidylcholine (PC), sphingomyelin (SM),
and gangliosides (GM) in the outer leaflet and phosphatidylcholines (PE),
phosphatidylserine (PS), and other charged lipids in the inner leaflet; also eukaryotic
plasma membrane contains approximately 20-50% sterols (Figure 6.2).6, 9 
Figure 6.2. Lipid organization of the plasma membrane extracted from Marrink et al.4 
The importance of study of receptors in a membrane environment may be used
to explore in detail the interactions of membrane proteins and specific lipids, yielding
predictions of lipid binding sites in good agreement with available structural data.
Molecular dynamics (MD) simulation approaches provide important tools which allow
us to simulate both individual membrane proteins and more complex membrane
systems. Thus, MD simulations have become a valuable addition to the range of
experimental structural and biophysical techniques for studying membrane proteins
and their interactions with lipids.10-12 
For all of this, the computational study of the membranes at atomic details has
become an essential tool for elucidate the structural and dynamic organization of
cellular membranes and to understand the different mechanims where the
membranes are implicated, such as: mechanims of diffusion through ions or
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6. MD SIMULATIONS MEMBRANES WITH TLR4
membranes, mechanisms of signalling and also the active transport throught
transporters.
TLR4 together with MD-2, is one of the main receptors involved in innate
immunity. TLR4/MD-2 modulation constitutes a challenging and sparkling area of
research with high potential for the development of novel drugs. The molecular
modelling approaches have been used to elucidate the molecular recognition
mechanisms of TLR4/MD-2 modulation, with focus on the agonist/antagonist
conformational changes of the TLR4/MD-2 system, and to provide some hints for the 
design of novel binders, hopefully with therapeutic potential. And the analysis of the
MD simulation of the dimer TLR4/MD-2 complex in the membrane environment could
help us to identify the key ligand-receptor and protein-protein interactions governing
the molecular recognition events and the dimerization process. Our previously
calculated complexes of TLR4 with reported agonists will be also calculated accounting
for the validation of the proposed binding modes.
6.2 Results and Discussion
Several models of the TLR4/MD-2 system inserted in different membranes have
been built and simulated. These different models will be useful for the final building of
the complete TLR4/MD-2 dimer and will provide us insights into the mechanism of
TLR4 agonism/antagonism. The MD simulations of the full complex will help us to
identify the key ligand-receptor and protein-protein interactions governing the
molecular recognition events and the dimerization process at atomic level.
We started carrying out the building and simulation of different models of
membranes. With these models, we inserted the monomer TLR4/MD-2 with three
molecules of myristic acid. X-ray structure is available for the extracellular domain
(ED) in complex with lipid A. The intracellular (ID) and transmembrane domains (TD)
were modelled by homology modelling by members of our group and were used for
this study. The building and simulation of the full dimer complex of TLR4/MD-2 system
in the bilayer membrane is in progress, especially the build and simulation of the full
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6. MD SIMULATIONS MEMBRANES WITH TLR4
dimer complex of TLR4/MD-2 system in the bilayer membrane in complex with
agonists ONO-4007 (LPS-like molecule)13 and Euodenine A (non-LPS-like molecule).14 
The binding poses have been already modelled by means of docking techniques plus
MD simulations (see Chapter 3). The proposed binding modes will be assessed and
compared with the model obtained for lipid A.
Membrane models:
We started this approach with the building of different simple symmetric
membrane models (Table 6.1). It is often important to understand the dynamics of the
bilayer itself before proceeding with protein systems.
The lipid bilayers models are: POPC (1palmitoyl-2-oleoyl-sn-glycero-3­
phosphocoline), POPE(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine)-POPC
[1:1], CHOL (Cholesterol)-POPC [1:1], DPPC(1,2-dipalmitoyl-sn-glycero-3­
phosphocholine)-POPC [1:1], DPPC-POPE [1:1] (Annex Table 6.1, structure of the lipid
and sterols).
Also reviewing the literature and given that the composition of the mammalian
plasma membranes are composed by different type of lipids and sterols, we decided to
approach the complexicity of real cell membranes and build a more complex
asymmetric membrane model and which resembled more the composition of the
mammalian plasma membrane, with following composition: The outer leaflet is
composed by 35% cholesterol and 65% lipids (60% DPPC, DPPE (0 insaturation), 20%
POPE, POPC (1 insaturation), 20% DOPE, DOPC (>1 insaturation)), and the inner leaflet
by 30% cholesterol and 70% lipids (50% DPPC, DPPE, 20% POPE, POPC and 30% DOPE,
DOPC) (Figure 6.3 and 6.4).
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Figure 6.3. Composition of the asymmetric membrane model built by us.
Figure 6.4. Our asymmetric membrane model built by us, with the lipids and sterols 
represented in different colors.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
Regarding TLR4/MD-2 system, an X-ray structure is available for the
extracellular domain in complex with lipid A (PDB-ID: 3FXI). The intracellular and
transmembrane domains have been modelled by members of our group by homology
modelling and were used for this study (Ref. Uniprot O00206).
The MD simulations of these models were carried out, and with the area per
molecule and the electron density were analyzed (see Figures 6.5 and 6.6).
Area per molecule:
Figure 6.5. Area per molecule for different models of membranes during MD simulation (50 
ns).
Figure 6.6. Electron density profile for the different models of membranes during MD
simulations (50 ns).
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6. MD SIMULATIONS MEMBRANES WITH TLR4
In order to undertand the behaviour of the TLR4/MD-2 system in the
membrane enviorment, we started to build different models from the most simple
until more complex with the different models of membranes as follows:
1- The building and simulation of the transmembrane and intracellular domain of
TLR4 in the different bilayer membranes environment complex (100 ns for POPC,
POPE-POPC and CHOL-POPC, DPPC-POPE and DPPC-POPC) was carried out, with the
corresponding analysis of different parameters.
2- The building and simulation of the full monomer system (extracellular,
transmembrane and intracellular domains) of the complete complex of agonist
TLR4/MD-2 system with three molecules of myristic acid in the different bilayer
membranes environment complex (100 ns for POPC, POPE-POPC and CHOL-POPC,
DPPC-POPE and DPPC-POPC) was carried out, with the corresponding analysis of
different parameters (Figure 6.7). 
3- The building and simulation of the full dimer system of the complete monomer
complex of agonist TLR4/MD-2 system in the different bilayer membranes
environment in our asymmetric complex bilayer model is in progress with the
corresponding analysis of different parameters.
Figure 6.7. Example of the monomer TLR4/MD-2 complex with three molecules of myristic 
acid in the CHOL-POPC bilayer membrane.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
ANALYSIS:
The analysis was performed using the cpptraj module of AmberTools15.15 After
production several lipid bilayer parameters, including area per lipid, electron density
profiles, RMSD, RMSF, distances and angles were analyzed. The results for the
transmembrane + intracellular domain in the membrane environment are very similar
compared with the full monomer system (extracellular + transmembrane +
intracellular domains of TLR4).
Area per molecule: The area per molecule is a common experimental structural
parameter used in the validation of lipid bilayer simulations. The area is determined
from the specified cross-section of the box.
Very little is known about the experimental data of membranes. For the case
POPC membrane, the experimental data indicate that area per lipid is between 64.3
16-17 and 68.3 Å2. Our models indicate that the area per lipid is around 65 Å2, so
satisfactory are in agreement with the experimental value. In the case of POPE, the
experimental data indicates that the area per lipid is around 59-60 Å2.18 The area per
molecule of the bilayer systems are seen to be stable during the simulation time and
shows lower fluctuations in all the cases. In the case if CHOL-POPC the area per
molecule is less, because the sterols occupy less area in relation to lipids (Figure 6.8).
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TLR4 (ED+TD+ID)/MD-2 with 3 myristic 
TLR4 (TD+ID)
acids
Figure 6.8. Area per molecule of the TLR4/MD-2 system with three molecules of myristic acids 
on the left  and TLR4 (TD+ID) on the right, for the different bilayer systems.
Electron density profile: The electron density profile provides a time-averaged
measurement of the density of electrons through the lipid bilayer. The total electron
density profile for the lipid bilayers was carried out. It is possible to compute the
thickness of the lipid bilayer using the peak-to-peak distance.
Regarding the experimental data, the thickness for different models of
membranes is: 37 Å for POPC, 17 and 39.5 Å for POPE.18 The results obtained for the
transmembrane and intracellular domains are very similar comparing with the full
system; in all the cases we have obtained a thickness around 40 Å (Figure 6.9).
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TLR4 (ED+TD+ID)/MD-2 with 3 myristic 
TLR4 (TD+ID)
acids
Figure 6.9. Electron density profile of the bilayer systems.
RMSD: The root mean-square deviation (RMSD) of the backbone of the protein (TLR4
and MD-2) and the heavy atoms of the ligands (three molecules of myristic acid) were
calculated around the molecular dynamic (MD) simulations (100ns). In the case of the
TLR4, we have monitorized also the extracellular (ED), transmembrane (TD) and
intracellular (ID) domain.
From studying the RSMD of the simulations in all the cases, it could be
observed that TLR4 (full system), at the beginning had some significant movements but 
acquire certain stability since 40 ns of the MD simulation, except in the case of CHOL­
POPC membrane which has drastic movements throughout all the MD simulation
(Figure 6.10) but in the case of the RMSD separate into fragments (ED, TD and ID), it
could be possible to observe stability in all the models for the TD, but in the case of the
ED and ID all the models are stable, except in the case of DPPC-POPC model which has 
some drastic movements throughout the whole of the simulation (Figure 6.11).
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6. MD SIMULATIONS MEMBRANES WITH TLR4
Figure 6.10. RMSD of the backbone of the TLR4/MD-2 monomer (EC, TM and IC domains) in
complex with three myristic acids (left) and the MD-2 protein (right).
TLR4 (ED+TD+ID)/MD-2 with 3 myristic acids
TLR4 (TD+ID)
Figure 6.11. RMSD of the backbone of the extracellular, transmembrane and intracellular TLR4
domains for the different models of membranes.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
In the case of the MD-2 and the three molecules of myristic acid (Figure 6.12),
MD-2 remains stable throughout the whole of the simulation; regarding the ligands,
the three molecules of myrisitc acid in the case of POPC membrane change the
positions since 30 ns, but from here remains stable until the end of the simulation. In
the case of POPE-POPC, the myristic acids 146 and 147 change the position from 45 ns.
In the DPPC-POPC model, the ligands change at the beginning but remain stable during
the whole of the simulation. For the others models, the molecules of myrist acid
remain stable during the whole of the simulation.
Figure 6.12. RMSD of the heavy atoms of the three molecules (145, 146 and 147) of  myristic 
acid for the different membranes.
RMSF: We have measure the root mean-square fluctuation (RMSF), a measure of the
average atomic mobility of backbone atoms (N, Cα and C atoms) during the MD
simulations, in order to evaluate internal fluctuation in the different models (figure
6.13). 
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TLR4 (ED+TD+ID)/MD-2 with 3 myristic acids
TLR4 (TD+ID)
Figure 6.13. RMSF of the backbone of different parts of TLR4 (ED, TD and ID) and MD-2 with 
myristic acids (top) and TLR4 (TD and ID) (bottom) for the different models of membranes.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
In the case of the MD-2 pocket, the graphics show the average RMSD of the 
amino acid residues. It is possible to observe that the mayor fluctuations correspond to
the residues in the loops implicate in the dimerization interface.
For the ED, the pics of fluctuation correspond to the amino acids residues in the
loops, the mayor fluctuations are due to the first residue which is the initial part of
TLR4, and the final residue correspond to threonine, which is in the end of the TLR4
extracellular domain, and very close to the membrane.
Distances: The lenght for the TD of TLR4 was measured from Lys631 to Lys653. The
distance is stabley around the MD simulations both cases (TD +ID domain of TLR4 adn
TLR4 complete in the models of membranes), the distance is around 35 Å (Figure 6.14).
TLR4 (ED+TD+ID)/MD-2 with 3 myristic 
TLR4 (TD+ID)
acids
Figure 6.14. Distances for the TM domain from Lys631 to Lys653 of TLR4 in the different 
models of membranes.
Also the distance from Lys653 to the middle of the ID of TLR4 was measured,
and it was possible to observe that the ID approaches to the membrane in all the
models, establishing interactions with the head gropus of the inner leaflet from the
membrane (Figure 6.15).
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Regarding the ID of TLR4 from CHOL-POPC membrane (Figure 6.15 and 6.16), 
this domain aprroach to the membrane establishing polar interactions the residues
Gly663, Tyr667, Arg689, Arg669, Glu698, Gly699 and Gln704 eith the polar head
groups of POPC inner leaflet, also CH-π interaction between the Phe656 and Pro714. 
The portion of linker since Tyr653 to Cys664 is inserted in the membrane. 
Figure 6.15. MD simulation of TLR4/MD-2 with three molecules of myristic acid in CHOL-POPC 
membrane. The ID is aprroach towards the inner leaflet of the membrane, establishing polar
interactions with the head groups of the inner leaflet.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
Figure 6.16. Polar interactions of the ID of TLR4 with the head groups of POPC from the inner 
leaflet of the CHOL-POPC membrane.
Regarding the model with POPC membrane, also de portion of the linker since 
Tyr653 to Gly668 is inserted in the membrane and is possible to observe polar
interaction from the residues Gly663, Lys666, Tyr667, Arg669, Glu698, Gly828, Thr829
and Trp833 of TLR4 with the head groups of the inner leaflet of the membrane.
Regarding the model with POPE-POPC membrane, the linker is also inserted in
the mebrane from Tyr653 to Cys664 and the residues from TLR4: Gly663, Lys666,
Arg669 and Gln704 establish polar interactions with the head groups of the lipids.
Regarding the model with DPPC-POPC, the residues of TLR4 Gly663, Lys666, 
Tyr667 and Arg669 and establish polar interactions with the head groups of the
membrane. Also the linker from Tyr653 to Cys664 is inserted in the membrane.
Regarding the model with DPPC-POPE Lys666, Arg669, Glu671, Arg763, Asp817
and Lys819 from TLR4 establish polar interactions with the head groups of the
membrane, also the linker since Tyr653 to Cys664 is inserted in the membrane.
For the models built with only TD and ID of TLR4 in the different membranes 
enviorment was possible observe the same interactions from the ID of TLR4 with the
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6. MD SIMULATIONS MEMBRANES WITH TLR4
head groups of the inner leaflet of the membranes and the linker is also inserted in the
membrane.
It could be said that the ID approach to the membrane, due to contains 
residues in this part that interact with the heads groups of the inner leaflet.
Secondary structure – helicity of the transmembrane and intrecellular domain of
TLR4: DSSP method of Kabsch and Sander19 were calculated for TD and ID of TLR4 ,
which assigns secondary structure types for residues based on backbone amide (N-H) 
and carbonyl (C=O) atom positions. We have measured the evolution of secondary
structure over 100 ns. In the case of the ID for all the models, we observed stable
structural features with minor variations in turn or loop regions around the MD
simulation. And the secondary structure of the transmembrane region was stable,
which was a α-helix around residues Ile633 and Val651 (Annex Figure 6.1 and Annex
Figure 6.2).
Angles: In order to see the torsion and movement of the TLR4 during the MS
simulation toward the membrane, we measured two angles, angle 123 between
Cys390-Cy391(1), Cys585- Cys627 (2) and Lys653 (3), and angle 234 between Cys585­
Cys627 (2), Lys653 (3) and Cys735-Cys736 (4) (Figure 6.17). We observed in both
models, TD+ID domain of TLR4 and TLR4 complete in the different models of
membranes, and we can conclude that it remains more or less stable throughout the
simulation, not be possible to observe great changes at different angles (Figure 6.18).
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Figure 6.17. Angles measured in the 
TLR4 during the MD simulation of 
the different models of membranes.
TLR4 (ED+TD+ID)/MD-2 with 3 myristic acids
TLR4 (TD+ID)
Figure 6.18. Angle 134 between Cys390-Cys391 (1), Cys585-Cys627 (2), Lys653 (3) and Cys735­
Cys736 (4) from TLR4.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
6.3 Conclusions
We have presented results from MD simulation of bilayers with different kind
of lipids and also including cholesterol in order to see the behaviour of the TLR4/MD-2 
system in different membrane enviorments. The analysis of the MD simulation led us
to understand better the key ligand-receptor and protein-protein interactions
implicated in the molecular recognition events and in the dimerization process.
Firslty, we started this approach with the building of different symmetric
models, and the analysis were carried out. The area per lipid is different depending if
the composition include saturation or insaturation lipids and also depending if their
composition include or not cholesterol. Regarding the membranes with cholesterol or
insaturated lipids the area per lipid is less than the others membranes with saturated
lipids. But very little is know about the experimental data of membranes.In relation to
the thickness of the models, is approximatley the same for all the models, 40 Å in all
the cases. An asymmetric membrane model including cholesterol has been built trying
to represent the complexity of the mamalian membranes. We have perfomed the MD
simulation, and we are going to use this model to insert now the TLR4/MD-2 system.
The TLR4/MD-2 monomeric complex has been simulated inserted in all the
membrane models (in the asymmetric model , the MD simualtion is still running), and
was possible to observe that the membranes with DPPC (saturated lipid) are more
instable comparing with the membranes with unsaturated lipids or choleterol. We are
trying to undertand this fact and to figure out what is happen, because the analysis of
the membranes with DPPC-POPC and DPPC-POPE give worse results in comparation
with the models POPC, CHOL-POPC, POPE-POPC and asymmetric models. 
We are working now in the full dimer structure (ED, TD and ID) with the
different models of membranes, in order to have more insights, to understand better
the full TLR4 dimer.
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6. MD SIMULATIONS MEMBRANES WITH TLR4
6.4 Materials and Methods
Recently has been developed a new generation of all-atom phospholipid force
fields for MD simulations of membrane bilayers (Amber Lipid Force Field).20 
Lipid bilayers were set up and molecular dynamics run with Amber and the
Lipid14 force field. Amber 14 includes Lipid14 (Table 6.1) a modular lipid force for
tensionless lipid phospholipid simulations. Lipid14 includes the modular charge
derivation framework developed in Lipid11 as well as a reparameterization of key van
der Waals and dihedral angles as performed in GAFFlipid. 21 21 20 21 
Table 6.1. Lipid14 residues name.
Lipid 14 Residues
Description LIPID14 Residue Name
Acyl Chain
Lauroyl (12:0) L!
Myristoyl (14:0) MY
Palmitoyl (16:0) P!
Stearoyl (18:0) ST
Head Group
Oleoyl (18:1 n-9) OL
Phosphatidylcholine PC
The lipid bilayers structures were built using the CHARMM Membrane Builder
GUI,22 an internet based solution to generating lipid bilayer structures as well as
membrane-bound protein structures. The membranes were created with a rectangular
box, 22.5 water layers thick on the top and bottom of the system and 200 length of XY
(Table 6.2). All systems are modeled using suitable AMBER parameters, and converted
to Lipid14 PDB format using the charmmlipid2amber.x script.23 Formatted structure
files were loaded into the program Leap, and parameters and topology were assigned.
Glycerophospholipid parameters from Lipid14 were used for the lipids.
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Table 6.2. Composition of the different models of membranes.
Membrane
Model
Lipid
Type
Upper
Leaflet 
Number
Lower
Leaflet 
Number
Average
Area (Å2)
Area
Upper
(Å)
Area
Inner
(Å)
CHOL-POPC
CHOL 370 370
40071.00 200.18 200.18
POPC 370 370
POPE-POPC
POPE 315 315
40036.50 200.09 200.09
POPC 315 315
POPC POPC 586 586 40023.80 200.06 200.06
DPPC-POPC
DPPC 305 305
40046.50 200.12 200.12
POPC 305 305
DPPC-POPE
DPPC 329 329
40072.20 200.18 200.18
POPE 329 329
ASYMMETRIC 
MODEL
CHOL
DPPC
DPPE
POPE
POPC
DOPE
DOPC
263 250 14221 119.25 119.25
Regarding TLR4/MD-2 system, an X-ray structure is available for the
extracellular domain in complex with lipid A (PDB-ID: 3FXI). The intracellular and
transmembrane domains have been modelled by our Computational Chemical Biology
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6. MD SIMULATIONS MEMBRANES WITH TLR4
lab (at CIB-CSIC) by homology modelling and were used for this study (Ref. Uniprot
O00206). 
The following protocol was used for molecular dynamics of lipid bilayer, lipid
bilayer with the intracellular and transmembrane TLR4 domains, and finally the full
system TLR4/MD-2: a minimization phase, following two steps of heat, holding to
equilibrate periodic box dimensions and finally production with constant pressure.
The full system was minimized for 10000 steps, of which the first 5000 steps
used the steepest descent method and the remaining steps used the conjugate
gradient method. The system was then heated from 0 K to 100 K using Langevin
dynamics24 for 5 ps at constant volume, with weak restraints on the lipid (force
constant 10 kcal mol−1 Å−2). The systems were heated through two sequential runs to
303 K while keeping the lipid fixed. First the systems were heated to 100 K and then
slowly to the production temperature. The Langevin thermostat was used for the initial
heating. The second phase of heating slowly increased the temperature to the desired
production temperature. This time an anisotropic Berendsen weak-coupling barostat
was used to also equilibrate the pressure in addition to the use of the Langevin
thermostat to equilibrate the temperature. 
To hold, in order to equilibrate the system's periodic boundary condition
dimensions, it was necessary to run 5ns MD with a barostat. The system's dimensions
and density must equilibrate before proceeding with production MD. Because the
periodic boundary condition box dimensions are changing, it was necessary to increase
the "skinnb" value and to restart the MD simulation after 500ns. This avoided most
"skinnb" errors. If these cells change size, due to the box changing size, by too much
then it will cause the code to halt with an error related to skinnb. Once the system was
equibrated the box size fluctuations were small and so this was not an issue during
production.During the production (100 ns), the temperature was controlled using the
Langevin thermostat while pressure was controlled using the anisotropic Berendsen
barostat.
The analysis was performed using the cpptraj module of AmberTools15.15 
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6.5 Annex VI
Annex Table 6.1. Different type of lipids and sterols.
POPC
POPE
(1-palmitoyl-2­ DPPC
(1palmitoyl-2­
oleoyl-sn-glycero­
3-phosphocoline)
oleoyl-sn-glycero­
3­
phosphoethanola 
(1,2-dipalmitoyl­
sn-glycero-3­
phosphocholine)
CHOL
(Cholesterol)
PA-PC-OL mine) PA-PC-PA
PA-PE-OL
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DPPE DOPE DOPC
(1,2-dipalmitoyl-sn-glycero- (1,2-Dioleoyl-sn-glycero-3- (1,2-dipalmitoyl-sn-glycero­
3-phosphoethanolamine) phosphoethanolamine) 3- phosphocholine)
PA-PE-PA OL-PE-OL OL-PC-OL
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Annex Figure 6.1. The helicity of the transmembrane domain of TLR4 for all the membranes
models.
Annex Figure 6.2. The helicity of the intracellular domain of TLR4 for all the membranes 
models.
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7. CONCLUSIONS
CONCLUSIONS
In this Thesis, we have contributed to the elucidation of the molecular
recognition events involving TLR4/MD-2 and some modulators at atomic level. This
work has been carried out by means of computational methodologies, such as MD
simulations, ligand-protein and protein-protein docking, virtual screening, and
membrane simulations. Ligand-protein docking and virtual screening has been
employed as a source of new compounds able to modulate the TLR4 behavior with
possible therapeutic applications. We have combined the computational work with
experimental biological assays, and a fruitful collaboration with Prof. Peri´s group for
the synthesis of compounds. Overall, we have helped to provide new insights for the
understanding of the molecular recognition events underlying the biological functions
of the TLR4.
Theoretical binding modes have been predicted for reported modulators of the
TLR4/MD-2 system, with agonist and antagonist activity. In particular, we focused our
work in synthetic glycolipids and non LPS-like molecules. For all these TLR4
modulators, it is clear that, despite their different chemical structure, they must share
a common pattern of interactions with TLR4. We have undertaken a computational
study of some representative compounds to unveil some of these patterns of
interactions.
The cationic glycolipid IAXO-102, a potent TLR4 antagonist targeting both MD-2 
and CD14 co-receptors, has been used as scaffold to design new potential TLR4
modulators and fluorescent labels for the TLR4 receptor complex (membrane
TLR4/MD-2 dimer and CD14). Our modelling studies have led to the proposal of 3D
models for the interaction with CD14 and TLR4/MD-2 accounting for their binding
properties and also for their antagonistic activity.
To propose new chemical scaffolds for the development of new ligands able to
modulate TLR4 functions, we have performed virtual screening. Virtual screening
strategies from commercial and in-house libraries, followed by biological assays, have 
allowed us to identify new chemical entities for the development of novel TLR4
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modulators with a LPS-non-related structure. So far, we have identified seven novel
compounds with a promising TLR4 antagonist activity.
The computational study of the full TLR4/MD-2 heterodimer was performed,
simulating the full complex inserted in the membrane environment. The analysis of the
molecular dynamics simulations led us to understand the key interactions implicated in
the dimerization process at atomic level.
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7. CONCLUSIONS
CONCLUSIONES
En esta Tesis, hemos contribuido a la elucidación de los eventos de
reconocimiento molecular del complejo TLR4/MD-2 y algunos moduladores a nivel
atómico. Este trabajo se ha realizado por medio de metodologías computacionales,
como simulaciones de dinámica molecular, acoplamiento ligando-proteína, cribado
virtual y simulaciones de la membrana. Técnicas de acoplamiento ligando-proteína y
cribado virtual han sido utilizadas, dando lugar a una fuente de nuevos compuestos
capaces de modular el comportamiento de los TLRs con posibles aplicaciones
terapéuticas, y también como sondas biológicas. 
Hemos combinado el trabajo computacional con ensayos biológicos
experimentales y hemos llevado a cabo una fructífera colaboración con el grupo del
Prof. Peri para la síntesis de compuestos. En general, hemos ayudado a proporcionar
nuevas ideas para la comprensión de los eventos de reconocimiento molecular
subyacente a las funciones biológicas de los receptores TLR4.
Se han predicho modos de unión teórica para los moduladores descritos del
sistema TLR4/MD-2. En particular, hemos centrado nuestro trabajo en glicolípidos
sintéticos y moléculas que no tienen estructura de tipo LPS. Para todos estos
moduladores de TLR4, está claro que, a pesar de su diferente estructura química, 
deben compartir un patrón común de interacciones con el receptor TLR4. Hemos
emprendido un estudio computacional de algunos compuestos representativos para
revelar algunos de estos patrones de interacciones.
El glicolípido catiónico IAXO-102, un potente antagonista de TLR4, se ha 
utilizado como esqueleto para diseñar nuevos moduladores de TLR4 y marcadores
fluorescentes para el complejo TLR4. Nuestros estudios de modelización nos han
permitido diseñar nuevos compuestos y a proponer modelos de interacción tanto para
el CD14 como para el complejo TLR4/MD-2. Todos estos compuestos han presentado
una actividad antagonista para el complejo del TLR4.
El estudio computacional del heterodímero TLR4/MD-2 completo se realizó
simulando el complejo completo insertado en la membrana. El análisis de las
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simulaciones de dinámica molecular nos llevó a entender las interacciones claves
implicadas en el proceso de dimerización a nivel atómico.
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